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ABSTRACT 
Streptococcus pneumoniae is a major human bacterial pathogen causing life 
threatening diseases such as meningitis, bacteremia, and pneumonia. Younger children 
are heavily affected by pneumococcal infections. Pneumococcal conjugate vaccines 
(PCVs) are serotype-specific and require data on local serotype distribution to predict 
the coverage of PCVs. Moreover, the escalating incidence of antibiotic resistance S. 
pneumoniae has prompted the development of novel antimicrobial agents. 
Antimicrobial peptides (AMPs) have been increasingly recognized as the new 
generation antibiotics due to their potent antimicrobial activity. In this study, we sought 
to design novel synthetic antimicrobial peptides against S. pneumoniae and determine 
the in vitro and in vivo activities of the peptides. 
A collection of 151 pneumococcal clinical isolates from University of Malaya 
Medical Centre, Kuala Lumpur were serotyped using multiplex PCR and the penicillin 
susceptibility was determined using agar dilution method. Biocomputational tools were 
employed to design the peptides based on the publicly available AMPs. The designed 
AMPs were tested for minimum inhibitory concentration, bacterial killing kinetics, and 
synergism activity. Broad spectrum antibacterial activity against eight common bacterial 
pathogens was also determined. Morphological changes of pneumococcal cells were 
observed using transmission electron microscopy. The designed AMPs were also 
assessed for hemolytic and cell cytotoxicity. In vivo therapeutic efficacy and acute 
toxicity of the peptides were assessed using an in-house mouse model. 
 Serotypes 19F and 23F were the two prevailing serotypes among Malaysian 
population with serotype 19F significantly associated with penicillin resistance. 
Penicillin-nonsusceptible S. pneumoniae constituted half (50.3%) of the total isolates. 
and as high as 87.5% of penicillin-resistant S. pneumoniae (PRSP) were PCV7-vaccine 
serotypes. From the peptide designs, antimicrobial testing showed that the five hybrid 
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peptides (DM1-5) exhibited strong antipneumococcal activity irrespective of penicillin 
susceptibility of the isolates. These isolates included the highly prevalent serotype 19F. 
The pneumococcal killing rates were higher than penicillin by 38 – 64%, 54 – 76%, and 
30 – 57% for penicillin-resistant, intermediate, and susceptible isolates at 30 min 
posttreatment, respectively. The DMs and other peptides produced synergism in 
combination with penicillin against S. pneumoniae and displayed broad spectrum 
antibacterial activities. The DMs induced overwhelming cellular damages leading to 
cell death. Besides, DMs exhibited low hemolytic activity (HC50 >250 μg/ml) with 
varying degrees of cell cytotoxicity against NL20 and A549 cell lines. Notably, DM3 
(40 mg/kg) given via intraperitoneal route at 12 hrs interval for three dosing regimens 
protected 50% of mice from lethal systemic infection by a PRSP strain. Interestingly, 
combination therapy using low doses (10mg/kg and 20mg/kg) DM3 and penicillin 
showed therapeutic synergism with 20-50% higher survival rates than the sum of the 
standalone treatments. Complete protection (100%) was achieved with DM3 (20 mg/kg) 
– penicillin (20 mg/kg) combination. 
 Pneumococcal infections continue to affect humans and antibiotic-resistant S. 
pneumoniae would further complicate the treatment outcomes. The current study 
demonstrated that AMPs represent the promising new generation antibiotics as 
standalone therapeutics or in combination with conventional antibiotics. Novel designed 
AMPs candidates can be designed following careful designing approaches to generate 
peptides with high therapeutic potential to be further developed into clinically useful 
antibiotics. 
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ABSTRAK 
Streptococcus pneumoniae merupakan sejenis patogen bakteria yang boleh 
menyebabkan pelbagai jenis penyakit yang mengancam nyawa manusia seperti 
meningitis, bakteremia, dan pneumonia. Kanak-kanak merupakan golongan utama yang 
sering diancam oleh jangkitan pneumokokal. Keberkesanan “pneumococcal-conjugate 
vaccine (PCV)” adalah spesifik kepada jenis serotype dan data mengenai taburan 
serotype tempatan amat diperlukan supaya liputan PCVs dapat dianggarkan. Selain itu, 
isu-isu peningkatan rintangan antibiotik S. pneumoniae telah meningkatkan permintaan 
terhadap antibiotik baru. Peptide antimikrobial (AMPs) mempunyai aktiviti antimikrob 
yang tinggi dan telah kian diiktiraf sebagai antibiotik generasi baru. Dalam kajian ini, 
kami telah mereka peptida sintetik terhadap S. pneumoniae dan menentukan aktiviti-
aktiviti in vitro dan in vivo peptida tersebut. 
Sebanyak 151 isolat pneumokokal klinikal dari Pusat Perubatan Universiti 
Malaya, Kuala Lumpur telah diserotypekan menggunakan PCR multipleks dan tahap 
rintangan penisilin ditentukan dengan kaedah pencairan agar. Teknik biokomputer 
digunakan untuk mereka peptida baru berdasarkan peptida yang sedia ada. Seterusnya, 
peptida sintetik tersebut diuji untuk menentukan “minimum inhibitory concentration 
(MIC)”, kinetik penghapusan bakteria, dan aktiviti sinergi. Peptida sintetik tersebut juga 
diuji untuk keberkesanan antibakteria specktrum luas terhadap lapan bakteria patogen. 
Perubahan morfologi sel pneumokokal telah divisualisasikan dengan menggunakan 
mikroskop elektron transmisi (TEM). Selain itu, tahap hemolitik dan ketoksikan peptida 
sintetik tersebut terhadap sel-sel manusia turut ditentukan. Keberkesanan terapeutik dan 
ketoksikan in vivo telah dinilai menggunakan model tetikus. 
Serotype 19F dan 23F merupakan dua jenis serotype lazim di kalangan penduduk 
Malaysia. Serotype 19F adalah dikaitkan dengan rintangan penisilin. Separuh daripada 
jumlah isolat merupakan S. pneumoniae yang toleran kepada penisilin (50.3%). 
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Sebanyak 87.5% S. pneumoniae yang rintang penisilin (PRSP) merupakan serotype 
yang terkandung dalam vaksin PCV7. Ujian antimikrobial menunjukkan bahawa aktiviti 
DAMP7 adalah sederhana manakala lima peptida hibrid (DM1-5) mempamerkan 
aktiviti antipneumococcal yang kuat terhadap semua isolat pneumokokal tanpa 
bergantung kepada rintangan penisilin isolat termasuk serotype 19F. Kadar 
penghapusan pneumokokal adalah lebih tinggi daripada penisilin dan mencapai 38 - 
64%, 54 - 76%, dan 30 - 57% bagi isolat resistan, sederhana, dan sensitif penisilin 
masing-masing selepas dirawat untuk 30 min. DAMP7 dan DMs dapat menghasilkan 
kesan sinergi terhadap S. pneumoniae semasa dikombinasikan bersama penisilin dan 
juga mempunyai aktiviti antibakteria spektrum luas. DMs juga menyebabkan kerosakan 
dinding dan membran sel yang akhirnya membawa kepada kematian sel. Peptida hibrid 
tersebut menunjukkan aktiviti hemolitik yang rendah (HC50 > 250 μg/ml) dan tahap 
ketoksikan yang berlainan terhadap sel-sel NL20 dan A549. Rawatan DM3 (40 mg/kg) 
secara  intraperitoneal pada setiap selangan 12 jam untuk tiga regim dapat 
menyembuhkan 50% tetikus daripada jangkitan maut sistemik oleh PRSP. Terapi 
combinasi dengan dos rendah DM3 dan penicillin menunjukkan sinergi teraputik di 
mana kadar pelindungan sebanyak 20 – 50% lebih tinggi daripada rawatan tunggal 
dicatatkan. Perlindungan menyeluruh (100%) dapat dicapai dengan kombinasi DM3 (20 
mg/kg) – penicillin (20 mg/kg). 
Jangkitan pneumokokal akan terus mengancam manusia dan dijangka akan 
merumitkan lagi rawatan untuk penyakit-penyakit yang melibatkan S. pneumoniae 
rintang antibiotik. Kajian ini menunjukkan bahawa AMPs merupakan calon antibiotik 
generasi baru yang berpotensi untuk rawatan secara tunggal ataupun diformulasikan 
dengan antibiotik konvensional. Penyelidikan secara systematik dan teliti dapat 
membantu menghasilkan AMPs yang mempunyai potensi terapeutik yang tinggi untuk 
kegunaan klinikal.  
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1.1. Overview of Streptococcus pneumoniae 
Streptococcus pneumoniae is a facultatively anaerobic, gram-positive lanceolate-
shaped cocci which is commonly present as normal flora in the human upper respiratory 
tract (Gray et al., 1980). The size of an individual cell ranges from 0.5 - 1.25 μm in 
diameter and frequently appears as a single cell, paired (diplococci), or short-chain form 
under the microscope. S. pneumoniae has no fimbriae and no fibrils (Tuomanen et al., 
1995). It produces hydrogen peroxide which oxidizes hemoglobin to methemoglobin. 
This gives the distinctive greenish-brown appearance under the growth of 
pneumococcal colony on blood agar and is termed α-hemolytic. Besides this, S. 
pneumoniae is catalase-negative, optochin (ethylhydrocupreine hydrochloride) 
susceptible, and bile (sodium deoxycholate) soluble. The optochin and bile solubility 
tests are common biochemical tests used to differentiate pneumococcus from the 
closely-related α-hemolytic viridans streptococci such as Streptococcus mutans, 
Streptococcus mitis, and Streptococcus sanguinis. S. pneumoniae undergoes autolysis 
after 12 - 16 hrs of incubation and this process can be enhanced in the presence of 
surface active agents such as sodium deoxycholate which inactivates the cell wall 
autolysin inhibitors. 
S. pneumoniae is a naturally transformable microorganism. The presence of as 
much as 40 open reading frames in the R6 strain, which is one of the most widely 
studied pneumococcal strains certainly reflects how much this bacteria is readily 
transformable by the uptake of DNA (Hoskins et al., 2001). Other features of the R6 
strain include genome size of 2,038,615 bp, GC content of 40%, and 2043 protein 
coding regions. Transformation can create recombinant strains with enhanced survival 
fitness, disease-causing ability, and tolerability to antibiotics (Chalkley & Koornhof, 
1990; Zhang et al., 2005). Being part of the complex microbiota especially in the 
respiratory tract, S. pneumoniae is constantly interacting with various other bacterial 
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species. This includes co-colonizing pneumococcal strains and the closely-related 
streptococcal species. At the same time, S. pneumoniae is exposed to exogenous DNA 
released from the dead/lysed pneumococcal streptococcal cells present in 
microenvironments (Steinmoen et al., 2002). Naturally competent pneumococci are able 
to pick up these exogenous DNA to be incorporated into its own genome and 
subsequently to have the recombinant genes expressed (Steinmoen et al., 2002; 
Steinmoen et al., 2003). However, upon acquisition of genes encoding the altered 
penicillin-binding proteins (PBPs), pneumococci can be transformed to express the 
recombined PBPs with lower affinity to ß-lactam antibiotics resulting in β-lactam 
resistance in the transformed pneumococcal cells (Dowson et al., 1994). 
 
1.2. Pneumococcal virulence factors 
1.2.1. Pneumolysin 
The processes of colonization and disease manifestations involve the cascades of 
coordinated switching and expression of an armamentarium of virulence factors to 
facilitate pneumococcal invasion from upper to lower respiratory tract (Kadioglu et al., 
2008). It is when S. pneumoniae spread to the respiratory lining epithelium at the site of 
infection do they express the disease-causing potential (Catterall, 1999). The complex 
interplay between pneumococcal virulence factors and host immune factors is crucial to 
prevent elimination by the host immune defense mechanisms and ensures efficient 
adaptation of pneumococci to the drastic changes in the microenvironment surrounding 
the cells (Gillespie, 1989). 
Pneumolysin (hemolysin) is a soluble protein of 52 kDa produced virtually by all 
clinical isolates of S. pneumoniae (Kanclerski & Mollby, 1987). It is a multifunctional 
virulence factor encoded by ply gene and belongs to the family of cholesterol-dependent 
cytolysins. The primary sequence of pneumolysin is highly conserved although a 
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number of variants have been reported (Kirkham et al., 2006; Lock et al., 1996). Upon 
contact with cell membrane, about 40 pneumolysin monomers oligomerize to form a 
large transmembrane pore following a series of structural alterations (Tilley et al., 2005).  
Pneumolysin plays crucial roles in the disease pathogenesis of S. pneumoniae 
especially in the establishment of pneumonia (Berry et al., 1995; Jounblat et al., 2003; 
Rubins et al., 1996). This protein enhances the survival of pneumococci in human 
respiratory tracts and facilitates pneumococcal invasion from lung into the bloodstream 
leading to bacteraemia (Kadioglu et al., 2002; Orihuela et al., 2004). In the course of 
bacteraemia, the production of pneumolysin has been linked to higher tendency of overt 
diseases manifestation (Berry et al., 1999; Orihuela et al., 2004). Conversely, 
pneumolysin-deficient mutant strains tend to produce chronic sepsis rather than acute 
infections as shown by Benton et al. using an experimental murine model (Benton et al., 
1995). On the other hand, the role of pneumolysin in the establishment of pneumococcal 
meningitis remains debatable (Friedland et al., 1995). However, an increasing body of 
evidence have shown that not only does pneumolysin play a key determinant role in 
meningitis (Braun et al., 2002; Wellmer et al., 2002), it is also responsible for various 
complications that arise from meningitis (Hirst et al., 2004; Hirst et al., 2000).  
The native form of pneumolysin is a protective immunogen component. Mice 
immunized by the purified pneumolysin had significantly higher mean survival time 
(5.52 days) as compared to the control mice (2.48 days) following intranasal challenge 
with  virulent type 2 pneumococci (Paton et al., 1983). However, native pneumolysin is 
rather hemolytic and Paton et al. had generated two pneumolysin toxoids via site-
directed mutagenesis, PdA and PdB. Mice immunized with these toxoids showed 
enhanced survival time in the immunized mice as compared to the sham-controlled mice 
(Paton et al., 1991). Alexander and colleagues further demonstrated the potential use of 
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pneumolysin toxoids as pneumococcal vaccine candidate by showing that PdB 
conferred non-serotype immune protection in mice (Alexander et al., 1994). 
   
1.2.2. Choline-binding proteins 
S. pneumoniae expresses a family of surface-exposed choline-binding proteins 
(CBPs) which serve as the specific glycoconjugate adhesins against the host cells 
(Gosink et al., 2000; Rosenow et al., 1997). A representation of pneumococcal cell 
surface components is shown in Figure 1.1. CBPs are the principal components 
responsible for pneumococcal cell surface net charge and hydrophobicity to facilitate 
the adherence of pneumococcus on host cell surface (Swiatlo et al., 2002). The presence 
of CBPs reduces the electronegative property of the pneumococcal cell. Also, the 
hydrophobicity of CBPs could substantially be masked by the presence of capsular 
polysaccharide (CPS) (Swiatlo et al., 2002).  
 
Members of CBPs group of proteins include PspA, PspC, and LytA. PspA is 
Figure 1.1: A representation of pneumococcal cell surface components (adapted from 
Bhatty et al., 2011). 
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responsible for anti-complementary activity of S. pneumoniae by preventing 
complement fixation of C3 component and complement-mediated opsonization. The 
inhibitions are suggested to be due to electrostatic repulsion imposed by the highly 
electronegative termini of PspA protein (Jedrzejas et al., 2001). Also, PspA protects 
pneumococcus from the bactericidal activity of apolactoferrin protein (iron-depleted 
form of glycoprotein lactoferrin) by binding to and subsequently inactivates the 
apolactoferrin (Shaper et al., 2004).  
Commonly known as choline-binding protein A (CbpA) and secretory 
pneumococcal surface protein A (SpsA), PspC is important for adherence and 
colonization of pneumococci to the epithelial cells of nasopharyngeal (NP) airways and 
lungs (Balachandran et al., 2002; Rosenow et al., 1997). The protein acts probably by 
binding to the glycoconjugates of host epithelia such as C3, sialic acid, and 
lactolactotetraoses (Rosenow et al., 1997; Smith & Hostetter, 2000). Binding of PspC to 
the polymeric immunoglobulin receptor on the NP epithelial cells which function to 
transport secretory IgA had been suggested to help in the translocation process of 
pneumococci across the epithelial and subsequent invasion into other body parts (Zhang 
et al., 2000a). Moreover, PspC is able to bind specifically to the human secretory 
immunoglobulin A which reduces bacterial clearance and in turn enhances 
pneumococcal survival in the host (Hammerschmidt et al., 1997). Similar to PspA, 
PspC also inhibits C3 component of the complement system (Cheng et al., 2000) and 
capable of preventing opsonization by binding to factor H which inhibits the formation 
of C3b of the alternative complement pathway (Quin et al., 2005).   
LytA is an autolytic enzyme responsible for cell autolytic activity and the 
formation and turnover of cell wall. It is functionally homologous to  amidase which 
catalyzes the breakdown of peptidoglycan via N-acetylmuramoyl-L-alanine bond 
cleavage (Howard & Gooder, 1974). The role of LytA in enhancing the virulence of S. 
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pneumoniae had been demonstrated using the murine bacteraemic and murine 
pneumonia models (Berry & Paton, 2000; Canvin et al., 1995; Orihuela et al., 2004). 
This component has recently been targeted to be the potential candidate towards the 
development of novel therapeutic agent (Rodriguez-Cerrato et al., 2007). 
 
1.2.3. Capsular Polysaccharide 
S. pneumoniae is encapsulated by a distinctive layer of CPS which gives the 
typical smooth and glistening appearance of pneumococcal colonies on solid agar 
medium known as the “S” cells. The nonencapsulated variants, either due to a lack of 
capsule expression or as a result of loss of capsule after prolonged growth on artificial 
medium have a rough appearance termed the “R” cells (Figure 1.2). The 
oligosaccharides of capsule are synthesized inside the cytoplasm and the polymerized 
components will be transported and resides on the outermost layer of cell via covalent 
attachment to the extracellular surface of cell wall C-polysaccharide and peptidoglycan 
(Sorensen et al., 1990).  
CPS produced by the individual strains of pneumococci differs in their chemical 
compositions which give rise to the classification of serogroups/serotypes based on the 
antigenic differences immunologically. Serotyping has been conventionally performed 
using the antisera agglutination method (Quellung reaction). Antigenically-related 
serotypes (e.g. 9N, 9L, and 9V) are grouped into serogroups while serotypes with no 
antigenic relatedness are numerically assigned (e.g. 1, 2, 3, and 4). In year 2006, the 
DNA sequences of capsular biosynthesis genes for all 90 pneumococcal serotypes have 
been determined (Bentley et al., 2006). The capsular loci are being organized in such a 
way that genes corresponding to specific serotypes are flanked upstream by dexB and 
downstream by aliA conserved genes. These regions are specific to the respective 
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serotype/serogroups. Recently, the newer PCR-based multiplex serotyping method has 
become increasingly common (Njanpop Lafourcade et al., 2010; Pai et al., 2006).  
Although phenotypic variations are readily observed for different strains of S. 
pneumoniae, certain serotypes such as the extensively mucoidal serotype 3 colonies 
appear more distinctive than the other serotypes. CPS represents one of the major 
virulence determinants in S. pneumoniae and can be viewed as a near perfect shield to 
the bacteria (Austrian, 1981; Henrichsen, 1995). The pneumococcal CPS is usually 200 
- 400 nm in thickness and the expression of CPS is indispensable for pneumococcal 
virulence and serves important roles during the processes of cell adherence and invasion 
(Briles et al., 1992; Kelly et al., 1994; Sandgren et al., 2005). Highly virulent strains 
tend to produce thicker capsule as compared to the less virulent strains (Mac & Kraus, 
Figure 1.2: Microscopic view of S. pneumoniae and the appearance of pneumococcal 
colonies on solid agar medium. Images on the left shows the encapsulated “S” type 
cells surrounded by capsule (top) and the smooth and glistening appearance of 
colonies on agar medium (bottom). Image on the right shows the “R” cells lacking 
capsule (top) and the rough appearance of colonies (adapted from Austrian, 1953). 
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1950). In addition, sterile site isolates are usually encapsulated and much more virulent 
than the nonencapsulated variants. 
Blood-borne pneumococci are extensively cleared by the macrophages which 
reside in the marginal zone of the spleen (Kang et al., 2004). This process is mediated 
by the SIGN-R1 receptor which is a C-type lectin present on the macrophage. Absence 
of SIGN-R1 receptor significantly increases the hypersensitivity of mice against 
challenge by pneumococci (Kang et al., 2004; Lanoue et al., 2004). Pneumococcus 
expressing CPS is also strongly antiphagocytic (Cross, 1990). The electrostatic 
repulsions between the highly charged polysaccharide and the phagocytes interrupts 
with phagocytes binding (Lee et al., 1991). Also, the capsular layer helps prevent the 
pneumococci from neutrophil killing by minimizing the neutrophil extracellular 
trapping effects (Wartha et al., 2007). The presence of CPS also reduces the 
accessibility of complement components on cell surface and thus prevent complement 
fixation (Abeyta et al., 2003). It was observed that CPS merely “buried” the 
complement component iC3b or the Fc region of IgG into deeper surfaces hence 
preventing the activation of the corresponding receptors on phagocytic cells (Musher, 
1992; Winkelstein, 1981). Additionally, CPS enhances the antibiotic tolerability of S. 
pneumoniae by reducing spontaneous or antibiotic-induced cell autolysis (Fernebro et 
al., 2004). However, the nonencapsulated strains are still able to cause superficial 
infections such as conjunctivitis (Crum et al., 2004; Martin et al., 2003).  
 
1.2.4. Pneumococcal colonization 
Upper airway colonization by S. pneumoniae is common and poses no harm to 
humans. However, colonization represents an important intermediary platform for the 
horizontal spread of bacteria and marks the initial adherence of pneumococci to the 
respiratory tract epithelial. It is considered the crucial step preceding further invasion 
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into deeper tissues leading to severe infections (Di Guilmi & Dessen, 2002; Weiser et 
al., 1996).  
The prevalence of pneumococcal carriage is influenced by several factors 
including antibiotic usage, day care center attendance, and crowding (Bakir et al., 2001; 
Bogaert et al., 2004b; Cohen et al., 2006; Rivera-Olivero et al., 2007). NP carriage in 
children is particularly important as the major reservoir and the source of horizontal 
disease transmissions among the close contact community members including parents, 
siblings, and nursery centers (Givon-Lavi et al., 2002; Hussain et al., 2005). NP 
colonization is more commonly seen in younger children as compared to other age 
groups. It begins as early as in newborns and one or more strains can be acquired 
simultaneously or sequentially over time. Subsequently, the rate of colonization 
increases and reaches a peak of approximately 55% at the age of three followed by a 
gradual fall thereafter (Bogaert et al., 2004a; Bogaert et al., 2004b). For example, the 
highest carriage rate had been determined among pre-school children in Malaysia and 
the prevalence decreased in school-age children (Le et al., 2012). In the developing 
world, pneumococcal carriage can reach up to 95% in children < 3 years old and 
approximately 40% among the adults (Austrian, 1986b; Lloyd-Evans et al., 1996). 
Acquisition of S. pneumoniae begins from as young as ≤24 months old (Le et al., 2012). 
 
1.2.5. Pneumococcal infections 
For decades, S. pneumoniae has been recognized as one of the major human 
bacterial pathogen responsible for serious invasive pneumococcal infections such as 
meningitis, sepsis, and pneumonia (Bryce et al., 2005; Gillespie, 1989; Musher, 1992; 
O'Brien et al., 2009; van der Poll & Opal, 2009). Invasive pneumococcal disease (IPD) 
is defined as the isolation of S. pneumoniae from a normally sterile body site/fluid. 
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Those at the extreme ages are especially at greater risk of pneumococcal infections 
(Rohani et al., 2011).  
Pneumococcal diseases have been the leading cause of vaccine-preventable deaths 
(VPDs) among children aged five and below (MMWR Morb Mortal Wkly Rep, 2006) 
(Figure 1.3). According to World Health Organization (WHO), 0.7 – 1 million deaths 
out of the 1.6 million total deaths due to pneumococcal diseases were children aged less 
than five (World Health Organization, 2007). Children from developing countries are 
the most heavily  impacted group by pneumococcal diseases (Scott, 2008). S. 
pneumoniae represents the leading etiological agent causing acute bacterial respiratory 
infection (ARI) deaths and nonepidemic meningitis in children in developing countries 
(Mulholland, 1999; Peltola, 2001). In Malaysia, respiratory system infections 
Figure 1.3: Percentage of VPDs according to disease among children < 5 years old in 
year 2002 (adapted from MMWR Morb Mortal Wkly Rep, 2006). 
t
Diphtheria, hepatitis B, Japanese encephalitis, meningococcal disease, poliomyelitis, 
and yellow fever. 
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particularly pneumonia represent the commonest pneumococcal diseases (Le et al., 
2012). Moreover, S. pneumoniae is the major etiological agent causing pneumonia and 
meningitis (Le et al., 2012). Several factors including age of patients (children and 
elderly adults), severity of illnesses, and underlying disease-causing 
immnocompromised conditions including human immunodeficiency virus (HIV) 
infected individuals have the highest mortality rates among the pneumonia and 
meningitis patients (Klugman et al., 2007; Yu et al., 2003). 
 Community-acquired pneumonia (CAP) is a common but potentially life 
threatening infection. Although the majority of the cases are treated as outpatients, 
younger children and elderly often require hospitalization due to the severity of the 
condition of patients (Ho et al., 2009). Among all other bacterial pathogens, S. 
pneumoniae represents the leading cause of CAP and the proportion could reached to as 
high as 50% (Andrews et al., 2003). However, the prevalence of S. pneumoniae in CAP 
appears to vary greatly by countries. In a study involving 127 hospitalized patients 
presented with CAP in Malaysia, S. pneumoniae was still ranked the second most 
common CAP pathogen after K. pneumoniae although it was responsible for only 5.5% 
of the cases (Liam et al., 2001). Moreover, S. pneumoniae had an incidence rate of 
75.4/100,000 patients among the Malaysia population irrespective of age of patients and 
included both invasive and noninvasive isolates (Rohani et al., 1999b).  
Pneumococcal pneumonia can occur as a result of pneumococcal invasion into the 
lower respiratory tract and rapid inflammatory responses ensue immediately leading to 
acute respiratory tract infection. It had been documented that HIV-1 infection would 
increase the risk of pneumococcal pneumonia (Valles et al., 2006). In general, two 
forms of bacterial pneumonia exist: bronchial pneumonia and lobar pneumonia. 
Bronchial pneumonia is caused by a variety of respiratory pathogens including S. 
pneumoniae. It involves the infection of alveoli to the bronchioles of the bronchial tree. 
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This usually affects infants, children, and older aged adults. Most often S. pneumoniae 
causes the typical lobar type pneumonia. Other pneumonic patterns such as lobar 
bronchopneumonia, interstitial, or mixed pneumonia can also be formed (Kantor, 1981; 
Ort et al., 1983). Lobar pneumonia usually involves a single lobe of the lung but 
sometime multiple lobes can be simultaneously infected. The infected area will appear 
as a consolidated mass. Younger adults are more prone to this type of pneumonia. 
Pneumococcal pneumonia often leads to secondary bacteremia (bacteraemic 
pneumococcal pneumonia) which poses greater risks of mortality and morbidity to the 
patients. In year 2006, S. pneumoniae alone caused about 41,400 IPD cases which 
resulted in 5,000 deaths in the United States, with the majority of them having attributed 
to bacteremic pneumonia (Centers for Disese Control and Prevention, 2008). 
Bacteremia can also occur as a result of direct pneumococcal invasion from the initial 
sites of colonization into the bloodstream. However, this is relatively uncommon. It is 
estimated that approximately 20 – 25% of pneumococcal pneumonia is associated with 
bacteremia (Austrian, 1986a; Mufson, 1981), and the mortality rate could reach up to 20% 
among the infected patients (Balakrishnan et al., 2000; Lim et al., 2001).  
Meningitis can be caused by multiple etiological microorganisms. However, 
bacterial meningitis due to S. pneumoniae could result in the higher mortality rate than 
others. As estimated by WHO‟s global Burden of Disease project, approximately 
100,000 cases of pneumococcal meningitis were reported among children < 5 years of 
age worldwide and the case fatality rate was more than 50% (O'Brien et al., 2009). In 
Egypt, S. pneumoniae has been a significant pathogen in bacterial meningitis with high 
mortality rates especially among those < 1 year old (Girgis et al., 1993; Guirguis et al., 
1990; Miner & Edman, 1978). Patients recovered from pneumococcal meningitis are 
also likely to have permanent neurological sequelae (Gouveia et al., 2011). 
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S. pneumoniae frequently causes some milder manifestations of mucosal 
infections such as otitis media and sinusitis. Nevertheless, pneumococcal-related 
arthritis, peritonitis, and pericarditis are relatively rare. Although pneumococcus is not a 
typical agent in urinary tract infection and report of such cases are extremely rare, 
sporadic cases of pneumococcosuria have been reported in newborns, children and adult 
patients (Burckhardt & Zimmermann, 2011; Miller et al., 1989; Nguyen & Penn, 1988). 
The pathogenicity and disease-causing ability of S. pneumoniae have been 
suggested to be linked to the genetic background of the pneumococcal strains (Blue & 
Mitchell, 2003; Kelly et al., 1994; Sandgren et al., 2005). Fortunately, none of the 
pneumococcal disease state promote pneumococcal transmission, hence suggesting that 
the virulence of S. pneumoniae is directed mainly towards adaptation and establishment 
of infection which is confined to the primary host rather than being highly contagious 
(Kadioglu et al., 2008). However, dissemination of the pathogen can occur through 
direct contact with respiratory secretions from infected person (van der Poll & Opal, 
2009).  
 
1.3. Pneumococcal serotype distribution 
1.3.1. Pneumococcal vaccinations 
Up to date, 93 pneumococcal serotypes have been documented with the latest 
addition of serotype 11E (Calix & Nahm, 2010) , 6D (Jin et al., 2009) , and 6C (Park et 
al., 2007). Current preventive strategy against pneumococcal infections relies primarily 
on the stimulation of serotype-specific immune protection via vaccination. The 23-
valent pneumococcal polysaccharide vaccine (PPV23, Pneumovax) is the first 
pneumococcal vaccine introduced which covers as much as 23 pneumococcal serotypes 
(1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F,18C, 19F, 19A, 20, 22F, 
23F, and 33F). However, the efficiency of PPV23 vaccination is relatively poor in 
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children < 2 years of age and in immunosuppressed individual (Overweg et al., 2000). 
The primary PPV23 target group are the adults (Moberley et al., 2008; Ogilvie et al., 
2009; Shapiro et al., 1991; Temple et al., 1991). Although the effectiveness of PPV23 
among the elderly is rather debatable, a prospective cohort study involving all 11,241 
community-dwelling elderly ≥ 65 years old in Spain studied from January 2002 through 
April 2005 provided strong arguments for the systematic vaccination of the elderly 
(Vila-Corcoles et al., 2006). The major outcomes from the study clearly stated that 
PPV23 essentially prevented pneumococcal pneumonia (with or without bacteremia), 
reduced the overall rates of pneumonia and the associated mortality although the 
protective effect against IPD were not statistically significant. 
The 7-valent pneumococcal conjugate vaccine (PCV7, Prevnar) comprises of 
serotype 4, 6B, 9V, 14, 18C, 19F, and 23F. It is formulated by conjugating the serotype 
antigen to the nontoxic diphtheria proteins CRM197 which elicits strong immune 
responses in infants and younger children < 2 years of age. PCV7 is also recommended 
for children < 5 years old who are at higher risks of invasive pneumococcal infections 
including those with immunocompromised conditions like HIV infection, diabetes 
mellitus, sickle cell diseases, and chronic heart and lung diseases (American Academy 
of Pediatrics, 2000; MMWR Recommendations and Reports, 2000). In mid 2000, this 
vaccine was being incorporated as part of the childhood vaccination program in the 
United States (American Academy of Pediatrics, 2000; MMWR Recommendations and 
Reports, 2000). This was later followed by several other countries including United 
Kingdom (Cameron & Pebody, 2006; 2006), Netherlands (Netherlands, 2005), and 
Norway (Bergsaker & Feiring, 2006). Later, newer formulations with the addition of 
serotype 1, 5, and 7F over PCV7 vaccine in the 10-valent pneumococcal conjugate 
vaccine (PCV10, Synflorix, GlaxoSmithKline) and the 13-valent pneumococcal 
conjugate vaccine (PCV13, Prevnar 13, Pfizer) with further incorporation of serotypes 3, 
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6A, and 19A over PCV10 vaccine are currently available. Recently, several countries 
have replaced PCV7 with the newer PCV13 vaccine to provide wider coverage against 
the six additional vaccine-serotypes (VTs). With the increasing number of VTs covered 
in the PCVs, further reduction in the reports of IPD cases is anticipated (Flasche et al., 
2011). Up to year 2010, PCVs had been introduced in a total of 55 countries (MMWR 
Morb Mortal Wkly Rep, 2011). 
The effectiveness of PCV7 vaccine against the respective VTs varied from 100% 
(serotype 9V) and 98% (serotype 23F) to 87% (serotype 19F) (Whitney et al., 2006). 
Apart from that, the efficacies of PCV7 vaccine are influenced by several factors such 
as doses of vaccine received, age of recipient at the point of vaccination, population 
coverage of vaccine, and geographical variations of serotype distribution (Hausdorff et 
al., 2005; Imohl et al., 2010b; Whitney et al., 2006). Interestingly, it was found that the 
level of antibiotic exposure will affect the efficacy of PCV7 vaccine whereby high 
PCV7 efficacy was achieved in the US which has low antibiotic exposure environment 
while the opposite was observed in France which has a relatively high antibiotic 
exposure environment (Cherry & Woodwell, 2002; Geslin et al., 1998; Guillemot et al., 
1998; Karlowsky et al., 2003; Perrocheau et al., 2002; Schuchat et al., 1997; Temime et 
al., 2005). These studies showed that antibiotic exposure level could have unexpected 
impact on the efficacy of PCV7 vaccine. On the other hand, it was suggested that the 
antibiotic selective pressures due to the use of antibiotics could affect the pneumococcal 
serotype distribution (Moore, 2009; Moore & Whitney, 2008). However, such impact 
should be minimal (Weinberger et al., 2011). 
 
1.3.2. Pre- and Postvaccination changes in serotype distribution 
A number of serotypes including serotype 19F, 23F, and 19A are in general the 
most prevalent serotypes reported elsewhere (Arredondo-Garcia et al., 2011; Bae & Lee, 
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2009; Le et al., 2011b; Soh et al., 2000). Following the routine use of PCV7 vaccine, 
drastic reduction in the incidences of VTs have been widely documented as in the US 
(Farrell et al., 2007; Grijalva et al., 2007; Kaplan et al., 2004; 2010), Norway 
(Vestrheim et al., 2008), Germany (Ruckinger et al., 2009), France (Dubos et al., 2007; 
Lepoutre et al., 2008), Canada (Kellner et al., 2009), and Australia (Roche et al., 2008). 
The reduced horizontal transmission of VTs from the primary PCV7-vaccinated group 
would have indirectly benefited the nonvaccinated children and adults in the 
populations (Lexau et al., 2005; MMWR Morb Mortal Wkly Rep, 2005). This 
phenomenon is called herd immunity (Hicks et al., 2007; Pilishvili et al., 2010a). 
Notably, the indirect benefits from PCV7 vaccination have marked the reduction in the 
prevalence of antibiotic-resistant pneumococci (Dagan & Klugman, 2008; Joloba et al., 
2001; Kyaw et al., 2006; Stephens et al., 2005), the multidrug resistant pneumococci 
(Dias & Canica, 2007), and the incidences of IPD (Kaplan et al., 2004; Whitney et al., 
2003) .  
The major issue arising following the widespread use of PCV7 vaccine has been 
the “serotype replacement” whereby the protective coverage conferred by PCV7 against 
VTs has gradually been diminished by the concomitant rise in the proportions of 
nonvaccine serotypes (NVTs) (Lipsitch, 1999; Spratt & Greenwood, 2000). Selective 
pressure from PCV7 vaccine would have eliminated the VTs (Kaplan et al., 2004; 
Messina et al., 2007), however, the open niches created might attract the expansion of 
NVTs which possess survival advantage in the microflora to fill up the empty sites 
(Weinberger et al., 2011). Moreover, due to the competent nature of S. pneumoniae, 
transformation at the intra- or inter-species level can lead to genetic recombination of 
CPS genes via horizontal genetic material transfer (Coffey et al., 1995b). The recipient 
cells may then undergo capsular switching leading to subtle change from one serotype 
to another (Silva et al., 2006). Transformation of VTs to NVTs would allow the 
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pneumococcal strains to escape the selective pressure by PCVs and enhance the survival 
fitness of the strains. A large number of studies have found in common the emergence 
of serotype 19A as well as serotypes 3, 15, 22F, and 33F following the introduction of 
PCV7 vaccine (Farrell et al., 2007; Mera et al., 2008; Messina et al., 2007; Pelton et al., 
2007; Pichichero & Casey, 2007; Richter et al., 2009; Techasaensiri et al., 2010). Most 
of these studies have also highlighted the increased findings of NVT-associated 
antibiotic resistance pneumococci. In fact, groups with immunodeficiency or conditions 
that predispose them to higher risks of pneumococcal infections were found to have 
higher tendency of pneumococcal diseases due to replaced-serotypes (Pilishvili et al., 
2010b). Serotype replacement had also been reported for the carriage serotypes among 
younger children in the US (Huang et al., 2009). Despite all these, in depth analysis by 
Weinberger and Whitney strongly suggested that the postvaccination emergence of 
NVTs did not occur merely by chance and certainly PCV7 vaccination accelerated the 
rapid increment in NVTs (Weinberger et al., 2011). However, it should be noted that 
changes in the seroepidemiology can occur as a result of natural background fluctuation 
(Normark et al., 2001). For instance, temporal fluctuation in serotype 1 had been 
reported in two studies (Fenoll et al., 2009; Harboe et al., 2010) and increase in 
serotype 19A had also been reported among the nonvaccinated populations (Choi et al., 
2008; Dagan et al., 2009).  
Furthermore, PCVs are serotype-specific and the primary strategy in designing 
newer PCVs focus primarily on increasing the number of serotypes antigen. However, 
this is also the main shortcoming due to the low number of serotypes being included 
over the total number of pneumococcal serotypes. There are still unidentified serotypes 
which indicate that many uncommon and minor serotypes are yet to be discovered. 
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1.3.3. Serotype-specific pneumococcal virulence 
The virulence of S. pneumoniae is relatively serotype-specific (Austrian, 1981). A 
study using mice infected with different serotypes/groups of pneumococci demonstrated 
the distinctive disease-causing ability of S. pneumoniae whereby serotype 4 was found 
to be highly virulent (100%) followed by serogroup 6 (60%) and serotype 3 (40%) 
(Briles et al., 1992). In contrast, serogroups 14, 19, and 23 were avirulent. Besides this, 
the virulence of pneumococci also differs with regards to the routes of challenge. As 
shown by Briles et al., the selected strains of pneumococci were lethal (one serotype 1 
and one serotype 6B) when injected via the intraperitoneal (IP) route but failed to infect 
the mice when given intravenously (IV) (Briles et al., 1992). In humans, serotypes 9 and 
14 are frequently associated with IPD while serotypes 6A and 23F are associated with 
carriage (Zemlickova et al., 2010). In addition, serotype 1 comprises > 6% of IPD cases 
in various regions of the world (Hausdorff et al., 2000). Notably, serotype 1 has 
frequently been associated with disease outbreaks (Gupta et al., 2008; Le Hello et al., 
2010; Leimkugel et al., 2005; Proulx et al., 2002; Yaro et al., 2006). Serotype 1 disease 
outbreaks can also occur in overcrowded places and/or alcoholism has been an issue 
(Dagan et al., 2000; DeMaria et al., 1980; Gratten et al., 1993; Mercat et al., 1991). 
Apart from that, a Spanish study conducted by Valles and colleagues had highlighted 
the frequent association of serotype 1 in pneumococcal CAP (Valles et al., 2006). The 
relative risk of IPD death associated with serotype 1 is low in contrast to serotype 3 
which has very high relative risk of death (Martens et al., 2004). Serotype 2 has been 
highly associated with childhood meningitis among the children in Bangladesh (Saha et 
al., 2012). On top of serotype 2, Bangladesh has a number of relatively uncommon 
serotypes among other countries including serotype 1, 12F/A, 5, and 45 which are not 
part of the PCV13 vaccine formulation. Besides, serotypes including 1, 5, 7F, and 9V 
have high tendency in causing childhood pneumonia (Greenberg et al., 2011). 
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1.4. Antibiotic-resistant Streptococcus pneumoniae 
Antibiotic susceptibility profiling of bacterial pathogens constitutes the routine 
practice in most diagnostic laboratories of major hospitals. Such information is essential 
to help the clinical practitioners to decide upon the best choice of empirical treatment 
for patients and for continuous monitoring of temporal fluctuation in antibiotic 
resistance of various human bacterial pathogens present in the region. Choices of 
antibiotics differ by regions and are frequently influenced by the patterns of antibiotic 
resistance in the respective regions. Escalating incidences of antibiotic-resistant S. 
pneumoniae have been reported throughout the world (Adam, 2002; Jacobs et al., 2008; 
Reinert, 2009). Of concern, the emergence of antibiotic-resistance especially the 
multidrug resistant (MDR) S. pneumoniae has complicated the disease burden of 
pneumococcal infections (Lynch & Zhanel, 2009). Treatment failure is associated with 
increased healthcare financial burden and the risks of morbidity and mortality (Garcia-
Vidal & Carratala, 2009; Menendez & Torres, 2007; Menendez et al., 2004; Roson et 
al., 2004). The course of treatment and patients management have to be modified 
depending on the antibiotic susceptibility of the strain isolated, current trend in 
antibiotic susceptibility as reported from case studies and surveillance data, as well as 
recommendations from the advisory committee of the respective country. Adherence to 
antibiotic guidelines implemented by the local authorities would be important to prevent 
discordant therapy (Garcia-Vidal & Carratala, 2009). 
Even though many antibiotics are currently available, ß-lactam antibiotics 
including penicillin, cephalosporins, and carbapenems remain as the preferred choice of 
antibiotics against pneumococcal infections (Yu et al., 2003). In the case of preliminary 
failure of ß-lactam antibiotics, other major antibiotic classes including macrolides, 
vancomycin, and fluoroquinolones can be considered as the alternative options 
(Mandell et al., 2007). Increasing antibiotic resistance especially with S. pneumoniae 
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has been a major concern as ineffective therapy would delay disease resolution and 
dramatically increase the risks of complication and death (Mandell et al., 2007).      
The treatment outcomes could sometimes be relatively inconsistent with the in 
vitro antibiotic susceptibility profiles of the pneumococcal strains isolated from patient 
(Feikin et al., 2000; Metlay et al., 2000). A multicenter study conducted by Cardoso et 
al. had observed no significant association between treatment failures and the level of 
antibiotic resistances of pneumococci isolated from children with severe pneumonia  
(Cardoso et al., 2008). In addition, the treatment outcomes might also be complicated 
by other factors such as co-infection by other pathogens or presence of underlying 
conditions which predispose one to pneumococcal infections. Furthermore, the site of 
infection and the treatment prescribed do affect the treatment outcome. (Ahronheim et 
al., 1979; Gartner & Michaels, 1979; Mace et al., 1977). 
There are many factors contributing to the widespread antibiotic resistance in S. 
pneumoniae. Generally, the bacteria begins to counteract and develop resistance under 
environment of strong antibiotic selective pressure especially in hospital and large scale 
usage of antibiotics in agricultural, veterinary, poultry and animal husbandry feeds for 
infection preventions and as growth promoters (Davies, 1994). Major outbreaks due to 
antibiotic resistant S. pneumoniae have been documented (Gupta et al., 2008; 
Leimkugel et al., 2005; Lynch & Zhanel, 2009; Proulx et al., 2002; Yaro et al., 2006). 
Of utmost concern is the reports of MDR S. pneumoniae which was first reported in 
Johannesburg in 1977 (Jacobs et al., 1978). MDR pneumococci were found to be highly 
prevalent in Asia (36.3%) as compared to other regions (approximately 5%) (Jones et 
al., 2003). 
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1.4.1. β-lactam resistance 
Before the availability of effective antimicrobial therapy, the mortality rate in 
patients with pneumococcal diseases could reach up to 80%. The discovery of ß-lactam 
antibiotics particularly penicillin had greatly reduced the morbidity and mortality 
associated with pneumococcal infections. Since then, penicillin has become the drug of 
choice in empirical therapy of pneumococcal infections (Appelbaum, 1996; Klugman, 
1990). Combination therapy with both penicillin and macrolide is sometimes chosen 
especially when the patient is in critical pneumococcal bacteremic condition (Baddour 
et al., 2004).    
PBPs are produced by many gram-positive and gram-negative bacteria including 
S. pneumoniae as cytoplasmic or membrane-bound proteins. The enzymes catalyze the 
polymerization and cross-linking of peptidoglycan precursors in bacterial cell wall 
biosynthesis (Navarre & Schneewind, 1999). S. pneumoniae produces a total of six 
PBPs which are grouped based on their molecular weight: The bifunctional high 
molecular weight class A PBPs – PBP1A, 1B, and 2A are responsible for 
transglycosylase and transpeptidase activities; the high molecular weight class B PBPs – 
PBP2B and 2X function as transpeptidases; and the low molecular weight PBP3 serves 
as DD-carboxypeptidases. PBPs contain essentially three conserved motifs: Ser-X-X-
Lys (SXXK), Ser-X-Asn (SXN), and Lys-Thr/Ser-Gly (KT/SG) motifs (Hakenbeck, 
1998).  
ß-lactam antibiotics act by acylation of serine residue at the active site of PBPs 
forming a covalent penicilloyl complex which in turn inactivates the PBPs leading to 
inhibition of transpeptidase and DD-carboxypeptidase activities (Ghuysen, 1991; 
Ghuysen & Dive, 1994). Expressions of altered forms of PBPs with reduced affinity 
against ß-lactam antibiotics can be attributed to mosaic genes that arose from 
interspecies recombination events (Dowson et al., 1994; Hakenbeck et al., 1980; 
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Zighelboim & Tomasz, 1980). Such mosaic pbp genes possess both regions of high 
sequences homology to the susceptible strains and regions with diverge nucleotide 
sequences (Andreu & Rivas, 1998; Coffey et al., 1995b; Dowson et al., 1989; Laible et 
al., 1991; Martin et al., 1992). It had been suggested that antibiotic pressure can lead to 
genetic rearrangement in S. pneumoniae which causes amino acids alterations and 
reduced the PBPs affinities toward ß-lactam antibiotics (Sanbongi et al., 2004).  
Different PBPs subtypes are associated with resistance against different ß-lactam 
antibiotics. Pneumococcal resistance against ß-lactam antibiotics is frequently 
associated with mutations in PBP1A, PBP2B, and PBP2X (Asahi et al., 1999; Barcus et 
al., 1995; Dowson et al., 1994; Hakenbeck, 1998; Sanbongi et al., 2004). Collectively, 
these three PBPs confer high level of penicillin-resistance to S. pneumoniae (Barcus et 
al., 1995). In addition, PBP2B is responsible for penicillin and carbapenem resistances 
whilst cephalosporin resistance is largely encoded by PBP2X (Sanbongi et al., 2004). 
As shown by Palanisamy et al., all penicillin-susceptible S. pneumoniae (PSSP) isolates 
in the study were found to have unaltered pbp2b gene while the penicillin-intermediate 
S. pneumoniae (PISP) and penicillin-resistant S. pneumoniae (PRSP) isolates possessed 
altered PBP2B gene which contributed to the penicillin resistance (Palanisamy et al., 
2008). Notably, PBP1A further enhances the antibiotic resistance in strains with 
mutations in PBP 2B or PBP2X and mutations of PBP1A and PBP2X are required for 
high level resistance against the third generation cephalosporins (Coffey et al., 1995a). 
It was also noticed that PISP and PSSP strains tend to have higher resistance to other β-
lactam antibiotics such as cephalosporins while strains susceptible to penicillin were 
likely to be susceptible to other classes of antibiotic (Palanisamy et al., 2008). Notably, 
the unique PBP2B restriction fragment length polymorphism (RFLP) pattern observed 
in pneumococcal isolates with reduced penicillin susceptibility was suggested to be 
correlated to the resistance level (Desa et al., 2005). In addition, pneumococcal isolates 
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exhibiting elevated macrolide-resistance similarly displayed unique RFLP patterns 
(Desa et al., 2005).  
Beside PBPs as the principal resistance mechanism, involvement of non-PBP 
components has also been documented. This includes the putative glycosyltransferase A 
(CpoA) and histidine protein kinase (CiaH) which confer low level β-lactam resistance 
(Grebe et al., 1997; Guenzi et al., 1994; Hakenbeck et al., 1999). It was proposed that 
these non-PBP genes might have significant metabolic role in cell wall components 
biosynthesis prior to the enzymatic reactions by PBPs (Hakenbeck et al., 1999). In 
contrast, the murMN genes also influence the susceptibility of pneumococci against β-
lactam antibiotics. These two genes display mosaicsm similar to PBPs (Hakenbeck, 
1998; Hakenbeck et al., 2001). The MurM enzyme is responsible for the biosynthesis of 
branched-stem muropeptides in the cell wall of S. pneumoniae. Mutation in MurM 
enzyme is crucial for high level penicillin and cefotaxime resistance in S. pneumoniae 
(Smith & Klugman, 2001). The number of murM alleles has been linked to the degree 
of muropeptides branching in the cell wall. The extensively branched muropeptides thus 
altered the cell wall structure and reduced the antibiotic affinity to the pneumococcus 
(Smith & Klugman, 2001). A recent study had also noticed that the additional murM 
allele could be the reason for the resistant strain exhibiting lower susceptibility to 
penicillin (Palanisamy et al., 2009). In addition, the resistant strain was found to have 
ethanolamine incorporated in the cell wall (Palanisamy et al., 2009). On the other hand, 
more recently a putative iron permease (spr1178) had also been discovered using the 
whole genome sequencing approach (Fani et al., 2011). 
Rapid emergence of antibiotic resistance has compromised β-lactam antibiotics as 
the preferred antimicrobial agents against pneumococcal diseases in the future (Jacobs, 
2003; Jones, 1999). Penicillin-nonsusceptible S. pneumoniae (PNSP) has become 
increasingly common ever since the first report of penicillin-intermediate S. 
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pneumoniae (PISP) strain in Australia in 1967 (Hansman & Bullen, 1967). The 
distribution of PNSP has been related to geographical variations (Lynch & Zhanel, 
2009). Epidemiological data revealed that rate of PNSP was especially high and could 
reach up to 50% in Asia (Lynch & Zhanel, 2009) and in two European countries, France 
and Spain (Adam, 2002; Lynch & Zhanel, 2009; Reinert et al., 2005a). Continued 
expansion of PNSP strains have been documented (Le et al., 2012). On the contrary, the 
figures were comparatively low in Germany, Sweden, and Finland (Lynch & Zhanel, 
2009). Of major concern is the documentation of PRSP. Indeed, isolates with very-high-
level penicillin resistance (> 8 μg/ml) had first been reported in 1995 in the US and the 
rate has been escalating ever since (Schrag et al., 2004). These strains also displayed 
resistance against at least three other antibiotic classes and patients of extreme ages (< 5 
and > 65 years old) were at higher risks of infection by these strains (Schrag et al., 
2004). Following reports of treatment failures in pneumococcal meningitis involving the 
PRSP strains, the American Academy of Pediatrics and Infectious Diseases Society has 
recommended the use of third generation cephalosporin to replace penicillin as 
pharmacokinetic evidences have showed that the concentration of penicillin presence in 
the central nervous system is inadequate against the PRSP strains (American Academy 
of Pediatrics Committee on Infectious Diseases, 1997; Begg et al., 1999; Kaplan & 
Mason, 1998). The high fatality rate associated with PRSP-related meningitis remains a 
major concern and newer findings have suggested the use of third generation 
cephalosporin even at low prevalence of penicillin-resistant pneumococci (Gouveia et 
al., 2011). 
In January 2008, the Clinical and Laboratory Standards Institute (CLSI) 
introduced major revisions in the interpretation of antibiotic susceptibility for S. 
pneumoniae. The penicillin susceptibility breakpoints for nonmeningitis infections 
(susceptible ≤ 2 μg/ml; intermediate 4 μg/ml; and resistant ≥ 8 μg/ml) had been revised  
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while breakpoints were unchanged (susceptible ≤ 0.06 μg/ml; intermediate 0.12 - 1 
μg/ml; and resistant ≥ 2 μg/ml) for oral penicillin (Clinical and Laboratory Standards 
Institute, 2008). CLSI also recommends that meningitis and nonmeningitis breakpoints 
should be reported for pneumococcal isolates obtained other than from the cerebrospinal 
(CSF) site. As expected, the proportion of nonmeningitis penicillin nonsusceptible 
isolates reduced considerably. In the US, data gathered from the Active Bacterial Core 
Surveillance which involved 10 sites for the year 2006 – 2007 revealed that the 
percentage of IPD nonmeningitis PISP and PRSP reduced from 15.0% and 10.3% to 5.6% 
and 1.2%, respectively (Centers for Disease & Prevention, 2008). This was 
accompanied with an increase from 74.7% to 93.2% for PSSP. In meningitis isolates, 
the reevaluation also categorized the PISP reported previously to be PRSP and thus 
contributed to the increased percentage of PRSP from 10.7% to 27.5% (Centers for 
Disease & Prevention, 2008). In addition, according to the previous breakpoints, 33.9% 
of the pneumococcal isolates reported by Rohani et al. were penicillin-resistant and the 
remaining 66.1% were penicillin-susceptible (Rohani et al., 2011). However, nearly all 
(99.2%) of the isolates were reclassified as penicillin-susceptible with only 0.84% were 
penicillin-intermediate according to the new breakpoints. Although the changes would 
be rather confusing among the clinicians, it is pertinent to note that pneumococcal 
isolates with reduced susceptibility to penicillin do not always result in treatment failure 
(Ho et al., 2009). 
Nevertheless, conflicting data have been reported with regards to the penicillin 
susceptibility of S. pneumoniae and treatment outcome. A number of oral 
cephalosporins such as cefaclor, cefixime, cephalothin, and ceftibuten have 
unsatisfactory effectiveness for infection involving the PRSP strains (Klugman, 2007). 
A study conducted by Yu et al. had determined that 9.6% of the blood cultured 
pneumococci among the 844 hospitalized patients were penicillin-resistant (minimum 
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inhibitory concentration, MIC ≥ 2 μg/ml) and 15% were penicillin-intermediate (Yu et 
al., 2003). However, penicillin resistance did not result in higher mortality rate. 
Moreover, discordant therapy (i.e. receipt of a single antibiotic with inactive in vitro 
activity against S .pneumoniae) with penicillins as well as cefotaxime and ceftriaxone 
was not associated with mortality. In contrast, cefuroxime-nonsusceptible S. 
pneumoniae caused increased mortality rates. Besides that, concordance of beta-lactam 
antibiotic treatment was not associated with time required for defervescence and 
frequency of suppurative complications (Yu et al., 2003). 
The association between penicillin susceptibility and serotypes had been 
frequently reported. In Germany, serotype 19A and 19F are the major serotypes 
associated with penicillin-resistance (Imohl et al., 2010c). On the other hand, serotypes 
23F, 19F, 6B, and 14 are associated with PNSP in Kuwait (Mokaddas et al., 2008) and 
Oman (Al-Yaqoubi & Elhag, 2011). Furthermore, the resistance pattern of strains from 
a particular population is more genetically related to the population from the same 
region. For instance, investigation on the altered pbp2b gene among the PNSP isolates 
from Thailand showed that the isolates were closely resemble those from other Asian 
countries such as Japan and Korea than the European isolates (Tribuddharat et al., 2010). 
 
1.4.2. Macrolide resistance 
Macrolide antibiotics are characterized by the presence of a large macrocyclic 
lactone ring. Also known as the macrolide rings, they are either  14-, 15-, or 16-
membered structure. This group of antibiotic includes erythromycin A, azithromycin, 
clarithromycin, and ketolides. Macrolides inhibit protein biosynthesis in bacteria via 
irreversible binding to the 50S ribosomal subunit which interrupts the 
peptidyltransferase activity leading to inhibition of peptidyl tRNA transpeptidation and 
translocation.  
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Pneumococcal macrolide resistance involves the target modification by ErmB 
pathway and the macrolide efflux pump Mef/Mel pathway (Ambrose et al., 2005; 
Leclercq & Courvalin, 2002; Sutcliffe et al., 1996). The ribosomal methylase ErmB 
encoded by erm(B) gene catalyzes the specific adenine dimethylation of 23S rRNA at 
position 2058 (A2058) (Leclercq & Courvalin, 2002; Weisblum, 1995). This confers 
high level macrolide-lincosamide-streptogramin B resistance to S. pneumoniae 
harboring ermB gene (MLSb phenotype) (Lambert, 2005). It was reported that 
macrolide-resistance was especially high among the European countries and high 
proportion (more than 80%) of erythrocymin-resistant strains was due to ermB-
mediated resistance (Reinert et al., 2005b). 
The second mechanism Mef/Mel membrane-bound efflux pump activity is rather 
specific for 14- and 15-membered macrolides such as erythromycin and its derivatives 
(e.g. azithromycin) but not clindamycin or streptogramins (Daly et al., 2004; Tait-
Kamradt et al., 1997). The aggregation of 12 transmembrane protein domains on the 
cell membrane produces active efflux machinery which is driven by proton motive force 
(Clancy et al., 1996). There are two Mef variants, mefA or mefE (Tait-Kamradt et al., 
1997). The prevalence of these variants differ by geographical distribution whereby 
mefE was more prevalent in Asia, US, and North and South America but mefA was the 
predominant efflux mechanism in Canada and parts of Europe (Amezaga et al., 2002; 
Daly et al., 2004; Hoban et al., 2001; Song et al., 2004a). Low level pneumococcal 
resistance against the 14- and 15-membered macrolides is due to MefA active efflux 
mechanism (Weisblum, 1995). High level erythromycin resistance is associated with the 
alteration of drug-binding sites encoded by ermB gene (Descheemaeker et al., 2000; 
Weisblum, 1995). In Malaysia, S. pneumoniae nonsusceptible to the macrolide 
antibiotic erythromycin were attributed to either ermB (59.7%) or mefE (35.5%) 
(Palanisamy et al., 2008). A previous study had also reported that pneumococcal 
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isolates with higher level of erythromycin resistance (MIC > 8 µg/ml) tend to possess 
ermB in standalone form or exist together with mefE (Desa et al., 2005).  
An increasing body of evidences have reported the potential risks of clinical 
failures even with pneumococci of low level macrolide-resistant (Daneman et al., 2006; 
File, 2006; Iannini et al., 2007; Lonks, 2004; Lonks et al., 2002) (Klugman, 2007). A 
prospective, population-based surveillance conducted between 2000 and 2004 involving 
1696 episodes of pneumococcal bacteremia in Canada reported that isolates with higher 
macrolide tolerability were associated with higher risk of macrolide failure but the risk 
of treatment failures did not increase further with erythromycin MIC of > 1 µg/ml 
(Daneman et al., 2006). Moreover, the study group also noticed that macrolide-resistant 
pneumococci were significantly more common in pneumococcal bacteremia cases after 
the failure of macrolide treatment as compared to those without prior antibiotic therapy 
or treatment using non-macrolide agents (Daneman et al., 2006). Similarly, a large 
series macrolide therapy failure had been documented from a retrospective, multicenter 
study involving 122 inpatient CAP patients due to S. pneumoniae whereby they 
observed increased macrolide resistance (> 60%) with inpatient mortality of 5.7% 
(Iannini et al., 2007). As high as six out of the seven patients who died were infected 
with macrolide-nonsusceptible strains (Iannini et al., 2007). Among 3,885 patients with 
chronic obstructive pulmonary disease, it was found that the likelihood of disease 
progression to CAP was significantly associated with S. pneumoniae and ineffective 
antibiotic therapy (File et al., 2009). PNSP also displays higher tendency to become 
resistant against other non-ß-lactam antibiotics as well (Lynch & Zhanel, 2009). In the 
US, it was reported that a high proportion of strains with penicillin resistance (34.2%) 
were determined to have accompanying erythromycin (31.9%) and trimethoprim-
sulfamethoxazole (29.5%) resistances (Doern et al., 2005). 
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The serotype-specific association of macrolide-resistance with invasive 
pneumococcal strains has also been documented. In Germany, serotype 14 was found to 
be highly macrolide-resistant (Imohl et al., 2010a). From the same study as well, 
children were most frequently affected by macrolide-resistant strains as compared to 
adults (Imohl et al., 2010a). In addition, 60% of the invasive serotype 14 isolates 
reported by Clarke et al. were erythromycin-resistant (MIC range 1 – 24 μg/ml) and of 
high clonal relatedness whereby 95% of these erythromycin-resistant serotype 14 
isolates belong to ST9 (PMEN England
14
-9 clone) (Clarke et al., 2004). Nevertheless, it 
was serotype 19F that was the most common macrolide-resistant strains in Lebanon 
(Taha et al., 2012). A recent study in Arizona had reported as high as 52% of the 
macrolide-resistant pneumococci were dual mefE/ermB-positive from the highly 
disseminated CC271 multidrug resistant clone carrying the transposon Tn2010 (Bowers 
et al., 2012). CC271 is a major multidrug lineage worldwide and constituted a 
significant portion of macrolide-resistant pneumococci reported in many countries 
especially Europe and Asia (Li et al., 2011; Reinert et al., 2008; Siira et al., 2009; Xu et 
al., 2010). 
 
1.4.3. Fluoroquinolones resistance 
Fluoroquinolones are derived from and have an additional fluorine atom attached 
to the central ring structure of the broad spectrum antibiotic quinolones. This class of 
antibiotics inhibits DNA replication by targeting the DNA gyrase and topoisomerase IV, 
both of type II DNA topoisomerases. DNA gyrase has two A and two B subunits which 
are encoded by gyrA and gyrB genes, respectively and is responsible for ATP-dependent 
negative supercoiling of DNA (Wang, 1985). Topoisomerase IV serves important roles 
in chromosomes partitioning during cell division (Luttinger, 1995). The ParC and ParE 
subunits are encoded by the closely-linked parC and parE genes, respectively. 
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Fluoroquinolones exhibit enhanced activity against gram-positive bacteria. 
Fluoroquinolones resistance in S. pneumoniae can be acquired through point mutation, 
intraspecies recombination, or interspecies recombination with S. mitis (Balsalobre et al., 
2003; Bast et al., 2001; Fenoll et al., 2000; Stanhope et al., 2005). The mechanism 
occurs in a sequential, stepwise manner and attributed mainly to specific mutations with 
gyrA or parC gene in the quinolone resistance-determining regions (QRDRs) (Gootz et 
al., 1996; Janoir et al., 1996; Munoz & De La Campa, 1996; Tankovic et al., 1996). 
First mutation in either parC or gyrA gene usually causes only low level resistance, 
however, subsequent second mutation in the other gene eventually lead to high level 
resistance (de la Campa et al., 2009; Janoir et al., 1996; Patel et al., 2010). For example, 
Pan et al. showed that S. pneumoniae with low level ciprofloxacin resistance had parC 
mutation but not gyrA whilst strain with high ciprofloxacin resistance had both parC 
and gyrA mutations (Pan et al., 1996). This preferred first targeting of either gene is 
termed primacy (Fisher & Heaton, 2003). Other fluoroquinolones with similar 
mechanisms of resistance in S. pneumoniae include trovafloxacin, norfloxacin, and 
levofloxacin (Fukuda & Hiramatsu, 1999). On the contrary, newer fluoroquinolones 
including gatifloxacin and sparfloxacin showed primacy against DNA gyrase (Fukuda 
& Hiramatsu, 1999; Pan & Fisher, 1997).  
Apart from that, the involvement of a putative reserpine-sensitive efflux 
mechanism encoded by the pmrA gene has been described which confers low-level 
fluoroquinolone resistance in S. pneumoniae as compared to topo IV and gyrase 
mutations (Baranova & Neyfakh, 1997; Brenwald et al., 1997, 1998; Zeller et al., 1997). 
However, the expression of pmrA alone could not explain the reduced ciprofloxacin 
susceptibility (Palanisamy et al., 2007; Piddock et al., 2002). The pmrA efflux pump 
was suggested to be rather specific to the older fluoroquinolones such as norfloxacin but 
not the newer fluoroquinolones such as ciprofloxacin, gatifloxacin, levofloxacin, and 
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others. Other efflux mechanisms could have involved simultaneously to produce the 
resistant phenotype (Palanisamy et al., 2007).               
Following the escalating incidences of MDR S. pneumoniae particularly against 
the empirical antibiotics β-lactam and macrolides, fluoroquinolones such as 
levofloxacin, moxifloxacin, and gatifloxacin represent the alternative agents of choice in 
treatment of pneumococcal infections (Bartlett et al., 1998; Mandell et al., 2003). 
Unfortunately, strong antibiotic selective pressures after years of widespread 
fluoroquinolone usage have eventually lead to expansion of fluoroquinolone-resistant S. 
pneumoniae (Chen et al., 1999). In the US, antimicrobial susceptibility surveillances 
through year 1994 – 2003 conducted by Doern et al. had determined that while 
resistances to major antibiotic classes including ß-lactams, tetracyclines,  macrolides, 
and other drugs were less common, fluoroquinolones resistance have expanded 
dramatically over the years (Doern et al., 1999; Doern et al., 1996; Doern et al., 2001; 
Doern et al., 2005). High fluoroquinolone resistance rates have been reported in Spain 
(7%) and several Asian countries/regions which include Hong Kong (14.3%), Sri Lanka 
(9.5%), Philippines (9.1%), and Korea (6.5%) (Canton et al., 2003; Jones et al., 2003; 
Mendes et al., 2004; Perez-Trallero et al., 2001; Song et al., 2004b). Although the 
pneumococcal isolates are being determined as fluoroquinolones-susceptible, however, 
the isolates would have acquired single-step mutation and become resistant dramatically 
upon acquired further mutation as had been reported by Lim et al. whereby 59% of the 
levofloxacin-susceptible pneumococci indeed possessed single-step mutation in the 
QRDR (Lim et al., 2003). 
Reports of fluoroquinolone-resistant pneumococci associated treatment failure 
have been increasingly documented though uncommon (Ambrose et al., 2004; de la 
Campa et al., 2003; Kays et al., 2002).  The elderly adult group was found to be prone 
to infection by fluoroquinolone-resistant pneumococci than the children (Yokota et al., 
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2002). In addition, it has been suggested that treatment failures are more likely to occur 
among the elderly patients with pneumococcal respiratory tract infections presented 
with co-morbid diseases and a recent episode of fluoroquinolones (Fuller & Low, 2005). 
This is likely to occur in strains with first-step mutation in the parC or gyrA genes 
(Fuller & Low, 2005). Older generations of fluoroquinolones including ofloxacin and 
ciprofloxacin should no longer be used in respiratory tract infection whether or not is 
due to S. pneumoniae (Ho et al., 2004; Ho et al., 2001). Moreover, initial treatment with 
fluoroquinolones in CAP is likely to have lower risk of treatment failure as compared to 
other antibiotics recommended by the guidelines (Menendez et al., 2004; Roson et al., 
2004). Comparing the rates of treatment failure among 3,994 patients based on claims 
analysis in the US it was noticed that treatment failures associated with levofloxacin 
was significantly low (Hess et al., 2010). The finding was supported by a previous study 
which was also claims-based, reporting that patients treated with levofloxacin 
experienced lower probability of treatment failure (Ye et al., 2008). 
 
1.5. Antimicrobial peptides 
1.5.1. General properties of antimicrobial peptides 
Living in a complex environment, the organisms are constantly exposed to and 
interact with other life forms. However, this includes microbial pathogens that can cause 
considerable harm to the host. As the first line of defense, the host innate immunity 
must be able to recognize and clear microbial invasions efficiently well before the 
acquired immune system is being stimulated. In many circumstances, it is important to 
have the pathogens eliminated without the need to stimulate inflammatory mechanism 
or the activation of acquired immunity in order to prevent overwhelming immune 
responses in the host (Bals, 2000). To achieve these, one of the crucial components 
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expressed by mammalian innate immunity is the production of antimicrobial peptides 
(AMPs).  
AMPs are generally short in length (12 - 50 amino acids), low molecular weight, 
amphipathic, contain multiple hydrophobic residues, and positive in charge (Brogden, 
2005; Hancock, 1997b; Hancock & Chapple, 1999; Nicolas & Mor, 1995; Oren & Shai, 
1998). A number of anionic AMPs have also been reported despite being relatively less 
common than cationic AMPs (Brogden et al., 1997; Harris et al., 2009). AMPs are 
produced by a vast variety of living organisms ranging from mammals, fish, amphibians, 
reptiles, arachnids, plants, fungi, and bacteria (Hancock & Scott, 2000; Stark et al., 
2002). In humans, AMPs belong to three major classes: cathelicidin, defensins, and 
histatin. Large number of AMPs have been isolated and characterized in the past 
decades (Hancock & Chapple, 1999). To date, more than 1,000 AMPs have been 
identified and a lot more are to be expected in the future. Although multiple isoforms of 
AMPs with wide sequential and structural variances have been reported (Bulet et al., 
2004; Zhu & Gao, 2009), the biological activity of AMPs are generally characterized by 
the universal structural signatures  and sets of molecular biophysical traits (Yount & 
Yeaman, 2004).  
AMPs exhibit broad spectrum antimicrobial activity against wide diversity of 
gram-positive and gram-negative bacterial species, fungi, as well as eukaryotic parasites 
and enveloped viruses (Epand & Vogel, 1999; Hancock, 2001; Kamysz et al., 2003; 
Nizet, 2006). AMPs are selectively crafted into effector compounds with specific and 
high order functionality in the host innate defense system. They are able to function 
without memory and high specificity. It has been postulated that the immune system of 
mammals and other higher organisms has been changing rapidly throughout the 
evolution to adapt to the ever-changing microbial ecology surrounding and within the 
host (Lynn et al., 2004).  
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AMPs can be supplemented by immune cells (mast cells, dendritic cells, 
macrophages, neutrophils) recruited to the injury sites during acute inflammatory 
response (Di Nardo et al., 2003; Rosenberger et al., 2004; Turner et al., 1998). Presence 
of local stimuli such as lipopolysaccharides (LPS) and lipoteichoic acids (LTAs) during 
bacterial infections may also activate the production of AMPs (Di Nardo et al., 2003; 
Diamond et al., 1996; Russell et al., 1996). These compounds serve multiple roles in the 
immune system as immunomodulating agents during the cell‟s inflammatory response, 
chemotaxis, cytokine release, cell proliferation, as well as tissue repair (Bateman et al., 
1991; Boman, 1995; Elsbach, 2003; Koczulla & Bals, 2003; Koczulla et al., 2003). One 
of the examples is human cathelicidin LL-37 which functions as human monocytes, T 
cells and mast cells chemoattractant (Niyonsaba et al., 2002) (De et al., 2000), 
regulation of chemokine production (Scott et al., 2002), and acts as a potent 
antiendotoxic agent (Scott et al., 2000). Eventually, the coordinated interactions 
between AMPs and various immune components lead to clearance of pathogens and 
enhanced tissue repair processes. Further invasion into deeper sites is prevented, thus 
inhibits the development of invasive diseases. The production of AMPs has been 
demonstrated to confer resistance against bacterial infections and enhanced the survival 
fitness of host  (Cheung et al., 2008). Deficiency in AMPs are increasingly being 
recognized as underlying factors contributed to manifestation of diseases and predispose 
one against infections (Zaiou, 2007). Recently, the role of AMPs in wound healing 
(Heilborn et al., 2003) and anticancer activity (Hoskin & Ramamoorthy, 2008; Lee et 
al., 2008; Mader et al., 2005) have been described.  The potential benefits of AMPs as 
disease enhancement agent have also been recognized in the agricultural and 
aquacultural industry (Jia et al., 2000). Of note, the transgenic expression of plants with 
AMPs-encoded genes have shown great agricultural application potential whereby the 
transformed plants were found to exhibit enhanced resistance against a variety of 
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phytopathogens and better productivity (Lee et al., 2011a; Oard & Enright, 2006; 
Rajasekaran et al., 2012).  
Secretory AMPs together with other molecules of innate immunity constitute the 
major components of host mucosal immunity. These AMPs are being released into the 
oral cavity, gastrointestinal tract, and respiratory tract to protect the mucosal surfaces 
from potentially harmful microbes and to maintain a steady state common microflora 
(Lee et al., 2004a; Zasloff, 2002c). In humans, secretory AMPs are mainly cathelicidin 
and α- and β-defensins (Agerberth et al., 1999). They are produced ribosomally and 
subjected to further optional posttranslational modifications that are fundamental for 
optimal activity and exportation. Secretory AMPs are produced by mucosal epithelial 
cells and skin keratinocytes at the baseline level which are tightly regulated by a 
sophisticated regulation system (Braff et al., 2005a; Braff et al., 2005b; Dorschner et al., 
2001; Nizet et al., 2001). The expression of secretory AMPs are being induced 
dramatically during the inflammatory response in the events of breaching of skin layer 
or in response to infection stimuli (Schonwetter et al., 1995). 
 
1.5.2. Structural classes 
AMPs consist of a diverse family of polypeptides which can be subgrouped into 
four main structural classes (Agerberth et al., 1991; Harwig et al., 1995a; Harwig et al., 
1995b): (a) amphiphilic α-helical peptides lacking cysteine residue. For examples, 
mammalian cathelicidins, insect-derived cecropins, and magainins from the skin of 
Xenopus laevis (b) Linear peptides predominated with one or more amino acid types 
such as mammalian PR-39, prophenins from porcine leukocytes, and Bac 5 and Bac 7 
from bovine neutrophils (c) Amphiphilic disulfide-bonded ß-sheet peptides (cysteine-
rich) such as porcine protegrins, tachyplesins from horseshoe crab, and mammalian 
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defensins (d) loop-structured peptides with cysteine-disulfide ring including bactenecin, 
brevinins, and ranalexin. 
 
1.6. Mechanism of actions 
1.6.1. Membrane-active peptides 
Bacterial cell wall and outer capsule represent the significant barriers against any 
incoming antibiotic or foreign substance that might cause considerable damage to the 
cell. Hence, it is generally considered that AMPs with broad spectrum antimicrobial 
activity must be able to traverse the protective layers (e.g. CPS in S. pneumoniae) 
whether to target the membrane directly or entering the cytosol to allow subsequent 
intracellular activity. For intracellular targeting AMPs, it appears that the AMPs would 
exert certain disruption effects during the transition process although there might not be 
detrimental to the cells. This also describes the functional duality of AMPs. 
The most widely accepted model of AMPs mode of killing is the non-receptor 
mediated membrane lytic mechanism (Bessalle et al., 1990; Wade et al., 1990). Most of 
the studies investigating AMPs mode of actions showed that AMPs exert its 
microbicidal activity by permeabilizing and depolarizing the membrane as the principal 
killing strategy (Boniotto et al., 2003; Lehrer et al., 1989; Shai, 2002; Yeaman & Yount, 
2003). In fact, AMPs binding and interaction with the cell membrane had been linked to 
bactericidal potency (Lehrer et al., 1988; Lehrer et al., 1985; Tran et al., 2002). 
The first contact between AMPs and the target bacteria is essentially driven by 
electrostatic interactions (Brogden, 2005; Hancock & Chapple, 1999; Nicolas & Mor, 
1995; Vaara, 1992). The electrostatic interaction is due to the opposite charge attraction 
between the cationic AMPs and the negatively charged bacterial cell surface due to the 
presence of teichoic acids (TAs) and LTAs in gram-positive bacterial cell wall and LPS 
in gram-negative bacterial cell wall. This occurs irrespective of whether the AMPs are 
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targeting cell membrane only for killing activity or will eventually be translocated 
across the membrane to inhibit intracellular components or both. The AMPs initial 
binding to cell membrane will cause a slight disruption in both the packing of outer 
membrane and phospholipids chain arrangements in a way termed “self-promoted 
uptake” (Hancock, 1999). Moreover, when the peptide-bound outer leaflet of membrane 
flips inward, the peptides draw along the adjacent lipid components create a slight 
membrane disruption that affects the integrity of the membrane (Matsuzaki et al., 1998). 
On the other hand, AMPs that exert antimicrobial activity by the formation of pores or 
ion channel (pseudoionophore) on cell membranes are able to immediately insert 
themselves into the lipid bilayers. Subsequently, the AMPs interact with the membrane 
by pore formation or mechanisms that perturb the membrane integrity (Hancock, 1997a; 
Hancock & Rozek, 2002; Koczulla & Bals, 2003; Yeaman & Yount, 2003; Zasloff, 
1992). This will eventually lead to transmembrane channel formation and membrane 
lysis which in turn causes irreversible osmotic-colloidal interactions leading to drastic 
and detrimental lost of proton motive forces (Huang, 2000; Oren & Shai, 1998). Besides 
this, some AMPs are able to form voltage-dependent channel. As in the case of HNP-3, 
the channel form on planar lipid bilayers is voltage-dependent and weakly anion 
selective that is linked to the antimicrobial activity observed with HNP-3 (Kagan et al., 
1990).  
On top of this, an increasing body of evidence had underlined the importance of 
hydrophobicity in modulating the interaction between AMPs and microbial surface 
(Hancock & Chapple, 1999; Vaara, 1992). Aggregation of amphipathic AMPs on 
membrane surface is particularly important for its activity (Hwang & Vogel, 1998; Oren 
& Shai, 1998). These peptides are able to adopt an amphiphatic structure which 
segregates the hydrophilic and hydrophobic residues to opposite sides upon coming in 
contact with the biological membrane (Nicolas & Mor, 1995; Shai, 1999; Tossi et al., 
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2000). Amphiphilic and lateral amphiphilic (hydrophobic and hydrophilic face toward 
opposite sides) are required to form hydrophilic ion channel while remain in hold with 
the adjacent hydrophobic components of cell membrane particularly the lipid moieties. 
This transmembrane channel is essentially α-helical to facilitate penetration into the 
membrane. Notably, the α- and ß-defensins characterized up to date show an 
amphiphilic topology which is suggested to be critical for their bactericidal activity. 
Lateral amphipathic peptide should have periodic interval of hydrophobic residues per 
circumference of a helical turn which is approximate to be 3.6 residues.  
The cell selectivity of AMPs is suggested to rely on the difference in membrane 
lipid composition favoring the invading microbes over host cells (Oren & Shai, 1998) 
(Teixeira et al., 2012). Eukaryotic cells are predominated by zwitterions and 
sphingomyelin phospholipids which give lower electrostatic affinity towards the 
cationic AMPs. Therefore, the host cells manage to escape unwanted binding that would 
cause cell toxicity otherwise. Several AMPs including the magainins, cecropins, and 
seminal plasmin display high bacterial cell selectivity over mammalian cells (Sitaram & 
Nagaraj, 1993; Wade et al., 1992; Wieprecht et al., 1997). Insufficient cell selectivity 
by LL-37, indolicidin, melittin, tachyplesins, protegrins, and others rendering the AMPs 
toxic to host cells (Blondelle et al., 1993; Kokryakov et al., 1993; Matsuzaki et al., 
1997b; Oren et al., 1999; Subbalakshmi et al., 2000). Thus, in order to achieve high and 
rapid microbicidal effects while avoiding the problem of cell toxicity, immune cells 
expressing cathelicidins and defensins will release very high local dose of AMPs to 
initiate immediate microbial killing at the injury sites followed by immediate 
breakdown of the unwanted remains of AMPs mainly via proteolysis after utilizing 
AMPs against the microbes (Hancock et al., 2012; Teixeira et al., 2012; Zaiou, 2007).  
There are three widely accepted models of membrane-active AMPs: toroidal-pore 
model, barrel-stave model, and carpet model. 
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Toroidal pore model 
In the toroidal pore model (Figure 1.4), first binding of AMPs to the membrane is 
followed by cascade aggregation of more peptide units. This action disintegrates the 
horizontal lipid components of the same membrane and subsequently causes the lipid 
moieties of outer and inner membrane to fold inwards forming a continuous channel 
(Brogden, 2005; Hale & Hancock, 2007). Each pore is lined by a number of peptide 
monomers that are tightly associated with the lipid headgroups making up the wall of 
the pores throughout the whole pore-forming process (Hale & Hancock, 2007). As a 
result, cell death occurs due to detrimental leakage of cytoplasmic contents to the 
surrounding. Example of toroidal pore forming AMPs are magainin 2 (Yang et al., 1998) 
and melittin (Sengupta et al., 2008). Recently, the first discovery of a gram-positive 
bacteria-producing toroidal pore forming bacteriocin, lacticin Q had been reported 
(Yoneyama et al., 2009). 
 
  
Figure 1.4: The toroidal pore model of AMPs (adapted from Brogden, 2005). 
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Barrel-stave model 
The barrel-stave model is quite similar to toroidal pore model in that both form a 
transmembrane pore each lined by multiple peptide monomers at the end of the process 
(Figure 1.5). However, several intermediary steps differ (Brogden, 2005; Hale & 
Hancock, 2007). The peptide monomers first bind to the membrane and insert 
themselves in a parallel formation to the lipid components of the membrane. Insertion 
can occur either by initial single monomer insertion into the membrane followed by 
lateral coalescence or through lump sum direct insertion of the aggregated oligomer. 
Hydrophilic side of the peptide monomer will point inward forming the lumen of the 
channel whereas the hydrophobic side will face outward from the channel in tight 
association with the lipid core of the bilayers. The stable pore then conduct the leakage 
of intracellular contents leading to cell death. Alamethicin is one of the many barrel-
stave forming AMPs (Yang et al., 2001). 
Figure 1.5: The barrel-stave model of AMPs (adapted from Brogden, 2005). 
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Carpet model 
Unlike the two pore forming mechanisms abovementioned, carpet model has no 
actual transmembrane pore or direct insertion of AMPs into the membrane (Figure 1.6). 
Instead, the AMPs remain associated with the outer leaflet of cell membrane. When the 
accumulated peptide monomers on the membrane surface are sufficient to disrupt the 
membrane electrostatic integrity, the peptides then induce local weakness in the 
membrane and eventually disintegrate the membrane in a micellar configuration known 
as the “carpet-like” formation. The leakage of cellular contents thus leads to cell death 
(Brogden, 2005; Hale & Hancock, 2007).  Example of AMPs include the cecropin P1 
from porcine intestines (Gazit et al., 1995). 
 
Figure 1.6: The carpet model of AMPs (adapted from Brogden, 2005). 
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1.6.2. Non-membrane targeting mode of actions 
Apart from the membrane active models, there have been increasing reports of 
intracellular targeting AMPs in the past decades (Brogden, 2005; Hale & Hancock, 
2007; Nguyen et al., 2011). Rather than recognizing specific single target site, AMPs 
are able to trigger multiple inhibitory and lethal events in the same cell whether by 
membrane or non-membrane targeting mechanism in a cooperative manner to ensure 
efficient and immediate killing (Nguyen et al., 2011; Peschel, 2002; Powers & Hancock, 
2003). A peptide that exerts bactericidal effect via membrane disruption might in other 
hand kill other species of bacteria using non-membrane targeting actions (Hale & 
Hancock, 2007). The mechanism of actions might as well be differed vastly between 
gram-positive and gram-negative bacteria due to the bacterial cell wall structural and 
compositional differences. Apart from these, AMPs with widely dissimilar primary 
sequence and solution structure can share similar bactericidal pathway as seen with 
histatin 5 and HNP-1 (Edgerton et al., 2000). A number of major non-membrane 
targeting mechanisms are discussed below. 
 
Protein synthesis inhibitors 
Interfering with macromolecules metabolism is likely to serve as the supporting 
mechanism in preventing cell growth. Such events usually begin at low peptide 
concentration before the rapid killing of bacteria due to perturbation of membrane at 
high peptide concentration. Notably, it is increasingly common to find protein 
synthesis-inhibiting AMPs having affinity against multiple targets. Several of these 
peptides have been studied in details. For example, The 13 residues 1HR1 is a synthetic 
variant of indolicidin (Friedrich et al., 2001) which belongs to the cathelicidin family of 
polypeptides (Durr et al., 2006). It is a polycationic, Trp-rich, and C-terminally 
amidated AMP isolated from the cytoplasmic granules of bovine neutrophils (Selsted et 
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al., 1992). Previous studies have documented that indolicidin and its synthetic 
analogues exhibited strong inhibitory effects against multiple bacterial, fungal, and 
viruses (Robinson et al., 1998; Selsted et al., 1992; Selsted et al., 1993; van Abel et al., 
1995). Unlike AMPs that act upon the bacterial plasma membrane (Ganz & Lehrer, 
1999; Lehrer et al., 1989; Zasloff, 2002b), indolicidin has been shown to interact with 
bacterial nucleic acids to inhibit the cell replication or transcription processes leading to 
cell death (Subbalakshmi et al., 1996). This unique mechanism of action is of great 
interest, as the ability to penetrate bacterial cell membrane and exert inhibitory effects 
on the intracellular targets can greatly avoid the problem of toxicity. Additionally, the 
indolicidin derivative CP10A exhibits multitude of inhibitory activities from membrane 
lysis to disruption of DNA, RNA, and protein synthesis (Friedrich et al., 2001). CP10A 
had been shown to reduce the incorporations of histidine, uridine, and thymidine in S. 
aureus (Friedrich et al., 2001). Apart from that, PR-39 interferes with the protein and 
DNA synthesis pathways to induces metabolic cessation (Boman et al., 1993). Sublethal 
dose of pleurocidin, an AMP isolated from the skin secretions of winter flounder (Cole 
et al., 1997), inhibited the growth of E. coli via protein synthesis arrest as observed with 
the reduction of histidine, uridine, and thymidine incorporations (Patrzykat et al., 2002). 
It was only at lethal dose that pleurocidin becomes both bactericidal and inhibited 
macromolecular synthesis (Patrzykat et al., 2002). Other AMPs such as dermaseptin and 
defensins also interrupt with protein synthesis (Jenssen et al., 2006). Human neutrophil 
α-defensin induced sequential permeabilization of the outer and inner membrane of E. 
coli which was accompanied with failure of DNA, RNA, and protein synthesis (Lehrer 
et al., 1989). However, loss of inner membrane integrity was found to be the key event 
associated with lethality. Therefore, multivalent membrane-active AMPs display high 
tendency to co-affect principally DNA synthesis thus suggesting the involvement of 
AMPs since the early translation steps in the protein expression system. 
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Nucleic acid synthesis inhibitors 
Several AMPs are able to inhibit the production of DNA and RNA of the target 
organisms. Buforins are a class of DNA inhibitor first isolated in year 1996 from the 
stomach tissues of Bufo bufo gargarizans toad (Park et al., 1996). Buforin I exhibited 
potent antimicrobial activity against fungi and wide range of gram-positive and gram-
negative bacteria. Buforin II, a 21 amino acids fragment peptide derived from the 
enzymatic cleavage of buforin I by endoproteinase Lys-C displays stronger 
antimicrobial activity than the parent peptide (Park et al., 1996). Later on it was clearly 
demonstrated by Park et al. that buforin II traverses the cell membrane and accumulates 
in the cytoplasm of E. coli (Park et al., 2000). However, membrane leakage was not 
observed even at concentration five-fold above the MIC (Kobayashi et al., 2000; Park et 
al., 1998). Experiment using gel-retardation technique had detected high nucleic acid 
binding affinity of buforin II which strongly implies that buforin II inhibits cellular 
functions by targeting the DNA and RNA (Park et al., 1998). The finding was supported 
by the notion that the parent AMP buforin I showed high sequence homology (37/39) to 
the N-terminal fragment of the DNA-binding protein histon H2A leading to the 
speculation that other AMPs which closely resemble H2A also exert their antimicrobial 
activity in a similar fashion as buforin II (Park et al., 1998; Park et al., 2000) such as 
parasin I and hipposin derived from the skin mucus of catfish (Birkemo et al., 2003).  
Even though both buforin II and other α-helical amphipathic AMPs are closely-
related in terms of structural and physicochemical properties, the actual mode of actions 
can be varied considerably (Park et al., 1998). Notably, the presence of proline hinge 
region in buforin II is critical for its transmembrane activity. Disruption or loss of hinge 
region hinders the peptide from entering the cell cytoplasm (Kobayashi et al., 2000; 
Park et al., 2000). In turn, these membrane-associated buforin II is able to induces 
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membrane permeation. This also suggests the functional duality in the actions of buforin 
II and how minor substitution in AMPs sequence produces novel antimicrobial activity.  
 The 13 amino acids indolicidin is a tryptophan-rich bovine neutrophil-derived 
AMPs belongs to the cathelicidin family of AMPs (Selsted et al., 1992). The potent 
antimicrobial activity of indolicidin is attributable to permeabilization of plasma 
membrane while also possessing DNA inhibitory effects (Ahmad et al., 1995; Ladokhin 
et al., 1997; Schibli et al., 2002). Interestingly, it was found that the membrane 
permeation activity was not accompanied with cell lysis (Falla et al., 1996). Rather, E. 
coli treated with indolicidin showed filamentous appearance of cells together with a lack 
of thymidin uptake. Combining these observations, the mechanism of action of 
indolicidin is deduced to inhibit DNA synthesis exclusively but not RNA 
(Subbalakshmi & Sitaram, 1998). This finding was later supported by two study groups 
concluding the DNA-binding activity of indolicidin (Hsu et al., 2005; Marchand et al., 
2006). Indolicidin targets specifically the abasic site of DNA and cross-links with the 
single- or double- stranded DNA (Marchand et al., 2006). Hence, it was proposed that 
indolicidin probably interacts with the cell membrane causing membrane 
permeabilization at high concentration but not lysis to facilitate peptide entry into the 
cytoplasmic site without killing the bacteria (Hsu et al., 2005).  
Besides direct DNA binding, indolicidin also prevents DNA relaxation by 
inactivating the DNA topoisomerase 1 (Marchand et al., 2006). Notably, this process 
occurs without DNA unwinding thus further suggesting the multiple inhibitory roles of 
indolicidin against various DNA-associated enzymes (Marchand et al., 2006). The 
presence of homologous sequences in other DNA-binding proteins (e.g. DNA 
methylltransferase) further indicates that N-terminal fragment of indolicidin rather than 
the PWWP motif is responsible for its DNA-binding activity (Marchand et al., 2006). 
Indolicidin had also been demonstrated to bind with high affinity against calmodulin in 
47 
 
 
a Ca
2+
-dependent fashion (Sitaram et al., 2003). Tachyplesin isolated from hemocytes 
of horseshoe crab Tachypleus tridentatus is another example of DNA inhibiting peptide 
(Nakamura et al., 1988). It binds to the minor groove of DNA to exert inhibitory effect 
(Yonezawa et al., 1992). Other AMPs such as PR-39 also exhibits nucleic acid 
inhibitory effects (Boman et al., 1993). 
 
Mitochondrion inhibitors 
Histatin-5 is known for its antifungal activity against Candida albicans, the 
opportunistic fungus causing oropharyngeal candidiasis in most of the HIV-1-infected 
patients (de Repentigny et al., 2004). It is a member of histatins, a group of histidine-
rich cationic peptides present in the salivary secretions of human submandibular and 
parotid glands (Troxler et al., 1990). Histatin-5 induced significant loss of 
mitochondrial transmembrane potential (Helmerhorst et al., 1999) and generated 
reactive oxygen species (Helmerhorst et al., 2001a) which caused damages to the 
treated C. albicans cells. The mechanism was demonstrated to begin with intracellular 
internalization of histatin 5 and then act upon the energized mitochondrion of the cell. 
Although histatin-5 does disrupt the cytoplasmic and mitochondrial membranes, the 
slow depolarization events reveal that histatin-5 is rather weak at the membrane level 
(Den Hertog et al., 2004; Helmerhorst et al., 1999; Ruissen et al., 2001). This was 
suggested to be due to the poor amphipathic property of the peptide to initiates 
membranal insertion and pore formation (Helmerhorst et al., 2001b; Raj et al., 1990). 
Besides, other cellular targets may also be involved (Hancock & Diamond, 2000). 
Microcins are a group of enterobacteria AMPs isolated mainly from E. coli. The 
microcins mcc25 which displayed potent antimicrobial activity against the closely-
related bacteria such as Shigella and Salmonella was isolated from a faecal strain of E. 
coli (Salomon & Farias, 1992). As opposed to histatin-5, mcc25 is a mitochondrion 
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membrane-active peptide that inhibits the cytochrome c reductase (Niklison Chirou et 
al., 2004). Mcc25 has been suggested as a potential antitumor agent as well (Niklison 
Chirou et al., 2004). 
 
Protein folding inhibitors 
Chaperones are crucial for the proper folding of newly synthesized proteins (Ellis, 
1990). Pyrrhocoricin, apidaecin, and drosocin are group of short (18 - 20) proline-rich 
insect-derived AMPs which inhibit bacterial chaperones, specifically the DnaK protein 
of E. coli but not GroEL which can be found in many bacteria including E. coli (Otvos 
et al., 2000). Binding of these AMPs to DnaK is essentially stereo-specific (Otvos et al., 
2000). Such high specificities confer advantages in term of cell toxicity as they do not 
target the human equivalent chaperone heat shock protein 70. In addition, pyrrhocoricin 
and drosocin also prevent DnaK from refolding of misfolded proteins by inducing 
permanent closure of the peptide-binding cavity by the multihelical lid of DnaK (Kragol 
et al., 2001). 
 
Cell wall-targeting peptides 
There are several ways in which AMPs affect cell wall synthesis and/or integrity. 
Mersacidin is a globular lantibiotic formed by the presence of four intramolecular 
thioether bridges (Prasch et al., 1997). It is the smallest lantibiotic (20 amino acids, 
1825 Da) known up to date and is neutral in charge. This peptide was originally 
expressed by Bacillus sp. strain HIL Y-85, 54728  which was not naturally competent 
(Chatterjee et al., 1992). Later, the production of mersacidin was successfully 
established in the closely-related Bacillus amyloliquefaciens FZB42 via competence 
transformation (Herzner et al., 2011). Mersacidin targets the peptidoglycan precursor 
lipid II to form a complex with the sugar phosphate head group (Brotz et al., 1998a). 
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This impaired the transglycosylation step in cell wall biosynthesis (Brotz et al., 1997). 
Since mersacidin targets the peptidoglycan biosynthesis pathway, it was found to attack 
particularly gram-positive bacteria such as methicillin-resistant S. aureus (MRSA) but 
not gram-negative or fungi  (Chatterjee et al., 1992; Hoffmann et al., 2002). Cells 
treated with mersacidin were observed with accumulation of peptidoglycan precursors 
UDP-MurNAc-pentapeptide in the cytoplasm (Brotz et al., 1997). By using a murine 
rhinitis model, mersacidin was able to eradicate MRSA colonization without stimulating 
inflammatory responses (Kruszewska et al., 2004). Nisin is another example of 
lantibiotic that similarly targets the lipid II components for its antimicrobial activity 
(Brotz et al., 1998b). Based on literature searches up to date, there was no PBPs-
targeting AMPs being documented.     
Staphylococcus epidermitis produces lantibiotic Pep5 which is characterized by 
the presence of three intramolecular rings (Sahl & Brandis, 1981). The peptide involves 
indirectly in cell wall lysis through the activation of cell wall-associated lytic enzymes 
(Bierbaum & Sahl, 1987). It has high binding affinity to the TAs and LTAs of gram-
positive bacterial cell wall which competitively displaces the cell wall-associated 
amidases. This leads to premature release of the autolytic enzymes resulting in cell lysis 
and cell death. Together with another lantibiotic epidermin which is also produced by S. 
epidermitis, they have been proposed to have potential usage as novel catheters 
disinfecting agents (Fontana et al., 2006). 
 
Cell division inhibitors 
A number of AMPs were demonstrated to have significant role in the process of 
septum formation during the bacterial cell division. As shown by Salomon and Farias, E. 
coli treated with mcc25 become significantly elongated without septation thus 
producing a filamentous morphology (Salomon & Farias, 1992). In addition, mcc25 acts 
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in a non-SOS-dependent mechanism hence suggesting its bacteriostatic mode of action 
(Salomon & Farias, 1992). AMPs-induced filamentation had also been described with 
indolicidin (Subbalakshmi & Sitaram, 1998), PR39 and the truncated variant PR26 (Shi 
et al., 1994). 
 
Lipopolysaccharide-binding peptides 
Gram-negative bacteria have two distinct layers, the inner and the outer 
membrane. LPS constitutes the outer leaflet component of the outer membrane (Osborn, 
1969). This structure is important in preventing and restricting the entry of harmful 
compounds into the cell. LPS molecule can be divided into three portions: the 
hydrophobic anchor Lipid A (LA) is a glucosamine-based phospholipids which 
constitutes the outer monolayer of LPS, the core polysaccharides, and the O-antigen 
repeats (Raetz et al., 2007; Raetz & Whitfield, 2002). LPS or more specifically the LA 
molecule is well known as the bacterial endotoxin largely responsible for the toxicity 
and clinical manifestations associated with gram-negative bacterial infections. LPS can 
be shed off from the cell during the process of infection or the course of antimicrobial 
chemotherapy treatment (Tracey et al., 1987). Endotoxin is detected by toll-like 
receptor 4 presented on the animal endothelial cells and immune cells including 
monocytes, neutrophils, macrophages, and dendritic cells (Akira et al., 2006; Hoshino et 
al., 1999; Poltorak et al., 1998). This in turn stimulates the inflammatory mediators 
such as TNF-α and IL1-B (Beutler & Cerami, 1988; Dinarello, 1991) and activates co-
stimulatory cells of the adaptive immune arm (Medzhitov & Janeway, 2000). However, 
in the case of endotoxemia where endotoxin is being released into the blood, 
overproduction of stimulatory molecules could lead to septic shock, severely damaging 
the blood vessels causing intravascular coagulations and eventually organ failures 
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(Bernard et al., 2001; Esmon, 2000; van Deuren et al., 2000). In the developing 
countries, endotoxemia represents a major cause of death (Parrillo, 1993). 
In recent years, increasing interests have been grounded on the interactions 
between AMPs and bacterial LPS. Endotoxin-targeting AMPs have great potential to be 
developed as antiendotoxin or endotoxin-neutralizing agents to eliminate endotoxic 
shock in patients during or after treatment (Gough et al., 1996; Hancock, 1999). AMPs 
binding to LPS are able to neutralize the endotoxin by preventing the overwhelming 
activation of inflammatory responses as a result of imbalance cytokines production (e.g. 
IL-1, TNF-α) mainly by the LPS-stimulated mononuclear and macrophage cells (Gee et 
al., 2003; Kubo et al., 2007; Mukhopadhyay et al., 2004). Amphipathic and high 
proportion of cationic residues of AMPs have been suggested to be the principal binding 
motifs against the oppositely charged LA (Hoess et al., 1993; Oren & Shai, 1998). Even 
for the relatively short ß-sheet AMPs, binding can still be formed between the ß-sheet 
cationic side chains and the anionic phosphates of LA (Frecer et al., 2000). Muhle and 
Tam had successfully developed a novel ß-stranded cyclic AMP by mimicking the 
putative LPS-binding sites based on the LPS-binding protein family (Muhle & Tam, 
2001). 
 
1.6.3. Mechanism of bacterial AMPs resistance 
Several reports have shown that resistance to AMPs might occur in certain 
microorganisms (McPhee et al., 2003; Weidenmaier et al., 2003). The reported 
mechanisms include D-alanylation of LTAs on cell surface, insertion of aminoarabinose 
to lipid A moiety of LPS, active efflux of AMPs via transporters, and enzymatic 
degradation of peptide chain (Kristian et al., 2005; Nizet, 2006; Peschel, 2002). 
The initiation of AMPs binding on bacterial membrane is primarily via 
electrostatic attraction forces. To interfere with the binding, the bacteria are able to 
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counteract by modification of the membrane chemical compositions leading to 
alteration of cell wall compositions and surface charges. In gram-positive bacteria, the 
cell wall is composed mainly of TAs and peptidoglycan. The cell wall-associated TAs 
are covalently linked to peptidoglycan and the membrane-associated TAs are anchored 
to cytoplasmic membrane via glycolipid linkage with its polyglycerophosphate (Gro-P) 
chain extending to the wall (Neuhaus & Baddiley, 2003). These negatively-charged TAs 
are the most abundant polyanions components of gram-positive bacteria which causes 
the accumulation of cationic AMPs on the anionic bacterial surface (Weidenmaier & 
Peschel, 2008). The bacteria are able to counteract by increasing the positive cell 
surface charges via D-alanylation of TAs and/or incorporation of L-lysine into 
phosphatidylglycerol which reduces the electrostatic attractions (Weidenmaier & 
Peschel, 2008). The former model represents the most described resistance mechanism 
against AMPs by the gram-positive bacteria. In fact, reduced electrostatic interaction 
with the cationic antibiotics gallidermin (Peschel et al., 1999) and vancomycin (Peschel 
et al., 2000) due to a decrease in the cell wall anionic property of S. aureus had been 
documented. D-alanylation of TAs involves the D-alanine-activating enzyme and a D-
alanine-D-alanyl carrier protein ligase (Chevion et al., 1974). These enzymes are 
encoded by genes on the dlt operon (Heaton & Neuhaus, 1992; Kristian et al., 2005; 
Perego et al., 1995). S. pneumoniae lacking dltA gene had been shown to be more 
susceptible to AMPs than the wild type strains (Kovacs et al., 2006). The deletion of dlt 
operons in S. aureus (Peschel et al., 1999), Enterococcus faecalis (Fabretti et al., 2006), 
group A (Peschel et al., 1999) and group B streptococci (Kristian et al., 2005) as well as 
the probiotic strain Lactobacillus rhamnosus GG (Perea Velez et al., 2007) 
demonstrated absence of D-alanyl esters of TAs and displayed enhanced susceptibility 
to AMPs. On the contrary, a recent study by Saar-Dover and colleagues found that 
reducing the anionicity of TAs did not contribute to AMPs resistance by decreasing the 
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membrane-bound AMPs in group B Streptococcus (Saar-Dover et al., 2012). It was the 
conformational changes in D-alanylated TAs which resulted in increasing cell wall 
density that prohibited AMPs penetration through the cell wall  (Saar-Dover et al., 
2012). 
CPS acts principally by mean of exploitations of anionic molecules as the ionic 
decoy against the oppositely charged AMPs (Campos et al., 2004; Llobet et al., 2008; 
Spinosa et al., 2007). Although the chemical compositions of CPS varied yet most of 
them are anionically charged. The action is comparable to that of chemokine decoy 
receptors whereby the production of decoy molecules by parasites and viruses are used 
to trap the chemokine hence preventing the activation of immune cells (Mantovani et al., 
2006). The presence of free CPS in the microenvironment surrounding the bacteria has 
significant role in the development of resistance and is of greater interest rather than the 
bound CPS. In fact, it had been demonstrated that encapsulated bacteria such as K. 
pneumoniae are able to shed free CPS to the extracellular complex (Straus et al., 1985). 
For S. pneumoniae, competence-induced pneumococci cause cell-to-cell contact lysis of 
the competence-deficient cells by the CBP-bound lysins to release the CPS (Steinmoen 
et al., 2002; Steinmoen et al., 2003). UV-killed cells can similarly release the CPS from 
the bacterial cells (Llobet et al., 2008). 
The mechanism by which AMPs induce CPS release from bacterial surface had 
been suggested to occur in a way analogous to the mechanisms by which AMPs 
interrupt and release LPS (Vaara, 1992), Fresno et al. demonstrated that CPS anchorage 
to the cell surface of K. pneumoniae is mediated by electrostatic interaction between the 
CPS and LPS core region and further stabilized by divalent cations  (Fresno et al., 2006). 
The presence of AMPs interrupts with the ionic bridges formed between the 
neighboring CPS molecules which trigger the simultaneous release of CPS from the 
bacterial surface (Llobet et al., 2008). The release of CPS was detectable at the 
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sublethal concentration and was inducible by the addition of AMPs (Llobet et al., 2008) 
or by the activated neutrophils during the course of infections in vivo (Ganz, 1987; 
Selsted & Ouellette, 1995). As compared to the non-CPS mutant strains, the presence of 
CPS (both release naturally or AMPs-induced) can lead to dramatic reduction in the 
bacterial susceptibility against AMPs (Campos et al., 2004; Llobet et al., 2008; Spinosa 
et al., 2007). Such mechanisms appear to reduce the killing efficacy by AMPs, resulting 
in delayed cell death hence allowing the bacteria to have more time to activate counter 
measures against AMPs. This leads to higher likelihood of developing secondary 
resistance mechanisms that are usually more time-consuming such as membrane charge 
alterations. 
Nevertheless, the actual mode of AMPs resistance by the bacteria is not 
completely clear and there are exceptions to the observations. For example, both wild-
type and CPS-deficient mutant of Campylobacter jejuni were as resistant to AMPs 
(Zilbauer et al., 2005). Also, S. pneumoniae of serotypes 1, 2, and 4 were more sensitive 
to AMPs than the isogenic CPS mutants (Beiter et al., 2008). One possible explanation 
to this is that the presence of CPS might in turn mask the surface modifications 
produced by the pneumococci in an attempt to reduce the susceptibility against AMPs 
(Beiter et al., 2008). In a recent study, serotype alone was found to be insufficient to 
deduce the susceptibility of S. pneumoniae against AMPs but rather the differences in 
susceptibility was suggested to be due to genetic variation of the individual 
pneumococcal strains (Habets et al., 2012).  Hence, the roles of CPS as well as other 
molecules in enhancing AMPs resistance are debatable and more findings are needed to 
support the notion.  
On the other hand, certain bacteria are able to secrete proteolytic enzymes to 
inactivate the microbicidal activity of AMPs. This had been determined in S. aureus 
whereby the release of aureolysin inactivated LL-37 and hence the bacteria resistance 
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against the clearance mechanism by the host innate immunity (Sieprawska-Lupa et al., 
2004). 
 
1.7. AMPs as novel antimicrobial agents 
The development and the eventual availability of novel antibiotics has never been 
in pace with the rate at which the bacteria adapt and develop resistant. This is of great 
concern as only very few new family of antibiotics have been discovered in the past 30 
years (Hancock, 2001). Conventional antibiotics have observed considerable decline in 
antimicrobial efficacy due to the progressive expansion of antibiotic-resistant organisms 
and increasing tolerability against the commonly used antibiotics (Davies, 1994; 
Schutze et al., 1994). With the reports of not only PISP and PSSP but also the very-
high-level resistant strains, novel classes of antibiotics active against pneumococcus are 
extremely in demand in the near future (Ganz, 2001; Schrag et al., 2004). For this 
reason, the discovery of AMPs and its potential application as novel therapeutic agents 
sheds light on this problem (Hancock & Sahl, 2006; Sang & Blecha, 2008).  
AMPs are rapid acting molecules whereby the killing activity begins 
instantaneously upon exposure of the cells to the AMPs. These direct and rapid modes 
of bacterial destruction greatly reduce the chances of resistance development by the 
bacteria. Indeed, even after such a long time of evolutionary, the continue survival of 
host indicates that the harmful microbes do not seem to acquire sufficient resistance 
against AMPs. Many studies have thus investigated into the potential use of AMPs as 
novel antibacterial agents against new targets (Boman, 1995; Devine & Hancock, 2002; 
Lehrer & Ganz, 1999; Zasloff, 2002a). 
From isolation of AMPs from natural sources and determination of their 
biological activity, researchers are investing intense efforts into developing synthetic 
analogues of AMPs with enhanced antimicrobial activity while reducing cell toxicity 
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effects to be developed as a clinically usable therapeutic agents. In fact, AMPs with 
multifunctional roles have been increasingly identified ever since. One good example is 
the continued expansion of the entries in various AMPs databases, particularly the 
Antimicrobial Peptide database which initially included only the antibacterial, 
antiparasital, and antifungal peptides but has then expanded to include antiviral, 
insecticidal, anti-HIV, antiprotist, spermicidal, as well as anticancer/antitumor peptides 
and AMPs with chemotactic activity (Wang et al., 2009). The design of novel synthetic 
analogues are mainly based on existing AMPs isolated from various sources and to 
which determined with strong antimicrobial activities. 
 
1.7.1. Cathelicidins 
Human polymorphonuclear neutrophilic leukocytes produce a wide variety of 
AMPs which are mainly localized in the granules (Giovannini et al., 1987) (Levy, 1996). 
Among them, cathelicidins family of AMPs is predominantly found in the peroxidase 
negative granules of vertebrate neutrophils (Zaiou & Gallo, 2002; Zanetti et al., 1995). 
These peptides represent an important effector component in human innate immunity 
(Zanetti, 2004). Despite showing considerable structural variations, cathelicidins as well 
as other amphipathic α-helical AMPs including IsCT, Magainins, Cecropins, LL-37, 
Ovispirins, Melittin, Pleurocidin, and SMAP29 are generally cationic, linear, and has no 
cysteine. 
The C-terminal fragment of cathelicidins is widely recognized as the biologically 
active domain responsible for the antimicrobial activity of cathelicidins. Unlike the C-
terminus which possess highly varied amino acid sequences and secondary structure, the 
12 kDa N-terminus of cathelicidins known as cathelin is highly conserved. Cathelin has 
been found to possess dual-functionality in coordinating the cystein-proteinase-
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mediated tissue damage and also inhibits the growth of E. coli and MRSA (Zaiou et al., 
2003). 
Despite large number of cathelicidins being isolated from porcine and bovine 
neutrophils, to date the only cathelicidin identified in human is the human cationic 
antimicrobial protein hCAP18 (Agerberth et al., 1995; Cowland et al., 1995; 
Gudmundsson et al., 1996; Larrick et al., 1995; Larrick et al., 1996). hCAP18 was first 
isolated from human bone marrow cells and testis (Agerberth et al., 1995). Later, 
hCAP18 had also been detected from various immune and epithelial cells (Frohm 
Nilsson et al., 1999) (Agerberth et al., 1999; Bals et al., 1998) (Frohm et al., 1997) 
(Malm et al., 2000) (Di Nardo et al., 2003). The C-terminus of hCAP18 is known as 
LL-37, a 37 amino acids peptide led by two leucine residues (De Smet & Contreras, 
2005). This short peptide had been detected in bronchial epithelial cells, bronchial 
glands, and alveolar macrophages (Agerberth et al., 1999; Bals et al., 1998). LL-37 is 
known for its indispensable role in pulmonary innate immunity (Zhang et al., 2000b). 
Moreover, LL-37 exhibits broad spectrum antibacterial activity (Turner et al., 1998) and 
the effect can be further synergized with the presence of defensins (Nagaoka et al., 
2000). Additionally, LL-37 serves important roles in wound healing and inflammatory 
responses by functioning as re-epithelialization promoting agent (Heilborn et al., 2003), 
as chemotactical agent to recruits T cells, monocytes, and neutrophils to the site of 
infections (De et al., 2000), and roles in angiogenesis and arteriogenesis (Heilborn et al., 
2003; Koczulla et al., 2003). LL-37 also possesses endotoxin-neutralizing effects 
(Golec, 2007; Nagaoka et al., 2001). Deficiency in LL-37 has been suggested to be 
associated with specific clinical conditions as seen with the manifestation of 
periodontitis in morbus Kostmann patients (Putsep et al., 2002). A significant drawback 
observed with LL-37 is the associated cytotoxicity against mammalian cells (Johansson 
et al., 1998). 
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1.7.2. Magainins 
Amphibian skin glands secrete a variety of AMPs as a measure to protect the 
constantly moisturized skin where essential metabolic processes are taken place from 
microbial infections (Barra & Simmaco, 1995; Rollins-Smith et al., 2005). Magainins 
are produced naturally by the skin gland of African clawed frog Xenopus laevis (Zasloff, 
1987). Magainins are α-helical cationic peptides that exhibit broad spectrum 
antibacterial activity against gram-positive and gram-negative bacteria, antifungal, and 
antiprotozoan activities while having low toxicity against eukaryotic cells (Bevins & 
Zasloff, 1990; Zasloff, 1987). Similar to other frog-skin derived peptides, magainins 
also have important roles in the regulation of mammalian hormones and 
neurotransmitters (Bevins & Zasloff, 1990). Magainin 1 and magainin 2 are 23 amino 
acids in length and differ by two residual substitutions between them (Zasloff, 1987). 
Magainin 2 is a membrane active peptide capable of forming transmembrane pores in 
the bacterial cell membrane leading to cell lysis (Kobayashi et al., 2000; Park et al., 
1998; Park et al., 2000; Wenk & Seelig, 1998). A schematic illustration of 
transmembrane pores formed by magainins is shown in figure 1.7 (Yang et al., 2000).  
 
 
 
 
 
 
 
Figure 1.7: Schematic representation of formation of magainin pores in membrane, 
inducing cellular leakage and cell death (adapted from Yang et al., 2000). 
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Another subtype, peptidyl-glyclyleucine-carboxyamide (PGLa) is a C-terminally 
amidated 21 amino acids peptide with sequence GMASKAGAIAGKIAKVALKAL 
(Andreu et al., 1985; Hoffmann et al., 1983). Interestingly, magainin 2 and PGLa are 
able to interact cooperatively in a synergistic manner against bacteria, artificial 
membranes, and also tumor cells (Matsuzaki et al., 1998). Magainin 2 is a slow pore 
former but the pores formed remain stable and long-lived. In contrast, PGLa is a rapid 
pore former but the pores formed are rather unstable as compared to magainin 2. When 
the peptides are presented to membranes in 1:1 ratio, the complex formed display the 
advantageous properties of the respective peptide producing fast pore formation rate 
with moderate stability. These properties warrant their potential use as new antibiotic 
agents (Matsuzaki, 1998). 
Apart from magainin and PGLa as described above, several other classes of 
amphibian AMPs have also been reported. This includes brevinins from the European 
frog Rana brevipoda porsa (Morikawa et al., 1992), temporins from R. temporaria 
(Simmaco et al., 1996), dermaseptin from Phyllomedusa sauvagii (Mor et al., 1991), 
and Ranalexin from R. catesbeiana (Clark et al., 1994). Recently, a novel class of frog 
AMPs has been isolated from the skin of Amolops loloensis in southwest China (Wang 
et al., 2008) and also the first documentation of sea frog R. cancrivora AMPs (Lu et al., 
2008). For these reasons, it was speculated that amphibians skin as well as other 
organisms in the nature might own a large pool of novel AMPs that is yet to be 
discovered for potential therapeutic applications (Barra & Simmaco, 1995). 
 
1.7.3. Prophenins 
Prophenins (PF) are group of AMPs isolated from porcine leukocytes. Prophenin-
1 (PF-1) is a proline- (53.2%) and phenylalanine-rich peptide (19.0%) having 79 
residues encoded on a cathelin-containing precursor (Harwig et al., 1995a). The 60 
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residues fragment at the N-terminus consists of two sets of identical and near-identical 
decamer repeats FPPPNFPGPR. Later, two major PF-2 variants prophenin-2-
pyroglutamic acid (PF-2-pyr) and prophenin-2-glutamine (PF-2-gln) had also been 
detected from the porcine pulmonary tissue extracts (Wang et al., 1999). PF-2-gyr is 80 
amino acids in length with an N-terminal pyroglutamic residue whereas the PF-2-gln 
consists of an amidated N-terminal glutamine (Wang et al., 1999; Wang et al., 2000). 
The level of PF-1 is higher in leukocytes as compared to the pulmonary tissue extracts 
(Wang et al., 2000). In addition, shorter peptides corresponding to the N-terminal 17- 
and 18- residues fragment of PF have also been reported. The 18 residues peptide 
showed comparatively higher antibacterial activity against the gram-positive Bacillus 
megatarium Bm11 than E. coli D21 in the absence of salt (Wang et al., 1999). 
Surfactant containing AMPs, especially the 18 residues peptide has been suggested as a 
potential local treatment agent for pulmonary infections (Wang et al., 2004). 
 
1.7.4. Defensins 
Defensins are one of the two major genetic categories of mammalian AMPs 
beside cathelicidins. Ganz et al. had first identified human defensins from the 
neutrophils (Ganz et al., 1985). The mature defensins peptides shared several 
physicochemical properties including short peptide length of 18 to 45 amino acids, net 
cationic charge (+1 to +11), lack of acyl or glycosyl-chain modifications, has six 
conserved cystein residues, three intramolecular disulfide bridges, and turn-linked β-
strands dominated tertiary structures (Kagan et al., 1994; Lehrer et al., 1993). Upon 
ingestion of invading bacteria by the immune cells, defensins in the phagocytic vacuoles 
will be delivered to the bacterial cells to induce immediate killing (Andreu & Rivas, 
1998), principally by targeting the plasma membrane (Liu et al., 2008a; Papo & Shai, 
2003). Defensins also modulate the intracellular signaling events, stimulating the 
61 
 
 
maturation of host defense leucocytes and exhibit multiple antiinfective activities 
(Boman, 1995; Xiong et al., 1999). 
Both α- and β-defensins are genetically and structurally more closely related as 
compared to θ-defensins (Selsted et al., 1993). They are distinguishable by the linear 
spacing and presence of tridisulfide bridges formed by six conserved cysteine residues 
in the peptide chain (Kagan et al., 1994; Lehrer et al., 1993). The disulfide bridges are 
suggested to be associated with antimicrobial activity (Daher et al., 1986; Mandal & 
Nagaraj, 2002). The N-terminally truncated human β-defensins 1 (hBD-1) isoform is of 
interest due to its strong antibacterial effects (Valore et al., 1998). Following that, two 
additional forms, hBD-2 and hBD-3 have been detected from the scales of a psoriatic 
skin patient (Harder et al., 1997, 2001). In skin diseases such as psoriasis (Harder & 
Schroder, 2005) and in bronchoalveolar inflammation (Hiratsuka et al., 2003; Ross et 
al., 2004), the concentrations of hBD-2 and hBD-3 were found to increase significantly. 
In a study conducted by Lee et al., lysozyme and β-defensin-2 were found to be 
interacting in a synergistic manner against S. pneumoniae (Lee et al., 2004a). Although 
the fourth type, hBD-4 has not yet been isolated from any natural source, the sequence 
based on cDNA analysis had been predicted and synthesized artificially (Garcia et al., 
2001).  
A number of studies have documented the importance and potential role of 
defensins in diseases and microbial infections. The concomitant lower level of hBD-2, 
hBD-3 due to T-helper type 2 cytokine upregulation (Nomura et al., 2003) had greatly 
increased the risks of skin infections by bacteria, fungi, or viruses among patients with 
atopic dermatitis (Ong et al., 2002). In the event of psoriatic lesions, patients suffer 
unexpectedly low episodes of infections (Harder & Schroder, 2005). Moreover, the 
enteric α-defensin subclass is particularly vital in maintaining the equilibrium of 
microbiota in the intestinal mucosal (Salzman et al., 2010). Deficiency in α-defensin 
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had been associated with ileal Crohn‟s disease and enteric infections (Wehkamp et al., 
2005; Wilson et al., 1999). In vivo studies using mice challenged by enteric Salmonella 
typhimurium indicated that the tight regulation on the production of defensins as well as 
other AMPs are critical as aberrant expression of enteric α-defensin can alter the 
composition of commensal microbiota considerably (Salzman et al., 2010). Interestingly, 
the role of β-defensin in sperm maturation had also been described (Yudin et al., 2003; 
Zhou et al., 2004). 
 
1.7.5. Protegrins 
Protegrins are membrane-active peptides act by forming weakly-anionic selective 
channel in the bacterial membrane (Lai et al., 2006; Mani et al., 2005; Sokolov et al., 
1999). Members from protegrins family of AMPs share the physicochemical properties 
of 16 to 18 amino acids in length, cationic, arginine- and cysteine-rich, and adopt a 
secondary structure of two-stranded antiparallel ß-sheet structure (Fahrner et al., 1996; 
Kobayashi et al., 2005; Sokolov et al., 1999). Amphiphilicity, charge, and the native 
peptide structure determine the antibacterial activity of protegrins (Chen et al., 2000). 
The overall structure maintains primarily by the bidisulphide bridges and also hydrogen 
bonding is crucial for antibacterial activity of protegrins rather than the presence of 
specific residues or its stereotype (Chen et al., 2000). It has been suggested that LPS-
targeting represents the principal mode of action by protegrins as protegrins showed 
higher affinity against gram-negative than gram-positive bacteria (Chen et al., 2000).  
To date, as much as five highly homologous native protegrin (PG-1 to 5) had been 
identified (Zhao et al., 1995; Zhao et al., 1994). They exhibit broad spectrum 
antimicrobial activity against a number of common pathogens such as E. coli, Candida 
albicans, Neisseria gonorrhoeae, and Listeria monocytogenes (Kokryakov et al., 1993; 
Qu et al., 1996; Tamamura et al., 1995; Yasin et al., 1996). In addition, the antiviral 
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activity against HIV had also been documented (Tamamura et al., 1995). The promising 
outcomes from the use of protegrins especially in oral mucositis (Bellm et al., 2000; 
Mosca et al., 2000) and respiratory-associated diseases (Cole & Waring, 2002) warrant 
further development of protegrins as novel therapeutic agents. 
 
1.8. Designing novel antimicrobial peptides 
Various strategies in designing novel synthetic analogues of AMPs have been 
described. One widely used method is the sequence-based approach which correlates 
antimicrobial activity as the function of change with regards to physicochemical 
properties of AMPs. This approach is more direct and simple in design and does not 
usually require high level computer modeling. Ueno et al. had attempted to design novel 
cationic AMPs based on a conservative strategy via acid-amide substitution (i.e. Glu to 
Gln, Asp to Asn) (Ueno et al., 2011). These substitutions will not cause major 
conformational alteration as compared to the parent peptide thus helps preserve the 
integrity of the original structure to the highest extent (Ueno et al., 2011). Interestingly, 
the newly generated peptides NP1P, NP2P, and NP3P showed marked increased in 
antibacterial activity against the gram-positive S. aureus, Bacillus subtilis, and 
Micrococcus luteus as well as the gram-negative P. aeruginosa, S. typhimurium, E. coli, 
and Serratia marcescens (Ueno et al., 2011). On the other hand, Pasupuleti et al. 
noticed that end-tagging AMPs with hydrophobic amino acids Trp or Phe enhanced 
antimicrobial activity against both S. aureus and E. coli. The high potency of peptide 
was suggested to be due to high bacterial binding which caused bacterial cell lysis 
(Ueno et al., 2011). On top of this, several of the novel synthetic AMPs designed based 
on considerations on four physicochemical parameters including NetC, hydrophobicity, 
hydrophobic moment, and polar angle were found to exhibited high selectivity against 
Vibrio spp. (Chou et al., 2008).  
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Great majority of natural AMPs were characterized by the cationicity window 
between NetC of +4 to +6 (Giangaspero et al., 2001), which appears that AMPs would 
have an optimal working window for best antimicrobial activity (Tossi et al., 2000).  
Dathe et al. demonstrated that increasing the NetC of magainins 2 up to the threshold 
+5 enhanced antimicrobial activity of the peptides (Dathe et al., 2001). However, no 
additional effect was noted up to a NetC of +7 but hemolytic activity become gradually 
significant (Dathe et al., 2001). Increased in NetC of AMPs at the polar face has been 
suggested to enhance antimicrobial activity of the peptides. This is evident where single 
amino acid substitution from serine to lysine at the polar face of S16 produced K11 with 
two-fold increments in therapeutic index (Jin-Jiang et al., 2012). A study conducted by 
Jiang et al. showed that both NetC and number of cationic residues on polar face of 
peptides were associated with antimicrobial activity and hemolytic activity of α-helical 
AMPs (Jiang et al., 2008). The antimicrobial potency of the peptides correlated well 
with NetC of peptides within the window of +4 to +8 with minimal hemolytic activity; 
lowering than +4 rendered the peptides ineffective while overly high positive charges (≥ 
+9) was associated with high level hemolytic activity (Dathe et al., 2001).    
The influence of peptide hydrophobicity on α-helical AMPs was investigated by 
Chen et al. in a study using V13KL as the lead peptide (Chen et al., 2007). 
Hydrophobicity of the peptides was altered systematically by alternatively substituting 
leucine with alanine. It was found that high antimicrobial activity of peptide fell within 
an optimum hydrophobicity window. Deviation from the specific range would render 
the loss of antimicrobial activity with the peptides (Chen et al., 2007). Moreover, high 
hydrophobicity and amphipathicity were associated with hemolytic activity (Chen et al., 
2007; Chou et al., 2008). Yan et al. extracted the 15 residues C-terminal segment of 
melittin and systematically altered the hydrophobicity of the peptides (Yan et al., 2003). 
It was found that increased in hydrophobicity but not amphipathicity enhanced 
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antimicrobial activity although the effects at specific positions were more significant 
than others (Yan et al., 2003). Interestingly, the antimicrobial and hemolytic activities 
were suggested to favor the opposite faces and this indicates that antimicrobial activtity 
could be dissociated from the side effects with careful consideration on region/face of 
the peptides (Yan et al., 2003).   
The presence of specific amino acid residue is sometime crucial for the 
antimicrobial activity of the peptides. Huang et al. noticed that substitution of the 
nonpolar face amino acid leucine which located at the 9
th
 position from the N-terminus 
of S16 with a polar amino acid (arginine, serine, or lysine) would cause a dramatic 
reduction in the antimicrobial potency of the peptide by more than sixteen-fold (S16 
MIC = 3.125 µg/ml, S9 MIC = 50 µg/ml, K9 and R9 MIC = > 50 µg/ml) (Huang, 2000). 
Indolicidin is an AMP from bovine neutrophils with high proportion of tryptophan and 
proline residues (ILPWKWPWWPWRR-NH2) (Selsted et al., 1992). Subbalakshmi and 
colleagues have investigated into the roles of these residues in the sequence in relation 
to antimicrobial and hemolytic activity (Subbalakshmi et al., 1996). It was determined 
that the presence of tryptophan contributed to the hemolytic activity of the peptide and 
the analogue with tryptophan replaced by phenylalanine displayed no hemolytic activity 
while having comparable antimicrobial activity (Subbalakshmi et al., 1996). On the 
other hand, Loose et al. undertaken a unique linguistic approach for the design of AMPs 
by looking at the sequence of amino acids as “grammar” of a formal language (Loose et 
al., 2006). The basis of the linguistic model is related to repeated occurrences of 
sequence modules which resembles phrases of a language (Loose et al., 2006). Set of 
regular grammars were constructed to describe this language. In the example given by 
the authors, the sequence QxEAGxLxKxxK (where “x” denotes random amino acid) is 
highly common among cecropins, the insect AMPs (Loose et al., 2006). 
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C-terminal amidation also represents a potential strategy to enhance the 
antibacterial potency of peptides and to increase the proteolytic resistibility of the 
peptides (Hou et al., 2011). A C-terminally amidated thanatin which is an insect-derived 
Podisus maculiventris showed strong antibacterial effect against gram-negative bacteria, 
in particular, the extended-spectrum B-lactamase-producing E. coli. (Fehlbaum et al., 
1996; Hou et al., 2011). 
 
1.9. Justification and objective of the study 
Although the first PCV7 vaccine has been available since year 2000, however, 
none of the PCVs are currently included under the childhood vaccination scheme in 
Malaysia. Documentations on the serotypes distribution among the Malaysian 
population is especially scarce and only a few studies being reported throughout the 
years (Le et al., 2012). Continued monitoring of serotype distribution is important to 
predict the potential coverage of PCVs among the local population and to recommend 
on the use of PCV for routine immunization. The prevalence of penicillin-susceptibility, 
invasiveness, and age groups of patients can be obtained as well.  
Pneumococcal resistance to conventional antibiotics especially β-lactam 
antibiotics has been increasingly reported worldwide. Novel antimicrobial agents are 
exceptionally in demand. Owing to its rapid and broad spectrum antibacterial activity, 
AMPs represents the most potential next-generation antimicrobial candidates. The 
hypothesis of the current study was synthetically designed novel antimicrobial peptides 
is potentially more effective in their antimicrobial activity and cell cytotoxicity than 
presently available antimicrobial agents. The potential therapeutic efficacies of the 
designed AMPs were assessed using in vivo murine pneumococcal infection models. 
Thus, the study was designed with the following objectives: 
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1. To determine the antibiotic susceptibility and serotype distribution of S. 
pneumoniae among the Malaysian population. 
2. To design synthetic antimicrobial peptides with high reactivity against penicillin-
resistant S. pneumoniae. 
3. To assess the in vitro antibacterial activity and cell toxicity of synthetic 
antimicrobial peptides. 
4. To develop mouse models of lethal pneumococcal infections for the determination 
of the suitable mode of administration of these synthetic antimicrobial peptides in 
vivo. 
5. To determine the toxicity, therapeutic efficacy and therapeutic synergism of 
synthetic antimicrobial peptides in vivo. 
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CHAPTER 2 
MATERIALS & METHODS 
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2.1. Isolates collection and identification 
A total of 151 pneumococcal isolates were obtained from clinical samples which 
were processed and stored at the Microbiology Laboratory of the University of 
Malaya Medical Centre (UMMC), Malaysia from March 1999 to February 2007 
(except year 2001 and 2004). Both invasive and noninvasive isolates from patients of 
all ages were included. The source of the isolates included blood, cerebrospinal fluid 
(CSF), nasopharyngeal (NP) secretion, tracheal secretion, sputum, bronchoalveolar 
lavage (BAL), and others. The isolates were grown on 5% (v/v) horse blood agar at 
37°C under 5% CO2 for 12 - 15 hours before being subjected to biochemical identification 
tests and molecular assays. 
 
2.1.1. Hemolytic pattern on blood agar 
S. pneumoniae isolates were grown overnight on defibrinated sheep blood agar 
(Oxoid, UK) at 37
o
C under 5% CO2. The bacteria produced α-hemolysis resulting in 
greenish-brown appearance of the agar (Figure 2.1). This is due to the incomplete 
breakdown of hemoglobin to methemoglobin by hydrogen peroxide of S. pneumoniae.  
 
 
 
 
 
 
Figure 2.1: α-hemolysis by S. pneumoniae producing greenish-brown agar area 
surrounding the colonies. 
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2.1.2. Gram stain 
Three to four well isolated pneumococcal colonies were directly suspended in 
phosphate buffered saline (PBS) on a clean glass slide and heat-fixed. The slide was 
then flooded with the primary stain crystal violet for 1 min, washed with distilled water, 
flooded with the mordant Lugol‟s iodine for 1 min, washed with distilled water, added 
with few drops of 70% (v/v) ethanol for rapid decolorization and again washed with 
distilled water before addition of diluted carbol fuschin for 1 min. The slide was washed 
with distilled water and air-dried for viewing using a light microscope. S. pneumoniae 
was observed as gram-positive in single, diplococci, or in long chain form (Figure 2.2). 
 
 
2.1.3.  Catalase test 
Three to four colonies from an overnight culture were picked using a wooden 
applicator stick and dipped onto a glass slide with two to three drops of 3% hydrogen 
peroxide. Observation of bubbling (oxygen) was positive reaction which indicated the 
production of catalase enzyme in the bacteria. S. pneumoniae is catalase-negative and 
can be differentiated from the catalase-positive Staphylococcus spp.. 
Figure 2.2: Gram positive staining of the overview (left) and close-in view (right) of 
S. pneumoniae at 1000X magnification. 
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2.1.4. Ethylhydrocupreine hydrochloride (optochin) susceptibility test 
Overnight culture of the isolate on sheep blood agar was adjusted to OD625 0.08 – 
0.1 in PBS. A lawn of the culture was then made on a fresh sheep blood agar and the 
ethylhydrocupreine hydrochloride (optochin) disk (Oxoid, UK) was placed at the centre 
of the lawn before incubation at 37°C under 5% CO2 for 18 - 24 hrs (Figure 2.3). S. 
pneumoniae is susceptible and produces an inhibition zone of ≥ 14mm in diameter 
according to the Clinical and Laboratory Standard Institute (CLSI) guidelines which is 
distinguishable from the closely-related viridans streptococci. 
2.1.5. Bile solubility 
S. pneumoniae is susceptible to bile lysis. A few drops of 10% (w/v) sodium 
deoxycholate were added into the bacteria suspended in Mueller-Hinton Broth (MHB) 
and incubated at 37°C for 10 mins. The turbidity of the suspension was cleared as 
compared to the non-bile soluble Streptococcus mitis (Figure 2.4).   
Figure 2.3: S. pneumoniae produced ≥ 14 mm zone of inhibition with optochin disk 
test. 
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2.2. Antibiotic susceptibility testing 
The penicillin susceptibility of S. pneumoniae was determined using the agar 
dilution method according to the CLSI guidelines (Clinical and Laboratory Standards 
Institute, 2005). Penicillin in powder form (Sigma Chemical Co., St. Louis, Mo) was 
dissolved in sterile deionized distilled water as recommended by CLSI according to the 
formula:  
  
    
 
 
 
where W is the weight of antibiotic powder (g); V is the volume of solvent; ρ is the 
potency of the antibiotic; and C is the desired concentration of the antibiotic to be 
prepared. The volume of the solvent was adjusted according to the weight of antibiotic 
weighed to ease and allow a more accurate preparation of stock concentration. The 
stock antibiotic prepared was then filter sterilized using a 0.20 µm disposable syringe 
filter. The stock antibiotic was then diluted to an appropriate working concentration 
Figure 2.4: S. pneumoniae was cleared by bile lysis (right) as compared to S. mitis 
(left). 
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followed by two-fold serial dilutions of the antibiotic in sterile deionized distilled water 
in multiple vials. This was to avoid repeated freeze-thawed cycle that would reduce the 
potency of antibiotics. The stock and working solutions prepared were stored in -20
o
C. 
The penicillin susceptibility tests were conducted on Mueller Hinton Agar (MHA) 
(Oxoid, UK) containing 5% (v/v) defibrinated sheep blood (Oxoid, UK) supplemented with 
penicillin. All growths were incubated at 37°C under 5% CO2 for 18 – 24 hrs. The MHA 
was prepared in distilled water according to manufacturer‟s protocol and autoclaved 
under standard condition (121
o
C, 15 mins). The molten agar was then equilibrated to 
55
o
C in a waterbath. Each petri dish was first added with 2 ml of the antibiotic at the 
respective desired working concentration and 1 ml of defibrinated sheep blood (Oxoid, 
UK) to 5% (v/v) final concentration. Subsequently, 17 ml of the molten agar was poured 
into the petri dishes and gently swirled immediately to ensure even distribution of the 
antibiotic in the agar. The plates were allowed to solidify at room temperature before 
storage at 4
o
C in refrigerator until use. S. pneumoniae ATCC 49619 was included in each 
run as quality control strain. Non-penicillin containing blood agar plates were also 
prepared as control in each run. 
 
2.3. Multiplex Polymerase Chain Reaction (PCR) serotyping 
2.3.1. DNA extraction 
Pneumococcal DNA extraction was performed as described previously (Unal et 
al., 1992). Briefly, bacterial colonies were suspended in 15 l of distilled water 
containing 50 g/ml lysostaphin and incubated at 37°C for 10 mins. Bacterial colonies 
suspended in 15 l of distilled water were treated with 10 g/ml Proteinase K and 
0.l mM Tris HCl pH 7.5 and incubated at 37°C for 10 mins. Subsequently, the 
suspension was boiled for 5 mins and finally centrifuged at 13000 rpm for 2 mins. 
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The supernatant obtained was used as the template in the multiplex polymerase chain 
(PCR) reaction. 
 
2.3.2. Multiplex PCR scheme 
The primers used in this study were extracted from previously published 
sequences and the PCR protocol was as previously described (Pai et al., 2006).
 
Briefly, 
the primers were grouped into seven multiplex reactions as shown in Figure 2.5. 
Each reaction was designed to include four primer pairs targeting four different 
serotypes/serogroups and another primer pair cpsA targeting the common region of 
the cps operon as internal positive control. Control strains of known serotypes by 
Quellung reaction representing different serotypes and serogroups were included as 
positive control in the respective serotyping pools. The serotypes included 1, 2, 3, 4, 5, 
8, 13, 14, 20, 21, 31, 34, 37, 38, 39, 40, 44, 46, 6A, 7A, 7B, 7C, 7F, 9A, 9N, 9L, 10A, 
10F, 11A, 11D, 11F, 12A, 12B, 12F, ISA, 15B, 15C, 15F, 16A, 16F, 17F, 33A, 35B, 
35F, 35A, 35C, and 47F. The optimal PCR condition for a 25l reaction included 
1X PCR buffer (Fermentas, Lithuania), 2.5 mM MgCl2, 0.2 mM dNTP mix, 2U 
Taq Polymerase (Fermentas, Lithuania) and primer pairs at varying concentrations as 
shown in Table 2.1 (Pai et al., 2006). The PCR cycling was carried out in an Eppendorf 
Gradient Mastercycler with initial denaturation step at 94°C for 4 mins and the 30 
amplification cycles were performed with denaturation at 94°C for 45 s, annealing 
temperature at 54°C for 45 s and extension temperature at 65°C for 2 mins and 30 s and 
finally completed with an extension at 72°C for 2 mins (Table 2.2). The PCR 
product was electrophoresed on a 2% (w/v) Tris-acetic EDTA (TAE) agarose gel 
(Fermentas, Lithuania) for 1 hour at 70V and the bands were analyzed using a UV 
transilluminator. 
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Reaction 2 
Primer pairs: 
4,9V/(9A),12F/(12A),14 
Internal 
positive control 
Reaction 5 
Primer pairs: 
8,15B/15C,31,38/(25F) 
Internal 
positive control 
Reaction 6 
Primer pairs: 
1,10A,34,35F/(47F) 
Internal 
positive control 
Reaction 3 
Internal 
positive control 
Primer pairs: 
7F/(7A),11A/(11D),23F, 
33F/(33A,37) 
Reaction 4 
Internal 
positive control 
Primer pairs: 
16F,18C/(18B,18A,18F)
,19F,35B 
Reaction 7 
Internal 
positive control 
Primer pairs: 
7C/(7B,40),15A,17F,20 
Reaction 1 
Primer pairs: 
3,6A/B, 19A, 22F/(22A) 
Internal 
positive control 
Figure 2.5: The seven multiplex PCR deduction reactions for pneumococcal 
serotyping. Internal positive control cpsA was simultaneously included in each 
reaction (Le et al., 2011b).  
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Table 2.1: The seven multiplex PCR deduction pools for pneumococcal serotyping 
(adapted from Pai et al., 2006) 
 
Reaction 
Product 
size (bp) Primers 
Primer 
concentration 
(µM) 
1 371 3-f, 3-r 1.5 
 250 6A/B-f (biotin), 6A/B-r 0.5 
 478 19A-f, 19A-r 1.0 
 643 22F-f, 22F-r 1.5 
    
2 430 4-f, 4-r 1.5 
 753 9V-f, 9V-r 1.5 
 376 12F-f, 12F-r 1.5 
 208 14-f, 14-r 1.0 
    
3 826 7F-f, 7F-r 2.0 
 463 11A-f, 11A-r 1.0 
 384 23F-f, 23F-r 1.5 
 338 33F-f, 33F-r 1.0 
    
4 988 16F-f, 16F-r 2.0 
 304 19F-f, 19F-r 1.5 
 677 35B-f, 35B-r 1.0 
 573 sg18-f, sg18-r 1.25 
    
5 294 8-f, 8-r 1.5 
 496 15B/C-f, 15B/C-r 1.5 
 701 31-f, 31-r 2.0 
 574 38-f, 38-r 1.5 
    
6 280 1-f, 1-r 1.5 
 628 10A-f, 10-r 1.5 
 408 34-f, 34-r 1.5 
 517 35F-f, 35F-r 1.5 
    
7 260 7C-f, 7C-r 1.5 
 436 15A-f, 15A-r 1.5 
 693 17F-f, 17F-r 1.5 
 514 20-f, 20-r 1.5 
* The cpsA primer targeting the common cps operon region was included in each 
reaction at 0.5 µM each. 
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 Table 2.2: PCR conditions for multiplex PCR serotyping of S. pneumoniae. 
  
Step Temperature (
o
C) Duration 
1 Initial denaturation 94.0 4 mins 
2 Denaturation 94.0 45 s 
3 Annealing 54.0 45 s 
4 Extension 65.0 2 mins 30 s 
Step (2) to (4) were repeated for a total of 30 cycles. 
5 Final extension 72.0 2 mins 
78 
 
 
2.4. Peptides design 
2.4.1. Selection of lead peptides 
A Small Peptides Library was set up by searching into two publicly available 
databases: RCSB Protein Data Bank (PDB) (http://www.rcsb.org/pdb/home/home.do) 
and Antimicrobial Peptide database (APD) (http://aps.unmc.edu/AP/main.php). 
Potential AMPs including the naturally occurring or the synthetic variants described in 
the literature with experimentally determined antibacterial activity were also included. 
These peptides were termed natural AMPs. No preferred selection on the 
physicochemical properties of AMPs, however, anionic AMPs were not included and 
only AMPs with chain length of 30 amino acids or less were of interest due to the better 
simplicity in designing.  
With the initial list of 54 natural AMPs, the next step was to narrow down and 
select a subset of peptides with the highest likelihood of having inhibitory effects 
against the target organism S. pneumoniae. Since the binding compatibility between 
these natural AMPs and PBPs have not been previously studied using X-ray 
crystallization and NMR methods, hence the actual structure of the complex cannot be 
defined, thus the need for binding prediction. The .pdb structural files of natural AMPs 
and PBPs were identified and downloaded from PDB. The ZDock server 
(http://cagt.bu.edu/page/ZDOCK_download) was utilized to predict the potential 
binding compatibility between the natural AMPs and the six pneumococcal PBPs (Table 
2.3). ZDock uses a fast fourier transform method to search for all possible binding 
modes based on shape complementarity, desolvation energy, and electrostatics. The 
application shortlisted the top 2000 possible structural combinations (PSCs) protein 
complexes and generated output data files showing the structural position in three-
dimensional space. This application was then executed for all 324 (6 PBPs x 54 natural 
AMPs) combinations. 
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In the next stage, we set out to elucidate the predictions using BioMoDroid 
algorithm (Rathinam, personal communication). The algorithm assumes the fact that the 
stronger the bond between the natural AMPs and the target, the closer it would be in 
structural space. The software was used to calculate the distance, d, between the 
centroid of each natural AMP and its PBPs in each PSC (output from the previous 
application). The application was written in C++ computer language and executed on 
Linux shells on a Intel Quad-Core powered server. The centroid was calculated by 
averaging the xyz coordinates of each atom of each amino acid in the sequence. This 
distance value was then used to count the number out of the 2000 PSCs and rank each 
natural AMPs - PBPs combination. The top ten natural AMPs were shortlisted for 
further investigations: 1D9J, 1Q71, 1M4F, 1HU5, 1MA2, 1HR1, 1T51, 1PG1, 1X7K, 
and 1VM4. 
 
Table 2.3: The six target pneumococcal PBPs obtained from PDB for peptide 
design. 
 
  
PDB ID Entry Description Literature 
1K25 
PBP2x from a highly penicillin-resistant S. pneumoniae 
clinical isolate 
Dessen et al., 
2001 
1PMD penicillin binding protein 2x 
Pares et al., 
1996  
1QME 
penicillin-binding protein 2x from S. pneumoniae 
implicated in drug resistance 
Gordon et al., 
2000 
1RP5 
PBP2x from S. pneumoniae strain 5259 with reduced 
susceptibility to beta-lactam antibiotics 
Pernot et al., 
2004 
2C5W 
crystal structure of penicillin-binding protein 1a reveals 
a mutational hotspot implicated in beta-lactam 
resistance in S. pneumoniae 
Contreras-
Martel et al., 
2006 
2JCI 
 
Structural insights into the catalytic mechanism and the 
role of S. pneumoniae PBP1b (Entry 2JCI obsoleted on 
26/5/2010, superceded by 2XD5) 
Macheboeuf et 
al.  2009 
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2.4.2. Design of synthetic AMPs 
There are many possible strategies to introduce sequence modifications and no 
single best method that is superior over another. For each of the natural AMPs selected, 
one designed AMP was generated by single or combination of the following techniques: 
single amino acid substitution, addition/deletion, truncation, and/or fragment 
hybridization. Charge and hydrophobic properties of peptides were the principal 
physicochemical descriptors in designing designed AMPs as the functions to correlate 
antipneumococcal activity. Moreover, the introduction of specific amino acids in the 
respective peptide sequences was carefully examined. Finally, this first group designed 
AMPs which consisted of two major series of peptides were generated with (DAMP1, 
DAMP2, DAMP4, DAMP8, DAMP10) and without peptide length alterations (DAMP3, 
DAMP5, DAMP6, DAMP7). All the designed AMPs have unaltered N-terminal and C-
terminal fragment as the template peptides except for DAMP6 to evaluate the effects of 
C-terminal deamidation on antimicrobial activity of the peptides. ,. 
 
2.4.3. Redesigning synthetic antimicrobial peptides with improved antibacterial 
activity and cell toxicity 
From the first phase peptide design, the hydrophobicity and net charge of peptide 
was determined as the principal descriptors. Towards redesigning better peptides, 
DAMP6 and DAMP7 were then used as the template for subsequent redesigning to 
achieve better peptides with high therapeutic potency and low toxicity. The current 
approach focused on the binding compatibility between two aligned sequences. 
BioMoDroid (Rathinam, personal communication) was used to predict and generate 
new peptides, based on the input sequences, with high charge and hydrophobicity 
compatibility between the residues.  
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The procedure began by searching the target PBP receptors for potential binding 
pocket using Metapocket 2.0 server (Huang, 2009) which is available at 
http://projects.biotec.tu-dresden.de/metapocket/. For each PBP, the run was computed 
using a 9.0 angstrom radius of probe to get potential binding site and only the top 
prediction was selected. The sequences predicted were assumed in close conformation 
and align in linear form according to the sequence of residues. For example, the 
prediction on PBP 1K25 using the metapocket server had identified the top potential 
pocket of 32 residues KRKVPTRRMEEIVGNARPIVVGLLIPDMYWTN. The 
predicted binding pocket for all 6 PBPs ranged from 24 - 32 amino acids in length 
(Table 2.4). All PBPs used in previous virtual screening served as target receptors, 
except for 1PMD which contains only CA atoms and is unsuitable to run on the server 
due to too many grid points produced for the clustering as this file. This receptor file 
was replaced with another S. pneumoniae PBP2X receptor file 2Z2L (Yamada et al., 
2003).    
To predict the binding compatibility between each residual amino acid on the 
ligand peptide and receptor protein, the hydrophopathy compatibility index (HCI) and 
charge compatibility index  were used to characterize the strength of binding between 
amino acid residues (Biro, 2006). The HCI was calculated based on the Kyte and 
Doolittle hydropathy index (the first scale) (Kyte & Doolittle, 1982) and the normalized 
consensus hydrophobicity scale (second scale) by Eisenberg et al. (Eisenberg et al., 
1984) using the formula: 
 
HCI = 20 - | [HM(A) - HM(B)] × 19/10.6] | 
 
The formula for CCI (third scale): 
CCI(AB) = 11 - [pI(A)-7] [pI(B)-7] × 19/33.8 
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The compatibility between amino acid A, and B are characterized by a scale range 
from 1 (not compatible) and 20 (highly compatible). For each amino acid, all three 
scales were combined to generate a consensus scale with 25:25:50 score distribution for 
each scale respectively. The scores were then normalized from 0 (non-compatible) to 1 
(highly compatible).  
Both the binding pocket sequence of the receptor and template peptide was 
aligned in parallel from N-terminal to C-terminal. Pairing involving the 1
st
 N-terminal 
residue of the pocket with the first N-terminal residue of peptide designated as position 
1/first iteration. For the 2
nd
 position/iteration, the peptide was shifted one residue toward 
the C-terminal and the pairing involves the 2
nd
 N-terminal residue of the pocket with the 
first N-terminal residue of peptide. The iterations will then be continued for the 
remaining residues. Thus, 
 
                                
                                                                 
   
The binding algorithm is based on a novel method call Double Y. In this method, 
the primary pair (residues reside directly on the opposite between the pocket and 
peptide) and the secondary pair (residues reside adjacent to the primary pair residue) 
were summed up to calculate a score. The scores for redundant pairs were ignored. For 
example, for the pairing between ARK and GLHAPPL, there are three primary pairs 
(AG, RL, KH) and five secondary pairs (AL, RG, RH, KL, KA) thus giving a total of 
eight pairs. At the 2
nd
 position/iteration, there are a total of nine pairing with pairs of 
AG, AL, AH, RL, RH, RA, KH, KA, KP. 
The calculations were performed in two continuous cycles. At each cycle, the 
residual substitutions were framed at a window size of two amino acids. Since there is a 
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total of 20 amino acids, a total of 400 possible substitutions (and thus the new 
sequences) are expected from each cycle of calculations for the respective peptide-
pocket pairs. Two windows each with a window size of two was framed to allow 
substantial alteration to the peptide sequence while limiting the changes to a maximum 
of four residues, which is approximately 30.8% of the template. Higher window size 
was not attempted as this may result in dramatic changes to peptide sequence. The 
length of the peptide was preserved at its original length of 13 amino acids as 
modification without length alteration was shown to be the better designing strategy.  
After calculations on all pairs at the first iteration were completed, the peptide 
was shifted one position towards the C-terminal and a similar calculation was performed 
until the last iteration at the C-terminal. All scores computed using the normalized scale 
based on double Y method was tabulated and sorted. The score for each iteration was 
compared and sequences with the top score was extracted and serve as the template 
peptide for the second cycle of computation performed using similar procedures on each 
pocket sequence. Subsequently, the scores for the peptides generated after two cycles of 
calculations were sorted among other peptides calculated against other pockets. The top 
three scoring sequences for each DAMP6 and DAMP7 were selected for in vitro testing. 
Peptides generated based on DAMP6 were designated DP61, DP62, and DP63 (DP6 
series) and peptides generated based on DAMP7 were designated DP71, DP72, and 
DP73 (DP7 series). This redesigning also includes 1T51, the only natural AMP found to 
be highly active against S. pneumoniae based on the MIC result and were designated 
DP51, DP52, and DP53 (DP5 series). 
Besides that, a separate series of five synthetic hybrid peptides (DM1, DM2, DM3, 
DM4, and DM5) were generated by hybridizing fragments of varying length from C-
terminus of DAMP6 and N-terminus of DAMP7. However, four of the residues at each 
terminal were unchanged. This is because DAMP6 was initially designed based on 
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1VM4 which belongs to the GLFD family of antimicrobial peptide, the four residues 
was reported to be crucial for its activity (Wang et al., 2005). Also, the four residues at 
the Arg-rich C-terminal fragment of DAMP7 was responsible for its activity (Selsted et 
al., 1992). Hence, these fragments were preserved while the central fragments were 
sequentially substituted. Since both templates were 13 amino acids in length hence the 
hybrid peptides were similarly restricted to the same length. All designed AMPs 
generated from the redesigning approach were collectively referred to as second group 
designed AMPs. 
 
 
 
 
Table 2.4: Pocket site sequences predicted using Metapocket 2.0 server.  
 
  
Target PBPs Pocket sequence predicted Length 
1K25 KRKVPTRRMEEIVGNARPIVVGLLIPDMYWTN 32 
2Z2L
a 
GSKDWDEHSSNQTKSGTAQYIFSY 24 
1QME NRKVRRMVGNPIVVGTLIEVPDMYWLAN 28 
1RP5 NKVPTRRMEEVGPGARPIVVGTIPDW 26 
2C5W WGSTKYNWDQSRNITKTGTSNFVADEL 27 
2XD5
b
 ASKMYANYSWNMTKTGTTNQDNMQY 25 
a
1PMD  which contains only CA atoms in the .pdb structural file could not be executed 
on the Metapocket 2.0 server due to the excessive amount of grid points generated for 
the clustering of this file. Replaced by 2Z2L (Yamada et al., 2007). 
b
superceded 2JCI. 
85 
 
 
2.4.4. Peptides physicochemical analytical tools 
Five molecular parameters describing the charge and hydrophobicity nature of 
peptides were used to characterize the physicochemical properties of both natural AMPs 
and designed AMPs: total net charge (NetC), Charge density (ChD), hydrophobic ratio 
(HR), total hydrophobic value (THV), and grand average of hydropathy (GRAVY). The 
ExPASy ProtParam tools (http://web.expasy.org/protparam/) and APD were used to 
perform the physicochemical analysis for each peptide. NetC was calculated by 
subtracting the sum of positively-charged amino acids (Arg, Lys, His) by the sum of 
negatively-charged amino acids (Asp, Glu). C-terminal amidation was assigned with 
one positive charge (+1). ChD was calculated by dividing NetC with the chain length of 
peptide. HR is the percentage of hydrophobic amino acid (Ile, Val, Leu, Phe, Cys, Met, 
Ala, Trp) in the peptide chain. THV was computed by summation of hydrophobicity 
value for each residue based on the Kyte and Doolittle hydropathy index (Kyte & 
Doolittle, 1982). GRAVY was the mean hydrophobicity value of the peptide, calculated 
by dividing THV by the number of residues. 
 
2.4.5. Peptide synthesis and testing 
All natural AMPs and the first group of designed AMPs were synthesized by 
Sigma Co. (Japan) except 1VM4 by Genscript (USA). The second group of designed 
AMPs was synthesized by Genscript (USA). Peptide synthesis was performed using 9-
fluorenylmethoxycarbonyl for solid phase peptide synthesis. Quality analyses of 
peptides were validated using high performance liquid chromatography and mass 
spectrometry. All peptides were then tested for in vitro antimicrobial and cell toxicity. 
Peptides for use in in vitro testing were synthesized to > 90% purity; peptides for use in 
in vivo therapeutic efficacy and toxicity studies in mice were synthesized to > 95% 
purity. 
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2.5. In vitro assessment of peptides 
2.5.1. Bacterial cultures and assay medium 
Twenty S. pneumoniae clinical isolates from each penicillin-susceptibility group 
(resistant, PRSP; intermediate, PISP; susceptible, PSSP) were obtained from a 
retrospective study (Palanisamy, 2008) which represents a subset of isolates used in the 
serotyping. Sheep blood agar (Oxoid, UK) was used for pneumococcal cultivation 
purpose. Nutrient agar (NA) (Oxoid, UK) was used for E. coli ATCC 25922, S. aureus 
ATCC 25923, and P. aerugenosa ATCC 15442, Acinetobacter baumanii ATCC 15308, 
and one clinical isolate for each methicillin-resistant S. aureus (MRSA), Enterococcus 
cloacae, Citrobacter spp., and K. pneumoniae. For antimicrobial testing, MHA and 
cationically-adjusted MHB (CAMHB) were used. All agar medium for S. pneumoniae 
was supplemented with 5% (v/v) defibrinated sheep blood (Oxoid, UK). The bacterial 
cultures were stored in multiple vials in Brain Heart Infusion Broth (BHIB) (Oxoid, UK) 
supplemented with 10% (v/v) glycerol at -80
o
C to avoid repeated freeze-thawed cycles 
on the cells. All freeze-stocked strains were passaged twice prior to experimentation. 
 
2.5.2. Broth microdilution assay 
Procedures were performed to determine the minimum inhibitory concentration 
(MIC) of peptides according to CLSI guidelines (Clinical and Laboratory Standards 
Institute, 2008) to determine the MIC of peptides. Bacterial strains were grown for 18 - 
24 hrs at 37
o
C under 5% CO2. Direct suspension of the colonies were made in CAMHB 
and adjusted to OD625 0.08 - 0.1 which corresponds to 1 ~ 2 x10
8
 colony forming units 
(CFU)/ml followed by serial ten-fold dilutions to give 1x10
6 
CFU/ml supplemented 
with 10% (v/v) laked horse blood (LHB) (Oxoid, UK). Fifty microliters of bacterial 
suspension was then aliquoted to 96-well microtiter plates (Corning, USA) containing 
equal volume of serially diluted peptides to give final concentrations of peptides 
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encompassing the range of 1.96 – 250 µg/ml. The MIC value for inactive peptides 
producing no inhibition in the range tested was denoted as > 250 µg/ml. The plates were 
incubated for 18 - 24 hrs at 37
o
C under 5% CO2. MIC was read as the concentration of 
peptide producing complete inhibition on the visible growth of the test organism. 
Results were pooled from three independent experiments with no more than one two-
fold dilution in variation. MIC value that appears at least twice was taken as the final 
MIC for the particular isolate/peptide. Effective range was defined as the range of 
concentrations where the peptides produce detectable activity. Effective percentage was 
the proportion of organism inhibited within the effective range. Since the isolates were 
obtained prior to year 2008 where major revision in antibiotic susceptibility breakpoints 
were introduced, the previous (prior 2008) penicillin susceptibility breakpoint was 
followed which corresponds to the penicillin (oral penicillin V) breakpoint of the 
revised criteria. 
The broad spectrum antibacterial activity of the peptides against a panel of eight 
clinically important bacteria were also tested, this includes Staphylococcus aureus 
ATCC 25923, E. coli ATCC 25922, P. aeruginosa ATCC 15442, Acinetobacter 
baumanii ATCC 15308, and one clinical isolate for each methicillin-resistant S. aureus 
(MRSA) Enterococcus cloacae, Citrobacter spp., and K. pneumoniae. 
 
2.5.3. Bacterial killing assay 
This assay was performed to evaluate the killing kinetics of peptides (Eckert et al., 
2006). One PRSP, PISP, and PSSP isolate were each grown and prepared to 5 x 10
6
 
CFU/ml. Each isolate in CAMHB was challenged with peptides at two times the 
respective MIC values. At the indicated time intervals (0, 30, 60, 120, 150, 180, 210, 
and 240 mins; “0” indicate pretreatment), 10 μl of suspension was removed and 
immediately serially diluted in PBS on ice to block further antibacterial activity and 
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bacterial growth and spread-plated on MHA to obtain viable colony counts. The 
percentage (%) surviving cell was calculated by dividing the surviving CFU of the 
treated cells over the surviving CFU of the untreated control cells at the respective time 
points. Results were pooled from three independent experiments and expressed as mean 
± standard deviation (SD). Penicillin was also included to evaluate the killing kinetics of 
peptides in comparison to this commonly use conventional antibiotic against S. 
pneumoniae.  
 
2.5.4. Synergism study 
Synergism assay was performed using the checkerboard method (Bajaksouzian et 
al., 1996) with minor modification. In order to prepare a range of concentrations which 
allows simultaneous detection of antagonism, indifference/additive, and synergism, the 
assay was performed in such a way that each column contained a fixed 0.25X MIC of 
the first peptide and 12 serial two-fold dilutions of the second peptide at each row 
beginning at 8X MIC. This yielded 12 peptide-peptide (peptide A: peptide B) 
combinations at varying ratios from  1 : 128 to 16 : 1. The combination effect of 
peptides was defined according to the fractional inhibitory concentration (FIC) index, 
whereby 
 
FIC =   MIC of peptide A in combination   +   MIC of peptide A in combination 
                   MIC of peptide A alone                            MIC of peptide A alone 
 
Two peptides were antagonistic if FIC > 4.0, indifference if 0.5 < FIC ≤ 4.0, and 
synergism if ≤ 0.5 (Bajaksouzian et al., 1996). Only peptides with antipneumococcal 
MICs within the range of concentrations tested were selected. This included DAMP6, 
DAMP7, DP71, DP72, DM1, DM2, DM3, DM4, and DM5. Penicillin was also included 
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to investigate the possible synergism the designed AMPs have with conventional 
antibiotic. One isolate from each PRSP, PISP, and PISP were selected and inoculums 
were prepared according to the broth microdilution assay without the addition of LHB 
to allow better visible observation of well clearance. 
 
2.5.5. Transmission electron microscopy 
An overnight culture of selected PRSP on sheep blood agar was passaged twice 
and directly suspended in CAMHB. As sample for Transmission Electron Microscopy 
(TEM) required high cell density of about 10
8 
to 10
10 
to be viewable (Hartmann et al., 
2010), the bacteria was prepared to 5 x 10
10
 CFU/ml and treated with supra-
concentration of peptides at 8 mg/ml for four hours at 37
o
C under 5% CO2. Cells treated 
with only water was served as the untreated control. For TEM sample preparation, 
standard protocol provided by the Electron Microscopic Unit, Faculty of Medicine, 
University of Malaya was followed. The cells were washed twice with CAMHB before 
overnight fixation in 4% (v/v) glutaraldehyde, two times postfix washes with cacodylate 
buffer, incubate, two hours incubation with osmium tetroxide buffer (OsO4 1: 1 
cacodylate), and washed twice with cacodylate buffer before overnight incubation in the 
same buffer. Next, the samples were washed twice with double distilled water, 10 mins 
of uranyl acetate incubation, and washed twice with double distilled water before 
subjected to dehydration by gradual ethanol series: 35% for 10 mins, 50% for 10 mins, 
70% for 10 mins, 95% for 15 mins, and three rounds of absolute (100%) ethanol for 15 
mins. Following these, samples were incubated with two rounds of propylene oxide for 
15 mins, propylene oxide 1 : 1 Epon for 1 hr, propylene oxide 1 : 3 Epon for 2 hrs, 
overnight incubation with Epon, embedded in Agar 100 resin at 37
o
C for five hours, and 
maintained in 60
o
C until viewing. Ultrathin sectioning were prepared on Reichert 
Ultramicrotome, copper grids 3.05 mm (300 square mesh) (agar Scientific), and stained 
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with ethanol-based uranyl acetate and lead citrate for 5 mins. TEM viewing was 
performed with Leo Libra 120 under standard operating conditions. 
 
2.5.6. Hemolytic activity 
Hemolytic assay was performed as previously described (Zelezetsky et al., 2005). 
Freshly drawn human erythrocytes were rinsed three times with PBS and resuspended in 
PBS to 4% (v/v). One hundred microliters of the suspension was added to 96-well 
microtiter plate (Corning, USA) containing equal volume of peptides to give final 
concentrations of peptides encompassing the range of  1.96 – 250 µg/ml. PBS and 0.1% 
(v/v) Triton-X 100 were used as 0% and 100% hemolytic control respectively. Plates 
were incubated at 37
o
C for 1 hr. Subsequently, the plate was centrifuged and the 
supernatant was transferred to a new plate. The release of hemoglobin in the supernatant 
was monitored at absorbance of 450 nm using Glomax Multidetection system (Promega, 
USA). Results were pooled from three independent experiments and expressed as mean 
± SD. HC10 and HC50 were defined as the peptide concentrations causing 10% and 50% 
hemolysis on human erythrocytes, respectively. Hmax was the percentage hemolysis 
observed at the maximum concentration as defined throughout this study (all peptides 
250 µg/ml, PEN 4 µg/ml). 
 
2.5.7. Cytotoxicity against human cell lines 
Both the NL20 human lung bronchial normal epithelial cell line and the A549 
human lung alveolar adenocarcinoma epithelial cell line were used for cell cytotoxicity 
tests. Besides investigating the cytotoxicity of peptides, differences in cell viability 
between the two cell lines can be used to evaluate the cell line selectivity and to assess 
potential anticancer potential of the peptides. NL20 cell line was grown in Ham‟s F12 
medium (Lonza, USA) and A549 cell line was grown in Roswell Park Memorial 
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Institute medium (RPMI-1640, Hyclone, USA). Both media were supplemented with 10% 
(v/v) fetal bovine serum (FBS) (Hyclone, Australia) as growth medium for cell culture 
purposes or with 2% (v/v) FBS as maintenance medium in cell cytotoxicity testing. The 
assay was performed as described by Lee et al. (Lee et al., 2011b). NL20 cells was 
seeded overnight at 3 x 10
4 
cells/well in 96-well cell culture-treated flat bottom 
microtiter plate (Corning, USA) and treated with serial dilutions of peptide at a final 
concentration of 1.95 - 250 g/ml. Penicillin was tested from 0.03 – 4 µg/ml, the same 
range used to classify the susceptibility of pneumococcal isolates in this study. Test 
using A549 cells followed the same procedures with 1 x 10
4 
cells/well. Plates were 
incubated at 37
o
C under 5% CO2 for 24, 48, and 72 hrs. Cell viability was detected by 
using CellTiter 96® AQueous Non-Radioactive Cell Proliferation assay (Promega, USA) 
and the colorimetric changes were read with Glomax multidetection system (Promega, 
USA). CellTiter 96® AQueousNon-Radioactive Cell Proliferation assay is composed of 
a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, inner salt; MTS(a)] and an 
electron coupling reagent (phenazine methosulfate; PMS). The dehydrogenase enzymes 
in metabolically active cells will convert the MTS into soluble formazan product which 
produces calorimetric change that can be quantitated directly by absorbance 
measurement at 490 nm. Results were pooled from three independent experiments and 
expressed as mean ± SD. IC50 was defined as the peptide concentration which resulted 
in 50% cell viability.  Imax was the percentage of cell viable treated with 
peptides/penicillin at the maximum concentration as defined throughout this study (all 
peptides 250 µg/ml, penicillin 4 µg/ml). 
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2.6. In vivo assessment of peptides 
2.6.1. Animal maintenance and handling 
The mouse represents the choice of animal model to study the therapeutic efficacy 
of novel drugs as they are the most susceptible animals to pneumococcal infections 
(Amory-Rivier et al., 1999) and are easy to handle as compared to other animals. Male 
ICR mice (4 weeks old) were used throughout the in vivo studies. The mice were 
acclimatized for seven days prior to any experimentation and allowed mouse feeding 
pellet and water ad libitum. Procedures involving subcutaneous (SC) and intranasal (IN) 
routes which requires anesthesia were given the standard dose of ketamine (Narketan®-
10, 100 mg/kg) and xylazine (ilium xylazil-20, 10 mg/kg) combination via 
intraperitoneal (IP) injection. All animal handling and experimental procedures were 
approved by the Faculty of Medicine Animal Care and Use Committee of University of 
Malaya, ethic number MP/05/05/2010/LCF(R). 
 
2.6.2. Injection/administration procedures 
All injections were performed using Myjector 1 ml U100 29G insulin syringe 
(Terumo). The mouse was held head-down and IP injection be given to the lateral side 
at lower-left quadrant of the abdomen. The posture was maintained for 15s before 
returning to the normal position. SC injection was given to the left thigh and followed 
by right thigh if repeated injections were required. Intrathoracic (IT) injection was given 
to the lateral side of the right thorax through the intercostals muscles between the 
adjacent ribs. Procedures for IN route used a long-tailed blunt-end 10 µl tips attached to 
a 1 ml syringe (Terumo) and be given through either nostril with head-up position. This 
position was maintained for 30 s with occasional assisted-closing of the mouth to 
facilitate inhalation. 
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2.6.3. In vivo toxicity assessment 
In vivo toxicity was performed to determine the possible side effects associated 
with the administration of peptides in mice. The five hybrid DMs were selected for in 
vivo testing due to their promising in vitro antipneumococcal and toxicity profiles. The 
mice were randomized and three to four mice per group were administered with the 
respective peptides at 2 hrs, 12 hrs, and 24 hrs for three dosing (three dose regimen) via 
SC, IN, and IP routes. The peptides were initially given at high dose (100 mg/kg via IP 
and SC routes, 20 mg/kg via IN route). Any physical or behavior abnormality was 
recorded and survival of mice was noted. In the events where adverse effects including 
highly physical stresses, highly lethargic, highly physical inactiveness, and/or death 
were observed in the mice, lower graded step-down doses were given. Dose 
administered via IN route was limited by the low volume (20 µl) deliverable through the 
nasal cavity of mouse and thus the highest dose given was 20 mg/kg. Untreated control 
group was administered with sterile distilled water only. The mice were observed for 
seven days or until dead/moribund, whichever earlier. At the seventh day, all mice were 
sacrificed and blood was collected via cardiac puncture using 25G syringe (Terumo) 
attached to 1 ml needle (Terumo). Whole blood for complete haematogram was 
collected in 500 µl dipotassium EDTA microtainer tube (BD bioscience, USA). Blood 
collected in another 1.5 ml tube was centrifuged at 8,000 rpm for 5 mins and the serum 
was aliquoted to a fresh 1.5 ml tube for serum biochemistry analysis. The whole blood 
and serum samples were transported on ice and sent to the haematology and clinical 
biochemistry laboratory, Veterinary Laboratory Service Unit (VLSU), Faculty of 
Veterinary Medicine, Universiti Putra Malaysia for analysis. The whole blood 
parameters analyzed were number of red blood cells (RBC), white blood cells (WBC), 
B neutrophil, S neutrophil, lymphocytes, monocytes, eosinophil, basophil, and 
thrombocytes, hemoglobin (Hb) concentration, packed cell volume (pCV), mean 
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corpuscular volume (MCV), mean corpuscular haemoglobin concentration (MCHC), 
and plasma protein concentration. Serum biochemistry analysis included the 
concentrations of alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), creatinine, urea, lactate dehydrogenase (LDH), and direct and 
total bilirubin. Major organs (brain, lung, liver, kidney, spleen) were harvested and 
fixed in 10% (v/v) buffered formalin for at least seven days. Histological tissues 
processing with hematoxylin and eosin stain were processed at the histopathology 
laboratory, VLSU, Faculty of Veterinary Medicine, Universiti Putra Malaysia. 
 
2.6.4. In vivo therapeutic efficacy assessment  
2.6.4.1. Development of lethal murine pneumococcal infection models 
Each selected peptide was to be tested in two pneumococcal infection models; the 
pneumococcal systemic infection model which mimicked pneumococcal bacteremia in 
human and the pneumococcal pneumonia model which mimicked the pneumococcal 
pneumonia in human. Towards developing the pneumococcal infection models, the 
specific strain used and the inoculums must be optimized carefully prior to therapeutic 
testing. This is because the in vivo virulence (disease-causing ability and time to death) 
of S. pneumoniae varied considerably among different strains, routes of infection, and 
the inoculums used (Amory-Rivier et al., 1999; Benton et al., 1997; Briles et al., 1992). 
Three PRSP strains were first assessed for its virulence to cause lethal infections 
in mice (n = 3). The selected PRSP strains were subcultured twice on sheep blood agar 
at 37
o
C under 5% CO2 for 18 – 24 hrs and adjusted to OD625 0.08-0.1 (approximately 1 
~ 2 x 10
8 
CFU/ml) in BHIB. The suspension was then serially diluted to appropriate 
inoculums on ice and immediately be inoculated into the mice at the desired routes. To 
induce systemic infection in mice, 100 µl of the inoculums was given at 1.5 x 10
4
, 1.5 x 
10
3
, 1.5 x 10
2
, and 1.5x10
1
 CFU/mouse via IP route. To induce pneumonia in mice, 50 
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µl of the inoculums were given at 5x10
4
, 5x10
3
, 5x10
2
, and 5x10
1
 CFU/mouse via IT 
route. The IT infection was able to induce consistent and reproducible lethal infection. 
Following inoculations, the number of cells inoculated in the mice was confirmed by 
plate count on sheep blood agar. Although inducing pneumonia infection in mice via the 
IN route of infection was attempted, however, none of the strains or inoculums to as 
high as 5x10
7 
CFU/mouse was able to induce infection. Uninfected control group 
(medium only) with equal number of mice as the test groups were included in each trial. 
From the optimization, one particular strain (SP12) was selected. The inoculum used to 
induce lethal systemic infection was 1.5 x 10
2
 CFU/mouse which cause 100% mortality 
between day 2 to day 4 postinfection. The inoculum used to induce lethal pneumonia 
infection was 5 x 10
3
 CFU/mouse which caused 100% mortality between day 2 to day 4 
postinfection. Two other strains were either avirulent in inducing lethal infections or 
were unable to produce 100% mortality within the time frame. 
 
2.6.4.2. Determination of survival rates in infected mice following treatment with 
peptides 
All mice were randomized before receiving the first treatment dose and be 
divided into the respective groups. The selected dose and regimens of treatment of the 
respective peptides were first tested using groups of three mice to determine potential 
peptides with protective effects in the two infection models. Selected peptides were then 
tested in a larger group (n = 10) for detailed evaluation. Graded doses of penicillin were 
also tested to determine the therapeutic efficacy of this standard antibiotic. Uninfected 
control (medium only) and untreated control (inoculums only) with equal number of 
mice as the test groups were included in each trial and treated with sterile distilled water 
only.  
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2.6.5. In vivo therapeutic synergism with penicillin 
After determining the in vivo therapeutic efficacy of peptides in standalone form, 
the protective effect of candidate peptides in combination with the standard antibiotic 
penicillin was carried out. The therapeutic efficacy of penicillin against the mouse 
infection model was determined for doses of 10 mg/kg. 20 mg/kg, 40 mg/kg, and 80 
mg/kg following the same procedures and treatment regimen as the DMs. To allow the 
detection of therapeutic synergism, doses of penicillin and peptide which produced 
minimal survivability in the infected mice were chosen and prepared to 2X the desired 
testing concentration at 0.1 ml in separating tubes. Immediately before treatment, both 
drugs were mixed together and this would dilute both the drugs to the desired testing 
doses at final volume of 0.2 ml. The therapeutic efficacy was then performed in the 
infection models (n = 10). 
          
2.7. Statistical analysis 
Statistical analysis was performed using SPSS 16. Association among serotypes, 
clinical sites of isolates, age groups, and penicillin susceptibility were tested using Chi-
square test of independence or Fisher‟s exact test, whenever appropriate. When these 
tests yielded significant association (p ≤ 0.05), adjusted residual value of ≥ +2 or ≤ -2 
was used to determine the underlying positively or negatively associated groups, 
respectively. For in vivo toxicity testing, the statistical difference in whole blood 
haematogram and serum biochemistry parameters between the treated versus the 
untreated control groups were conducted using One-way ANOVA with post-hoc 
Dunnett-t test. For in vivo therapeutic efficacy and synergism testing, survival analysis 
of each treated versus untreated control groups were performed using Kaplan-Meier 
analysis with log-rank test (Mantel-Cox). Survival plots were generated from the SPSS 
based on Kaplan-Meier analysis.  
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CHAPTER 3 
RESULTS 
 
  
 
98 
 
 
3.1. Antibiotic susceptibility and multiplex serotyping of S. pneumoniae 
Prior to year 2008, the penicillin susceptibility breakpoint for S. pneumoniae was 
collectively defined by penicillin-susceptible S. pneumoniae (PSSP, MIC ≤ 0.06 µg/ml), 
penicillin-intermediate S. pneumoniae (PISP, MIC = 0.12 – 1 µg/ml), and penicillin-
resistant S. pneumoniae (PRSP, MIC ≥ 2 µg/ml) (Clinical and Laboratory Standards 
Institute, 2005). From year 2008 onwards, the penicillin susceptibility breakpoint has 
undergone major revision. The penicillin interpretive criteria for S. pneumoniae are now 
classified into three subgroups; penicillin (oral) group follows the same penicillin 
susceptibility classification as the pre-revision breakpoint: PSSP (MIC ≤ 0.06 µg/ml), 
PISP (MIC = 0.12 – 1 µg/ml), and PRSP (MIC ≥ 2 µg/ml); parenteral penicillin for 
meningitis isolates defines S. pneumoniae as PSSP (MIC ≤ 0.06 µg/ml) and PRSP (MIC 
≥ 0.12 µg/ml) only and has no PISP grouping; major change is the parenteral penicillin 
for nonmeningitis isolates which defines PSSP (MIC ≤ 2 µg/ml), PISP (MIC = 4 µg/ml), 
and PRSP (MIC ≥ 8 µg/ml) following higher MIC values for the respective 
susceptibility groups (Table 3.1). This also means that the previously defined PSSP, 
PISP, and PRSP (MIC = 2 µg/ml) will now be classified as PSSP according to the 
revised breakpoint.  
In this study, since the pneumococcal isolates were collected prior to year 2008 
(1999 – 2007), the isolates were classified using the pre-revision breakpoint (Clinical 
and Laboratory Standards Institute, 2005), which is also equivalent to the revised 
penicillin (oral) breakpoint. Of the 151 isolates, there were 21.2% (32/151) PRSP, 29.1% 
(44/151) PISP, and 49.7% (75/151) PSSP (Table 3.2, highlighted in yellow). The ratio 
of penicillin susceptible to nonsusceptible isolates (PNSP) was at near equal (PSSP 
49.7%, PNSP 50.3%). In addition, 42.6% (20/47) of isolates obtained from patients 
below 5 years old were PSSP and 27.7% (13/47) were PRSP (Table 3.3, highlighted in 
yellow). On the other hand, a large proportion (60.6%, 20/33) of the isolates from 
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elderly adults aged ≥ 60 were PSSP and only 15.2% (5/33) were PRSP (Table 3.3, 
highlighted in blue). Additionally, a great majority of PISP (79.5%, 35/44) and PRSP 
(81.2%, 26/32) were isolated from noninvasive sites although no statistical significant 
association was noted (p = 0.100). Altogether, they constituted 80.3% (61/76) of the 
PNSP isolates. No significant association was observed between penicillin susceptibility 
and age of patients (p = 0.524) as well as invasiveness of isolates (p = 0.07). 
Nonetheless, clinical sites of pneumococcal isolations were highly associated (p < 0.001) 
with age of patients (Table 3.4). Most (80.9%, 38/47) of the isolates from children < 5 
years old were noninvasive among which 73.7% (28/38) of these isolates were sourced 
from the NP site (59.6%, 28/47) (Table 3.4, highlighted in yellow). In contrast, a 
significant proportion (42.4%, 14/33) of isolates from the elderly adult ≥ 60 years old 
was obtained from blood (Table 3.4, highlighted in green). 
A representative complete seven multiplex reactions performed on 10 PRSP 
isolates was shown in Figure 3.1. Serotypes detected among the Malaysian isolates were 
1, 3, 10A, 11A/11D, 12F/12A, 14, 15A, 15B/15C, 16F, sg18(18C/18B/18A/18F), 19A, 
19F, 23F, 35B, 35F/47F, 6A/6B, 7C/7B/40, 7F/7A, 9V/9A, 34 (Table 3.2). Serotype 
19F was the most prevalent serotype (37.1%, 56/151) followed by serotype 23F (10.6%, 
16/151), serotype 1 (6.0%, 9/151) and serotype 6A/6B (6.0%, 9/151) (Table 3.2, 
highlighted in green). Together, serotype 19F and 23F accounted for almost half of all 
cases (47.7%, 72/151). The majority of serotype 19F (78.6%, 44/56) were 
nonsusceptible to penicillin and approximately half of the serotype 19F PNSP were 
PRSP (45.5%, 20/44). Statistical analysis showed significant relationship between 
serotype and penicillin susceptibility (p < 0.001). In particular, serotype 19F was 
significantly associated with PNSP while serotype 19A was associated with PSSP 
(Table 3.2, highlighted in blue). Besides this, a pool of less prevalent serotypes was 
detected including serotypes 3, 10A, 12F/12A, 15A, 15B/15C, 16F, 
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sg18(18C/18B/18A/18F), 7C/7B/40, 7F/7A while the nontypeable pneumococci 
constituted 13.2% (20/151) of the total isolates collected in the current study.  
A large proportion (72.2%, 109/151) of the clinical isolates was obtained from 
noninvasive sites (Table 3.4). Among the noninvasive sites, sputum (27.8%, 42/109) 
and NP (25.2%, 38/109) constituted the two main sites of pneumococcal isolations 
(Table 3.4, highlighted in purple). Together with S. pneumoniae from blood cultures 
(Table 3.4, highlighted in blue), these three sites represented the major sources of 
pneumococcal isolations which accounted for 77.5% (117/151) of all isolates. Other 
clinical sites include tracheal secretion (7.9%), ear swab/pus (6.0%), pleural fluid 
(2.0%), eye swab/pus (2.0%), cerebrospinal fluid (1.3%), broncheoalveolar lavage 
(1.3%), and others (2.0%). Isolates from rare sites such as Bartholin‟s abscess and 
vaginal discharge were reported in this study as well. Pneumococcal serotypes were 
found to be highly associated (p = 0.001) with invasiveness of the isolates (Table 3.5). 
Among them, serotype 19A was associated with invasive sites (75%, 6/8) while 
serotypes 19F was determined to be the dominant serotype (89.3, 50/56) in noninvasive 
sites (Table 3.5, highlighted in yellow).  
On the other hand, statistical testing showed significant relationship (p = 0.03) 
between the age of patients and serotypes (Table 3.6). Patients aged 5 – 59 years old 
represented the largest age group which accounted for approximately half of all cases 
(47.0%, 71/151). A large proportion of serotype 19A (75.0%, 6/8), 23F (75.0%, 12/16) 
and 6A/6B (66.7%, 6/9) were isolated from patients within this age group (Table 3.6, 
highlighted in yellow). Serotype 19F constituted the major serotype (46.8, 22/47) 
among children < 5 years old (Table 3.6, highlighted in blue). 
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Table 3.1: S. pneumoniae penicillin susceptibility breakpoints before and after year 
2008 revisions. 
 
MIC (µg/ml) 
Before revision After revision 
S I R  S I R 
P
en
ic
il
li
n
 
≤ 0.06 0.12 - 1 ≥ 2 
Penicillin parenteral 
(nonmeningitis) 
≤ 2 4 ≥ 8 
Penicillin parenteral 
(meningitis) 
≤ 0.06 - ≥ 0.12 
Penicillin (oral 
penicillin V) 
≤ 0.06 0.12 - 1 ≥ 2 
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Table 3.2: Distribution of pneumococcal serotypes with respect to penicillin susceptibility.  
Serotype
a
 
Frequency (adjusted residual, % within serotype, % within penicillin susceptibility group) 
 Susceptible  Intermediate  Resistant  Total 
1  7 (1.7, 77.8, 9.3)  2 (-0.5, 22.2, 4.5)  0 (-1.6, 0.0, 0.0)  9 (6.0) 
3  1 (1.0, 100.0, 1.3)  0 (0.6, 0.0, 0.0)  0 (-0.5, 0.0, 0.0)  1 (0.7) 
14  1 (-1.3, 20.0, 1.3)  4 (2.5, 80.0, 9.1)  0 (-1.2, 0.0, 0.0)  5 (3.3) 
34  0 (-1.4, 0.0, 0.0)  0 (-0.9, 0.0, 0.0)  2 (2.7, 100.0, 6.3)  2 (1.3) 
10A  1 (1.0, 100.0, 1.3)  0 (-0.6, 0.0, 0.0)  0 (-0.5, 0.0, 0.0)  1 (0.7) 
11A/11D  1 (-0.6, 33.3, 1.3)  2 (1.4, 66.7, 4.5)  0 (-0.9, 0.0, 0.0)  3 (2.0) 
12F/12A  3 (1.8, 100.0, 4.0)  0 (-1.1, 0.0, 0.0)  0 (-0.9, 0.0, 0.0)  3 (2.0) 
15A  1 (1.0, 100.0, 1.3)  0 (-0.6, 0.0, 0.0)  0 (-0.5, 0.0, 0.0)  1 (0.7) 
15B/15C  1 (1.0, 100.0, 1.3)  0 (-0.6, 0.0, 0.0)  0 (-0.5, 0.0, 0.0)  1 (0.7) 
16F  2 (1.4, 100.0, 2.7)  0 (-0.9, 0.0, 0.0)  0 (-0.7, 0.0, 0.0)  2 (1.3) 
sg18  2 (1.4, 100.0, 2.7)  0 (-0.9, 0.0, 0.0)  0 (-0.7, 0.0, 0.0)  2 (1.3) 
19A  7 (2.2, 87.5, 9.3)  1 (-1.1, 12.5, 2.3)  0 (-1.5, 0.0, 0.0)  8 (5.3) 
19F  12 (-5.3, 21.4, 16.0)  24 (2.8, 42.9, 54.5)  20 (3.4, 35.7, 62.5)  56 (37.1) 
23F  9 (0.6, 56.3, 12.0)  1 (-2.1, 6.3, 6.3)  6 (1.7, 37.5, 18.8)  16 (10.6) 
35B  2 (0.0, 50.0, 2.7)  2 (0.9, 50.0, 4.5)  0 (-1.1, 0.0, 0.0)  4 (2.6) 
35F/47F  2 (0.6, 66.7, 2.7)  1 (0.2, 33.3, 2.3)  0 (-0.9, 0.0, 0.0)  3 (2.0) 
6A/6B  3 (-1.0, 33.3, 4.0)  5 (1.8, 55.6, 11.4)  1 (-0.8, 11.1, 3.1)  9 (6.0) 
7C/7B/40  1 (1.0, 100.0, 1.3)  0 (-0.6, 0.0, 0.0)  0 (-0.5, 0.0, 0.0)  1 (0.7) 
7F/7A  3 (1.8, 100.0, 4.0)  0 (-1.1, 0.0, 0.0)  0 (-0.9, 0.0, 0.0)  3 (2.0) 
9V/9A  0 (-1.0, 0.0, 0.0)  0 (-0.6, 0.0, 0.0)  1 (1.9, 100.0, 3.1)  1 (0.7) 
NT  16 (2.9, 80.0, 21.3)  2 (-2.0, 10.0, 4.5)  2 (-1.3, 10.0 6.3)  20 (13.2) 
Total  75   (49.7)  44   (29.1)
 
 32   (21.2)
 
 151 
aFisher‟s exact test found significant association (p < 0.001) between serotypes and penicillin susceptibility of pneumococcal isolates (significant at p ≤ 
0.05). Adjusted residual value of ≥ +2 or ≤ -2 was used to determine the underlying positively or negatively associated groups, respectively. 
Highlighted in yellow: The number (percentage) of penicillin susceptible, intermediate, and resistant pneumococcal isolates. 
Highlighted in green: The four major serotypes detected in the order of 19F, 23F, 1 and 6A/B. 
Highlighted in blue: Serotypes positively or negatively associated with penicillin susceptibility of pneumococcal isolates. 
Abbreviation: NT, nontypeable. 
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Table 3.3: Distribution of age groups of patients with respect to penicillin susceptibility. 
 
  
Age 
(year)
a
 
Frequency (adjusted residual, % within age group, % within penicillin susceptibility group) 
 Susceptible  Intermediate  Resistant  Total 
< 5
 
 20 (-1.2, 42.6, 26.7)  14 (0.1, 29.8, 31.8)  13 (1.3, 27.7, 40.6)  47 (31.1) 
5 – 59  35 (0, 49.3, 46.7)  22 (0.5, 31.0, 50.0)  14 (-0.4, 19.7, 43.8)  71 (47.0) 
≥ 60  20 (1.4, 60.6, 26.7)  8 (-0.7, 24.2, 18.2)  5 (-1, 15.2, 15.6)  33 (21.9) 
Total  75   (49.7)  44   (29.1)
 
 32   (21.2)
 
 151 
a
Chi-squared test found no significant association (p = 0.524) between age of patients and penicillin susceptibility of 
pneumococcal isolates (significant at p ≤ 0.05). 
Highlighted in yellow: The number (percentage) of penicillin-susceptible and –resistant pneumococcal isolates among children 
< 5 years old. 
Highlighted in blue: The number (percentage) of penicillin-susceptible and –resistant pneumococcal isolates among elderly 
adults ≥ 60 years old.   
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Table 3.4: Distribution of age groups of patients with respect to sites of pneumococcal isolations.  
 
Agea 
Frequency (adjusted residual, % within age group, % within clinical sites) 
Invasive Noninvasive 
Total 
Blood CSF 
Pleural  
fluid 
Sputum NP Eye swab/pus Ear swab/pus 
Tracheal  
secretion 
BAL Otherb 
< 5 
7 
(-1.8,14.9,18.9) 
1 
(0.6,2.1,50.0) 
1 
(0.1,2.1,33.3) 
2 
(-4.3,4.3,4.8) 
28 
(6.5,59.6,73.7) 
0 
(-1.2,0.0,0.0) 
5 
(1.6,10.6,55.6) 
2 
(-1.1,4.3,16.7) 
1 
(0.6,2.1,50.0) 
0 
(-1.2,0.0,0.0) 
47 
(31.1) 
5 - 59 
16 
(-0.5,22.5,43.2) 
1 
(0.1,1.4,50.0) 
2 
(0.7,2.8,66.7) 
27 
(2.6,38.0,64.3) 
10 
(-3,14.1,26.3) 
3 
(1.9,4.2,100.0) 
4 
(-0.2,5.6,44.4) 
6 
(0.2,8.5,50.0) 
0 
(-1.3,0.0,0.0) 
2 
(0.7,2.8,66.7) 
71 
(47.0) 
≥ 60 
14 
(2.7,42.4,37.8) 
0 
(-0.8,0.0,0.0) 
0 
(-0.9,0.0,0.0) 
13 
(1.7,39.4,31.0) 
0 
(-3.8,0.0) 
0 
(-0.9,0.0,0.0) 
0 
(-1.6,0.0,0.0) 
4 
(1.0,12.1,33.3) 
1 
(1.0,3.0,50.0) 
1 
(0.5,3.0,33.3) 
33 
(21.9) 
Total 37(24.5) 2(1.3) 3(2.0) 42(27.8) 38(25.2) 3(2.0) 9(6.0) 12(7.9) 2(1.3) 3(2.0) 151 
aFisher‟s exact test found significant association (p < 0.001) between age of patients and clinical sites of isolations (significant at p ≤ 0.05). 
Adjusted residual value of ≥ +2 or ≤ -2 was used to determine the underlying positively or negatively associated groups, respectively. 
bOther sites include left tonsil, Bartholin‟s abscess, and vaginal discharge. 
Highlighted in yellow: Pneumococci isolated from children aged < 5 were predominantly isolated from NP sites. 
Highlighted in green: Pneumococci isolated from elderly adults ≥ 60 were predominantly isolated from blood. 
Highlighted in purple: Sputum and NP represent the two main noninvasive sites of pneumococcal isolation. 
Highlighted in blue: Blood represent the main invasive site of pneumococcal isolation. 
Abbrevations: CSF, cerebrospinal fluid; NP, nasopharyngeal; BAL, bronchoalveolar lavage. 
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Rx1 Rx2 Rx3 
Rx3 Rx4 Rx5 Rx6 
   1      2     3    4    5     6    7     8    9    10   11  12   13  14   15   16  17   18   19   20  21   22   23  24   25  26   27  28   29   30               
    31  32  33   34  35   36  37   38   39  40   41   42   43  44   45   46  47   48   49  50    51   52  53  54   55   56   57  58   59   60               
Figure 3.1: Representative complete seven multiplex reactions (Rx1 – Rx7) performed on 10 PRSP strains for serotyping. 
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  61    62    63    64   65    66    67    68    69    70    71    72    73 
Rx6 Rx7 
Figure 3.1(continued): Representative complete seven multiplex reactions (Rx1 – Rx7) performed on 10 PRSP strains for 
serotyping. Each reaction consisted of four different primers corresponding to the respective serotypes/serogroups as 
listed under Table 2.1. The strains were arranged in the order of (from left to right): S40(1), S41(12F), S44(19F), 
S46(11A/D), S47(12F), S48(1), S49(23F), S50(19F), S55(NT), and S56(23F) in each reaction (annotations in parenthesis 
denotes the serotype). Abbreviations: NT, Nontypeable; Rx, reaction.  
Lane 2 – 11: Reaction 1, Strains S40, S41, S44, S46, S47, S48, S49, S50, S55, and S56. 
Lane 12 – 21: Reaction 2, Strains S40, S41, S44, S46, S47, S48, S49, S50, S55, and S56. 
Lane 22 – 30, 32: Reaction 3, Strains S40, S41, S44, S46, S47, S48, S49, S50, S55, and S56. 
Lane 33 – 42: Reaction 4, Strains S40, S41, S44, S46, S47, S48, S49, S50, S55, and S56. 
Lane 43 – 52: Reaction 5, Strains S40, S41, S44, S46, S47, S48, S49, S50, S55, and S56. 
Lane 53 - 60, 62-63: Reaction 6, Strains S40, S41, S44, S46, S47, S48, S49, S50, S55, and S56. 
Lane 64 – 73: Reaction 7, Strains S40, S41, S44, S46, S47, S48, S49, S50, S55, and S56. 
Lane 1, 31, 61: 100kb DNA ladder. 
61    62    63    64   65    66    67    68    69    70    71    72    73 
Rx6 Rx7 
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Table 3.5: Pneumococcal serotypes distribution with respect to invasiveness of isolates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aFisher‟s exact test found significant association (p = 0.001) between serotypes and invasiveness of pneumococcal isolates (significant 
at p ≤ 0.05). Adjusted residual value of ≥ +2 or ≤ -2 was used to determine the underlying positively or negatively associated groups, 
respectively. 
Highlighted in yellow: Serotypes 19F and 19A were associated with noninvasive and invasive pneumococcal isolates, respectively. 
Abbreviation: NT, nontypeable 
Serotype
a 
Frequency (adjusted residual, % within serotype, % within invasiveness) 
 Invasive  Noninvasive  Total 
1  3 (0.4, 33.3, 7.1)  6 (-0.4, 66.7, 5.5)  9 (6.0) 
3  0 (-0.6, 0.0, 0.0)  1 (0.6, 100.0, 0.9)  1 (0.7) 
14  3 (1.6, 60.0, 7.1)  2 (-1.6, 40.0, 1.8)  5 (3.3) 
34  0 (-0.9, 0.0, 0.0)  2 (0.9, 100.0, 1.8)  2 (1.3) 
10A  0 (-0.6, 0.0, 0.0)  1 (0.6, 100.0, 0.9)  1 (0.7) 
11A/11D  2 (1.5, 66.7, 4.8)  1 (-1.5, 33.3, 0.9)  3 (2.0) 
12F/12A  2 (1.5, 66.7, 4.8)  1 (-1.5, 33.3, 0.9)  3 (2.0) 
15A  0 (-0.6, 0.0, 0.0)  1 (0.6, 100.0, 0.9)  1 (0.7) 
15B/15C  1 (1.6, 100.0, 2.4)  0 (-1.6, 0.0, 0.0)  1 (0.7) 
16F  1 (0.7, 50.0, 2.4)  1 (-0.7, 50.0, 0.9)  2 (1.3) 
sg18  0 (-0.9, 0.0, 0.0)  2 (0.9, 100.0, 1.8)  2 (1.3) 
19A  6 (3.1, 75.0, 14.3)  2 (-3.1, 25,0, 1.8)  8 (5.3) 
19F  6 (-3.6, 10.7, 14.3)  50 (3.6, 89.3, 45.9)  56 (37.1) 
23F  4 (-0.3, 25.0, 9.5)  12 (0.3, 75.0, 11.0)  16 (10.6) 
35B  1 (-0.1, 25.0, 2.4)  3 (0.1, 75.0, 2.8)  4 (2.6) 
35F/47F  1 (0.2, 33.3, 2.4)  2 (-0.2, 66.7, 1.8)  3 (2.0) 
6A/6B  1 (-1.2, 11.1, 2.4)  8 (1.2, 88.9, 7.3)  9 (6.0) 
7C/7B/40  1 (1.6, 100.0, 2.4)  0 (-1.6, 0.0, 0.0)  1 (0.7) 
7F/7A  1 (0.2, 33.3, 2.4)  2 (-0.2, 66.7, 1.8)  3 (2.0) 
9V/9A  1 (1.6, 100.0, 2.4)  0 (-1.6, 0.0, 0.0)  1 (0.7) 
NT  8 (1.3, 40.0, 19.0)  12 (-1.3, 60.0, 11.0)  20 (13.2) 
Total
 
 42   (27.8)  109   (72.2)  151 
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Table 3.6: Pneumococcal serotypes distribution with respect to age groups. 
 
aFisher‟s exact test found significant association (p = 0.03) between serotypes and age of patients (significant at p ≤ 0.05). Adjusted 
residual value of ≥ +2 or ≤ -2 was used to determine the underlying positively or negatively associated groups, respectively. 
Highlighted in yellow: The three major serotypes 19F, 23F, and 6A/6B detected among those aged 5 – 59 years old. 
Highlighted in blue: Serotype 19F was the predominant serotype among children < 5 years old. 
Abbreviation: NT, nontypeable.
 Frequency (adjusted residual, % within serotype, % within age group) 
Serotype
a
  < 5 years  5 – 59 years  ≥ 60 years  Total 
1  3 (0.1, 33.3, 6.4)  2 (-1.5, 22.2, 2.8)  4 (1.7, 44.4, 12.1)  9 (6.0) 
3  0 (-0.7, 0.0, 0.0)  0 (-0.9, 0.0, 0.0)  1 (1.9, 100.0, 3.0)  1 (0.7) 
14  3 (1.4, 60.0, 6.4)  0 (-2.1, 0.0, 0.0)  2 (1.0, 40.0, 6.1)  5 (3.3) 
34  2 (2.1, 100.0, 4.3)  0 (-1.3, 0.0, 0.0)  0 (-0.8, 0.0, 0.0)  2 (1.3) 
10A  0 (-0.7, 0.0, 0.0)  1 (1.1, 100.0, 1.4)  0 (-0.5, 0.0, 0.0)  1 (0.7) 
11A/11D  0 (-1.2, 0.0, 0.0)  2 (0.7, 66.7, 2.8)  1 (0.5, 33.3, 3.0)  3 (2.0) 
12F/12A  1 (0.1, 33.3, 2.1)  0 (-1.6, 0.0, 0.0)  2 (1.9, 66.7, 6.1)  3 (2.0) 
15A  0 (-0.7, 0.0, 0.0)  1 (1.1, 100.0, 1.4)  0 (-0.5, 0.0, 0.0)  1 (0.7) 
15B/15C  0 (-0.7, 0.0, 0.0)  0 (-0.9, 0.0, 0.0)  1 (1.9, 100.0, 3.0)  1 (0.7) 
16F  0 (-1.0, 0.0, 0.0)  1 (0.1, 50.0, 1.4)  1 (1.0, 50.0, 3.0)  2 (1.3) 
sg18  1 (0.6, 50.0, 2.1)  1 (0.1, 50.0, 1.4)  0 (-0.8, 0.0, 0.0)  2 (1.3) 
19A  1 (-1.2, 12.5, 2.1)  6 (1.6, 75.0, 8.5)  1 (-0.7, 12.5, 3.0)  8 (5.3) 
19F  22 (1.7, 39.3, 46.8)  26 (-0.1, 46.4, 36.6)  8 (-1.7, 14.3, 24.2)  56 (37.1) 
23F  3 (-1.1, 18.8, 6.4)  12 (2.4, 75.0, 16.9)  1 (-1.6, 6.3, 3.0)  16 (10.6) 
35B  2 (0.8, 50.0, 4.3)  2 (0.1, 50.0, 2.8)  0 (-1.1, 0.0, 0.0)  4 (2.6) 
35F/47F  1 (0.1, 33.3, 2.1)  1 (-0.5, 33.3, 1.4)  1 (0.5, 33.3, 3.0)  3 (2.0) 
6A/6B  1 (-1.3, 11.1, 2.1)  6 (1.2, 66.7, 8.5)  2 (0.0, 22.2, 6.1)  9 (6.0) 
7C/7B/40  0 (-0.7, 0.0, 0.0)  1 (1.1, 100.0, 1.4)  0 (-0.5, 0.0, 0.0)  1 (0.7) 
7F/7A  0 (-1.2, 0.0, 0.0)  1 (-0.5, 33.3, 1.4)  2 (1.9, 66.7, 6.1)  3 (2.0) 
9V/9A  0 (-0.7, 0.0, 0.0)  0 (-0.9, 0.0, 0.0)  1 (1.9, 100.0, 3.0)  1 (0.7) 
NT  7 (0.4, 35.0, 14.9)  8 (-0.7, 40.0, 11.3)  5 (0.4, 25.0, 15.2)  20 (13.2) 
Total
b 
 47   (31.1)  71   (47.0)  33   (21.9)  151 
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3.2. Design of synthetic antimicrobial peptides 
A total of 54 potential natural antimicrobial peptides (AMPs) were shortlisted 
under the Small Peptide Library. These natural AMPs were originally sourced from 
human, amphibian, mammals, fishes, arthropods, insects, arachnids, plants, and bacteria. 
Ten natural AMPs were selected (PDB ID: 1Q71, 1D9J, 1M4F, 1MA2, 1T51, 1PG1, 
1X7K, 1HU5, 1VM4, 1HR1) with length ranging from 13 – 25 amino acids, net charge 
(NetC) of 0 to +8, charge density (ChD) of 0.00 – 0.45, hydrophobic ratio (HR) of 33% 
to 76%, total hydrophobic value (THV) of -19.5 – 10.1, and grand average of hydropathy 
(GRAVY) of -1.026 – 0.777 (Table 3.7). A total of 10 designed AMPs were then 
rationally designed by systematic residual modifications based on the template sequences 
of natural AMPs concerning the charge and hydrophobicity of the peptides (Table 3.7). 
All designed AMPs were designed to have positive charges or neutral since the AMPs 
collected under the Small Peptide Library were of similar properties and that in general 
cationic AMPs have greater antimicrobial potential. 
The first series of the first group designed AMPs was generated based on residual 
substitutions without chain length alteration mainly by single (DAMP5 and DAMP6) or 
double amino acids substitutions (DAMP3 and DAMP7): DAMP5 was generated by 
single amino acid substitution of the highly hydrophobic residue  Val
11 
of 1Q71 to Ser
11
 
which reduced the HR and THV by 5 and lower GRAVY by 0.238; 1VM4 had reduced 
THV by 5.1 and GRAVY by 0.392 with Val
6
 to Trp
6
 substitution to generate DAMP6 
while the C-terminal deamidation also reduced the NetC by 1; DAMP3 was highly 
cationic (+8) and highly hydrophilic (-18.2) generated by double consecutive amino acids 
substitutions at Ile
6,7
 to Trp
6
 - Pro
7 
from 1HU5; Similarly, DAMP7 was highly 
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hydrophilic (HR = -12.7, THV = -0.977) due to Ala
3,10
 substitutions to Trp
3
 - Arg
10
 which 
also increased the NetC by one unit. 
The second series of the first group designed AMPs was redesigned based on 
residual modifications with chain length alterations. The designed AMPs were mainly 
truncated at the terminal side or constituted partial fragment of the template natural 
AMPs. DAMP1 was generated by hybridization of the ten amino acids N-terminal 
fragment of 1Q71 with nine amino acids C-terminal fragment of 1D9J, bridged by one 
Ser residue. DAMP2 was the large central fragment of 1M4F with two and three amino 
acids truncations at both N- and C-terminal and introduced with Gly
10
 substitution to the 
bulky residue Phe
10
 which greatly increased the hydrophobicity of the peptide. DAMP4 
and DAMP9 were the central nine and eleven amino acids fragments of 1MA2 and 1PG1, 
respectively. Both have lowered positive charge and less hydrophilic than the respective 
templates. The N-terminus of 1T51 was truncated to the eight amino acids DAMP8 while 
maintaining the C-terminal amidation. In contrast, DAMP10 was the N-terminal fragment 
of 1X7K with Cys
4
, Phe
5
, and Cys
8
 substitutions to Arg
4,5
 and Trp
8
.  
To further enhance the antipneumococcal activities of designed AMPs, three series 
of second group designed AMPs with 13 amino acids in length have been redesigned 
based on the selected DAMP6, DAMP7, and 1T51. DAMP6 and DAMP7 were the most 
potential designed AMPs among the first group peptides while 1T51 was the natural 
AMP with the highest antipneumococcal activity. The algorithm of BioModroid software 
automatically substituted the peptide with all 20 amino acids at each position and then 
calculated the compatibility scores based on both NetC and hydrophobicity for each of 
the modified peptide with the target protein sequence which is the PBPs. However, each 
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modification was limited to four amino acids substitution to prevent excessive alterations 
to the peptides. As looping the peptide sequence through the whole sequence of the huge 
PBPs protein could be computationally intensive and time-consuming, the most potential 
binding site (pocket) from each of the six PBPs were first identified by Metapocket 2.0 
server. Modified peptides with the best compatibility scores for each PBP pocket were 
scored and ranked. Hence, for each peptide there were six scoring pairs (to each PBP 
pocket). These newly generated peptides were then combined under a master ranking 
which consisted of all the peptides and the respective scores. Three of the top scoring 
peptides were selected and synthesized for testing. These second group designed AMPs 
based on DAMP6, DAMP7, and 1T51 were referred to as DP6 (DP61, DP62, and DP63), 
DP7 (DP71, DP72, and DP73), and DP5 (DP51, DP52, and DP53), respectively and are 
listed under Table 3.7. The flow of the peptide design was illustrated in Figure 3.2.  
A separate series of five hybrid peptides (DM1, DM2, DM3, DM4, and DM5) were 
generated by combining partial fragments of DAMP6 (GLFDIWKKLVSDF) and 
DAMP7 (ILWWKWAWWRWRR-NH2). To design DM1, The first four residues at the 
N-terminus of DAMP6 (GLFD) was unaltered while the remaining fragment from the 5
th
 
residue onwards (IWKKLVSDF) was replaced with fragment of same length at the 
homologous position of DAMP7 (KWAWWRWRR-NH2). DM2, DM3, DM4, and DM5 
were designed using the same approach by substituting the N-terminal fragments of 
DAMP6 beginning from the 6
th
/7
th 
(produced identical sequences as both DAMP6 and 
DAMP7 have Trp at position 6), 8
th
, 9
th
, and 10
th
 residue with fragments of DAMP7 at 
the homologous positions, respectively (Figure 3.3). The four amino acids at the C-
terminal were also unaltered in all five hybrid peptides. 
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Table 3.7: Physicochemical properties of the natural AMPs and designed AMPs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peptide Sequences Length NetC
b
 ChD HR
 
THV
c 
GRAVY
c 
Series with length alterations   
1Q71 GGAGHVPEYFVGIGTPISFYG 21 0 0.00 33 8.4 0.400 
1D9J KWKLFKKIGIGKFLHSAKKF
a
 20 +9 0.45 45 -6.2 -0.310 
     DAMP1 GGAGHVPEYFSKFLHSAKKF
a
 20 +5 0.25 35 -7.3 -0.365 
1M4F DTHFPICIFCCGCCHRSKCGMCCKT 25 +4 0.16 52 9.7 0.388 
     DAMP2 HFPICIFCCFCCHRSKCGMC 20 +4 0.20 65 19.2 0.960 
1MA2 KWCFRVCYRGICYRRCR 17 +6 0.35 47 -8.8 -0.518 
     DAMP4 VCYRGICYR 9 +2 0.22 44 1.7 0.189 
1T51 ILGKIWEGIKSLF
a
 13 +2 0.15 53 10.1 0.777 
     DAMP8 WEGIKSLF
a
 8 +1 0.13 50 1.6 0.200 
DP51 ILGGDWEGIVLLF
a
 13 -1 -0.08 61 18.3 1.408 
DP52 ILGGGWEGIVGLF
a
 13 0 0.00 53 17.2 1.323 
DP53 ILGKILVHHKSLF
a
 13 +5 0.38 53 12.0 0.923 
1PG1 RGGRLCYCRRRFCVCVGR 18 +6 0.33 44 -4.5 -0.250 
     DAMP9 CYCRRRFCVCV 11 +3 0.27 63 6.4 0.582 
1X7K RRWCFRVCYRGRFCYRKCR 19 +8 0.42 42 -19.5 -1.026 
     DAMP10 RRWRRRVWYRGRF 13 +7 0.54 30 -28.0 -2,154 
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Table 3.7 (continued): Physicochemical properties of the natural AMPs and designed AMPs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
C-terminal amidation (-NH2). 
b
Lys (K), Arg (R), His (H), and C-terminal amidation was assigned with +1 charge. Asp (D) and Glu (E) was assigned with -1 charge. 
c
Higher positive values denote higher hydrophobicity and vice versa. 
Abbreviations: NetC, net charge; ChD, charge density; HR, hydrophobic ratio; THV, total hydrophobic value; GRAVY, Grand Average of 
Hydropathy. 
Peptide Sequences Length NetC
b
 ChD HR
 
THV
c 
GRAVY
c 
Series without length alterations       
1HU5 KNLRRIIRKIIHIIKKYG 18 +8 0.44 38 -6.7 -0.372 
     DAMP3 KNLRRWPRKIIHIIKKYG 18 +8 0.44 33 -18.2 -1.011 
1Q71 GGAGHVPEYFVGIGTPISFYG 21 0 0.00 33 8.4 0.400 
     DAMP5 GGAGHVPEYFSGIGTPISFYG 21 0 0.00 28 3.4 0.162 
1VM4 GLFDIVKKLVSDF
a
 13 +1 0.08 53 10.1 0.777 
     DAMP6 GLFDIWKKLVSDF 13 0 0.00 53 5.0 0.385 
DP61 GLFDTNKKKKSDF 13 +2 0.15 23 -18.6 -1.431 
DP62 GTTDIWKKKKSDF 13 +2 0.15 23 -18.8 -1.446 
DP63 GSKDKKKKLVSDF 13 +3 0.23 23 -17.7 -1.362 
1HR1 ILAWKWAWWAWRR
a
 13 +4 0.31 76 -3.7 -0.285 
     DAMP7 ILWWKWAWWRWRR
a
 13 +5 0.38 69 -12.7 -0.977 
DP71 PHWWKWAWWHHRR
a
 13 +7 0.54 46 -26.8 -0.977 
DP72 KHWWKHDWWRWRR
a
 13 +7 0.54 38 -35.7 -2.746 
DP73 ILWWLLAWWRWPH
a
 13 +3 0.23 76 3.9 0.300 
       
                Hybrid series       
DM1 GLFDKWAWWRWRR
a
 13 +4 0.31 53 -16.5 -1.269 
DM2 GLFDIWAWWRWRR
a
 13 +3 0.23 61 -8.1 -0.623 
DM3 GLFDIWKWWRWRR
a
 13 +4 0.31 53 -13.8 -1.062 
DM4 GLFDIWKKWRWRR
a
 13 +5 0.38 46 -16.8 -1.292 
DM5 GLFDIWKKLRWRR
a
 13 +5 0.38 46 -12.1 -0.931 
 114 
 
 
 
P H W W K W A W W R W R R             peptide 
A S K M Y A N Y S W N M T K T G T T N Q D N M Q Y pocket 
P H W W K W A W W R W R R             
A S K M Y A N Y S W N M T K T G T T N Q D N M Q Y 
 P H W W K W A W W R W R R            
A S K M Y A N Y S W N M T K T G T T N Q D N M Q Y 
Pocket ASKMYANYSWNMTKTGTTNQDNMQY 
Peptide PHWWKWAWWRWRR 
Score 0.616227 
P H W W K W A W W H H R R             peptide 
A S K M Y A N Y S W N M T K T G T T N Q D N M Q Y pocket 
Step 1: Align both sequences from N-terminal (position 1) and randomly substitute two 
residues (red). 
Step 2: Calculate the scores for the direct pairs (red) and both neighboring pairs for 
each peptide residue simultaneously (illustrating only the direct (red) and 
neighboring pairs (blue) for His
2
 and Ala
7
 (Green)) 
Step 3: The same peptide sequence is shifted to position 2, 3, 4…etc and the same 
calculations are performed. 
Step 5: All scores were ranked. 
Step 4: Continue with substituting the remaining 19 X 19 amino acids combinations and 
perform the same procedures for each of the pocket sites. 
Step 6: The best scoring peptide (with two residual substitution) for the respective pocket 
site is now the template peptide. 
Step 7: Substitutions continued and limited to the other 11 residues. The altered residues 
from the round 1 design will not be disturbed. 
Step 8: The top 3 best scoring peptides with different pocket sites were selected. 
Figure 3.2: The flow in generating the DP5, DP6, and DP7 of the second group 
designed AMPs based on double Y algorithm using BioModroid software.   
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Peptide Sequence 
DAMP6 G L F D I W K K L V S D F 
DAMP7 I L W W K W A W W R W R R 
 
 
 
 
DM Sequence 
DM1 G L F D K W A W W R W R R 
DM2 G L F D I W A W W R W R R 
DM3 G L F D I W K W W R W R R 
DM4 G L F D I W K K W R W R R 
DM5 G L F D I W K K L R W R R 
Figure 3.3: The generation of the five hybrid peptide DM1 – DM5 via fragment 
hybridizations of DAMP6 and DAMP7. 
Highlighted in yellow: Peptide sequence from DAMP6. 
Highlighted in blue: Peptide sequence from DAMP7. 
 116 
 
 
3.2.1. In vitro antimicrobial activity of peptides 
3.2.1.1. Determination of peptides’ MICs against S. pneumoniae 
The minimum inhibitory concentrations (MICs) of the peptides were tested 
against 60 pneumococcal isolates which consisted of 20 isolates each for PSSP, PISP, 
and PRSP. These included the 10 natural AMPs (1Q71, 1D9J, 1M4F, 1MA2, 1T51, 
1PG1, 1X7K, 1HU5, 1VM4, and 1HR1), 10 designed AMPs from the first group 
(DAMP1- DAMP10), and 14 designed AMPs from the second group (DP6 series: 
DP61 - DP63; DP7 series: DP71 - DP73; DP5 series: DP51 - DP53; Hybrid series: 
DM1 – DM5). 
Among the 10 template natural AMPs, 1T51 was the most potent peptide which 
showed antipneumococcal activity of 15.63 – 250 µg/ml against all 60 pneumococcal 
isolates tested (Table 3.8). The antipneumococcal activity of seven other natural 
AMPs (1Q71, 1D9J, 1MA2, 1PG1, 1X7K, 1HU5, 1VM4) were considerably weak 
(overall effective percentage of 3.3% - 38.3%) while no detectable MIC in the range 
of concentrations tested were noted for 1M4F and 1HR1. 
The first group of designed AMPs based on the natural AMPs can be divided 
into two series: with and without chain length alterations. For series without chain 
length alterations, DAMP7 was found to inhibit 45.0% (9/20) PRSP, 30.0% (6/20) 
PISP, and 65.0% (13/20) PSSP giving an overall effective percentage of 46.7% (28/60) 
in the effective range of 31.3 – 250 µg/ml (Table 3.8, highlighted in yellow). As 
compared to the template 1HR1 which was non-effective against S. pneumoniae, the 
antipneumococcal activity of DAMP7 was significantly higher. DAMP6 was rather 
weak showing high MIC level (125 – 250 µg/ml) against 30% of PRSP isolates only. 
The antipneumococcal activity of DAMP6 (10.0% overall effective percentage) was 
lowered as compared to the template 1VM4 (28.3% overall effective percentage). For 
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series with chain length alterations, no MIC was detected for the six designed AMPs 
(DAMP1, DAMP2, DAMP4, DAMP8, DAMP9, and DAMP10).     
To generate peptides with improved antipneumococcal activity, three series of 
the second group designed AMPs were redesigned based on the selected DAMP6, 
DAMP7, and the natural AMP 1T51 (Table 3.8). While the effective ranges of both 
DP71 (PRSP, 62.5 – 250 µg/ml; PISP, 62.5 – 250 µg/ml; PSSP, 125 – 250 µg/ml) and 
DP72 (PRSP, 62.5 – 250 µg/ml; 125 – 250 µg/ml; PSSP, 62.5 – 250 µg/ml) of the 
DP7 series (Table 3.8, highlighted in green) were comparable to DAMP7 (PRSP, 62.5 
– 250 µg/ml; 125 – 250 µg/ml; PSSP, 31.3 – 250 µg/ml) (Table 3.8, highlight in 
yellow) considering the respective penicillin susceptibility groups, both DP71 and 
DP72 displayed strong antipneumococcal activity which was approximately two-fold 
higher in overall effective percentage (DP71, 86.7%, DP72, 96.7%) as compared to 
DAMP7 (46.7%). The DP6 and DP5 series which were redesigned from DAMP6 and 
1T51 had no antipneumococcal MIC reported. 
The most remarkable result was observed with the hybrid series which consists 
of DM1 – DM5. In general, all five DMs displayed high potent antipneumococcal 
activity against all sixty pneumococcal isolates tested (100% overall effective 
percentage) irrespective of the penicillin susceptibility of the isolates (Table 3.8, 
highlighted in blue). These isolates included serotypes 19F, 23F, 6A/B, 11A/D, 15A/F, 
16F, 22F/A, 3F, and the nontypeable pneumococci. The effective ranges of the five 
DMs were fairly similar for the respective PRSP, PISP, and PSSP and differed by no 
more than four-fold dilution. For each of the pneumococcal penicillin susceptibility 
groups, the effective ranges and thus the MICs of all five DMs were equal to or lower 
(except DM1 against PSSP) than DAMP7. This indicates that the antimicrobial 
activity of DMs were stronger than DAMP7. Among the five DMs, DM3 was the 
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most potent peptide with an overall effective range of 7.81 - 62.5 µg/ml. This peptide 
was also the most potent peptide against all three groups of PRSP, PISP, and PSSP. 
Of note, DM3 showed a particular sixteen-fold reduction in the lowest detectable MIC 
against PISP comparing to DAMP7. Overall, the antipneumococcal activity of DMs 
has been enhanced dramatically as compared to both DAMP6 and DAMP7, the 
templates used to generate the hybrids. All five DMs, DP71, DP72, and DAMP7 were 
water-soluble while DAMP6 has moderate water solubility.      
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Table 3.8:  Minimum inhibitory concentrations of natural AMPs and designed AMPs against S. pneumoniae.  
Peptide 
PRSP  PISP  PSSP 
Overall ER  
(µg/ml) 
Overall EP 
(%) ER (µg/ml) 
no. of isolates 
(EP %) 
 ER (µg/ml) 
no. of isolates 
(EP %) 
 ER (µg/ml) 
no. of isolates 
(EP %) 
Series with length alterations  
1Q71 250 9 (45.0)  250 5 (25.0)  >250 0 (0.0) 250 23.3 
1D9J 125 - 250 4 (20.0)  125 – 250 2 (10.0)  >250 0 (0.0) 125 – 250 10.0 
DAMP1 > 250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) 
 
0.0 
              
1M4F >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
DAMP2 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
              
1MA2 250 5 (25.0)  125 – 250 3 (15.0)  >250 0 (0.0) 125 – 250 13.3 
DAMP4 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
              
1T51 31.3 – 125 20 (100.0)  31.3 – 250 20 (100.0)  15.63 – 125 20 (100.0) 15.63 - 250 100.0 
DAMP8 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
DP51 250 1 (5.0)  >250 0 (0.0)  >250 0 (0.0) 250 1.7 
DP52 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0 
DP53 125 1 (5.0)  250 1 (5.0)  250 2 (10.0) 125 – 250 6.7 
              
1PG1 >250 0 (0.0)  250 1 (5.0)  250 1 (5.0) 250 23.3 
DAMP9 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
              
1X7K 62.5 – 250 3 (15.0)  62.5 – 250 2 (10.0)  125 – 250 2 (10.0) 62.5 – 250 11.7 
  DAMP10 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
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Table 3.8 (continued):  Minimum inhibitory concentrations of natural AMPs and designed AMPs against S. pneumoniae. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide 
PRSP  PISP  PSSP 
Overall ER  
(µg/ml) 
Overall 
EP (%) ER (µg/ml) 
no. of isolates 
(EP %) 
 ER (µg/ml) 
no. of isolates 
(EP %) 
 ER (µg/ml) 
no. of isolates 
(EP %) 
Series without length alterations 
1HU5 125 – 250 4 (20.0)  125 – 250 5 (25.0)  62.5 – 250 14 (70.0) 62.5 – 250 38.3 
DAMP3 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
              
1Q71 250 9 (45.0)  250 5 (25.0)  >250 0 (0.0) 23.3 250 
DAMP5 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
              
1VM4 125 – 250 5 (25.0)  62.5 – 250 6 (30.0)  125 – 250 6 (30.0) 62.5 – 250 28.3 
DAMP6 250 6 (30.0)  >250 0 (0.0)  >250 0 (0.0) 250 10.0 
DP61 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
DP62 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
DP63 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
              
1HR1 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
DAMP7 62.5 – 250 9 (45.0)  125 – 250 6 (30.0)  31.3 – 250 13 (65.0) 31.3 – 250 46.7 
DP71 62.5 – 250 19 (95.0)  62.5 – 250 17 (85.0)  125 – 250 16 (80.0) 62.5 – 250 86.7 
DP72 62.5 – 250 20 (20.0)  125 – 250 19 (95.0)  62.5 – 250 19 (95.0) 62.5 – 250 96.7 
DP73 >250 0 (0.0)  >250 0 (0.0)  >250 0 (0.0) - 0.0 
              
             Hybrid series 
DM1 31.3 – 125 20 (100.0)  31.3 – 125 20 (100.0)  62.5 – 250 20 (100.0) 31.3 – 250 100.0 
DM2 15.63 – 250 20 (100.0)  7.81 – 250 20 (100.0)  15.63 – 250 20 (100.0) 7.81 – 250 100.0 
DM3 15.63 – 62.5 20 (100.0)  7.81 – 62.5 20 (100.0)  7.81 – 62.5 20 (100.0) 7.81 – 62.5 100.0 
DM4 31.3 – 125 20 (100.0)  15.63 – 125 20 (100.0)  15.63 – 125 20 (100.0) 15.63 – 125 100.0 
DM5 31.3 – 125 20 (100.0)  15.63– 125 20 (100.0)  15.63 – 125 20 (100.0) 15.63 – 125 100.0 
Highlighted in yellow: Antipneumococcal ER and EP of DAMP7 against PRSP, PISP, and PSSP, respectively. 
Highlighted in green: Antipneumococcal  ER and EP of DP71 and DP72 against PRSP, PISP, and PSSP, respectively. 
Highlighted in blue: Overall ER and overall EP of DM1 – DM5. 
Abbreviations: PRSP, penicillin-resistant S. pneumoniae; PISP, penicillin-intermediate S. pneumoniae; PSSP, penicillin-
susceptible S. pneumoniae;  ER, effective range; EP, effective percentage. 
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3.2.1.2. Broad spectrum antibacterial activity of peptides 
The second group designed AMPs together with DAMP6, DAMP7, and 1T51 
were further tested using broth microdilution technique against eight bacterial species 
commonly encountered in the clinical setting to assess the spectrum of antibacterial 
activity of the peptides. The bacteria included Staphylococcus aureus ATCC 25923, E. 
coli ATCC 25922, P. aeruginosa ATCC 15442, Acinetobacter baumanii ATCC 
15308, and one clinical isolate for each methicillin-resistant S. aureus (MRSA), 
Enterococcus cloacae, Citrobacter spp., and K. pneumoniae. DAMP7 was found to 
display antibacterial activity against the gram-positive S. aureus (62.5 µg/ml) and 
MRSA (31.25 µg/ml) but was weakly effective (125 - 250 µg/ml) against E. coli, A. 
baumanii, and E. cloacae except Citrobacter spp. (62.5 µg/ml) (Table 3.9, highlighted 
in yellow). No antibacterial activity was observed for DAMP6 and the redesigned 
DP6 series peptides. 
For the DP7 series, DP71 was non-effective (≥125 µg/ml) while DP72 
displayed lower antibacterial MICs in the range of 31.3 – 125 µg/ml (except for K. 
pneumoniae) than DP71. As compared to DAMP7, DP72 exhibited four-fold lower in 
antiMRSA activity (DAMP7, 31.3 µg/ml; DP72, 125 µg/ml), however, the 
antipseudomonal activity was more than four-fold higher (DAMP7, > 250 µg/ml; 
DP72, 62.5 µg/ml). Antibacterial activities other than these two bacteria were 
comparable by no more than two-fold difference in MICs. Apart from that, DP72 
displayed the highest antibacterial activity against Citrobacter spp. (31.25 µg/ml) 
among the panel of bacteria tested. Despite DP73 was non-active against any of the 
bacteria tested, it showed a potent activity specifically against S. aureus at very low 
MIC level (7.81 µg/ml).  
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The hybrid DMs which were strongly effective against S. pneumoniae also 
displayed antibacterial activity against multiple bacteria. DM3 exhibited potent 
antibacterial activity in the range of 7.81 – 62.5 µg/ml against seven out of the eight 
bacteria tested except for P. aeruginosa (125 µg/ml) (Table 3.9, highlighted in blue). 
Notably, the DM3-susceptible strain included K. pneumoniae (DM3 MIC = 62.5 
µg/ml) whereby K. pneumoniae was not susceptible (MIC > 250 µg/ml) to as many as 
14 of the total peptides tested in this study. Furthermore, DM3 also showed enhanced 
broad spectrum activities as compared to DAMP7 by at least four-fold reduction in 
antibacterial MICs against all the eight bacteria.  
While DM4 exhibited comparable antibacterial activity to DAMP7, DM1 and 
DM5 showed similar (against E. cloaceae) or at least two-fold reduction in MICs 
against gram-negative bacteria as compared to DAMP7. In addition, DM5 showed 
drastic improvement in antibacterial activity as compared to DAMP7; for E. coli and 
P. aeruginosa, the MICs were at least eight-fold lower (E. coli, DAMP7 MIC = 250 
µg/ml, P. aeruginosa, DAMP7 MIC = > 250 µg/ml; DM5, 31.3 µg/ml for both); and 
for A. baumanii, the MIC was four-fold lower (DAMP7 MIC = 125 µg/ml; DM5 MIC 
= 31.3 µg/ml). DM1 also showed four-fold lower in MICs against E. coli (DAMP7 
MIC = 250 µg/ml, DM1 MIC = 62.5 µg/ml) and P. aeruginosa (DAMP7 MIC = > 
250 µg/ml, DM1 MIC = 125 µg/ml). However, the MICs of DM1 and DM5 were 
two-fold higher (125 µg/ml and 62.5 µg/ml) than DAMP7 (62.5 µg/ml and 31.3 µg/ml) 
against the gram-positive bacteria S. aureus and MRSA, respectively. Although the 
MICs against S. aureus and MRSA were comparable, the susceptibility of MRSA to 
DM1, DM3, and DM5 was two-fold higher than S. aureus. In contrast, the opposite 
was observed for DM2 whereby the susceptibility of MRSA was two-fold lower than 
S. aureus. It was noticed that the effective ranges of DAMP7 and hybrid DMs fell 
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closely within the overall effective range as that for S. pneumoniae. This implies that 
the antipneumococcal effective ranges of DAMP7 and hybrid DMs were also 
effective against wide variety of bacterial species. 
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Table 3.9: Broad spectrum antibacterial testing of peptides against eight common human bacterial pathogens. 
 
Peptide 
 MIC (µg/ml) 
 Gram-positive  Gram-negative 
 S. aureus MRSA  E. coli P. aeruginosa A. baumanii E. cloaceae Citrobacter spp. K. pneumoniae 
DAMP6  >250 >250  >250 >250 >250 >250 >250 >250 
DP61  >250 >250  >250 >250 >250 >250 250 >250 
DP62  >250 >250  >250 >250 >250 >250 >250 >250 
DP63  >250 >250  >250 >250 >250 >250 >250 >250 
 
 
  
  
     
DAMP7  62.5 31.3  250 >250 125 125 62.5 >250 
DP71  >250 >250  >250 >250 125 >250 >250 >250 
DP72  125 125  125 62.5 125 125 31.3 >250 
DP73  7.81 >250  >250 >250 >250 >250 >250 >250 
 
 
  
  
     
1T51  31.3 31.3  125 >250 31.3 250 125 125 
DP51  >250 >250  >250 >250 >250 >250 >250 >250 
DP52  >250 >250  >250 >250 >250 >250 >250 >250 
DP53  >250 >250  >250 >250 >250 >250 >250 >250 
 
 
  
  
     
    Hybrid DM 
DM1  125 62.5  62.5 125 62.5 125 31.3 >250 
DM2  31.3 62.5  250 >250 31.3 >250 62.5 >250 
DM3  15.63 7.81  62.5 125 15.63 31.3 15.63 62.5 
DM4  62.5 62.5  62.5 31.3 31.3 250 31.3 >250 
DM5  125 62.5  31.3 31.3 31.3 125 31.3 250 
Highlighted in yellow: MICs of DAMP7 against the eight gram-positive and gram-negative bacteria tested. 
Highlighted in blue: MICs of DM3 against the eight gram-positive and gram-negative bacteria tested. 
Abbreviations: MIC, minimum inhibitory concentrations 
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3.2.1.3. In vitro synergism activity 
The in vitro synergism effects of peptide-peptide and peptide-penicillin 
combinations were tested using the checkerboard method on selected peptides with 
antipneumococcal activity including DAMP6, DAMP7, DP71, DP72, and the five 
DMs. Combination of peptide-peptide pairs at differing ratios were prepared in 96-
well round bottom plates followed by addition of bacterial suspensions as described 
under section 2.5.4. Fractional inhibitory concentration (FIC) index of ≤ 0.05 denotes 
synergism, > 0.5 – 4 denotes additive/indifference, and > 4 denotes antagonism 
(Bajaksouzian et al., 1996). Results showed that DAMP7, DP71, DP72, and the five 
hybrids all displayed FIC indexes of ≤ 0.5 when given in combination with penicillin 
against PRSP, PISP, and PSSP (Table 3.10, Table 3.11, and Table 3.12, highlighted in 
yellow), noting antipneumococcal synergism irrespective of penicillin susceptibility 
of the isolates. The FIC range determined was between 0.16 – 0.5. DAMP6 was tested 
against PRSP only as no PISP or PSSP were susceptible to this peptide (Table 3.8). 
No synergism was detected for DAMP6 and penicillin pair against PRSP. Among all 
the peptide-peptide combinations, synergism was noted when DM5 was paired with 
DM1, DM2, DM4, or DAMP7 (Table 3.10, highlighted in green) and when DM3 was 
paired with DAMP7 (Table 3.10, highlighted in blue) against PRSP. Other peptide-
peptide combinations against PRSP as well as PISP and PSSP detected no synergism 
with FICs in the range of > 0.5 – 1.25. They were still able to inhibit pneumococci in 
an additive/indifference fashion implying that these components in combination had 
no significant interaction between them to enhance the antimicrobial activity of one 
another (Meletiadis et al., 2010). No antagonism (FIC > 4) was detected in any of the 
pairs. 
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Table 3.10: FIC index of peptide-peptide/penicllin combinations against PRSP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aFIC ≤ 0.05 denotes synergism, > 0.5 – 4 denotes indifference, and > 4 denotes antagonism. 
Combinations showing in vitroantipneumococcal synergism: 
Highlighted in yellow: Penicillin-DM1/DM2/DM3/DM4/DM5/DAMP7/DP71/DP72. 
Highlighted in green: DM5–DM1/DM2/DM4/DM7 
Highlighted in blue: DM3-DAMP7.  
Abbreviation: FIC, fractional inhibitory concentration. 
Peptide pair FIC index Interpretation
a 
DM1 DM2 0.75 Additive/indifference 
 DM3 0.75 Additive/indifference 
 DM4 0.75 Additive/indifference 
 DM5 0.50 Synergy 
 DAMP6 1.00 Additive/indifference 
 DAMP7 0.75 Additive/indifference 
 DP71 1.25 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 0.38
 
Synergy 
DM2 DM3 0.75 Additive/indifference 
 DM4 0.75 Additive/indifference 
 DM5 0.50 Synergy 
 DAMP6 1.00 Additive/indifference 
 DAMP7 0.75 Additive/indifference 
 DP71 1.25 Additive/indifference 
 DP72 1.00 Additive/indifference 
 PEN 0.38
 
Synergy 
DM3 DM4 0.75 Additive/indifference 
 DM5 0.75 Additive/indifference 
 DAMP6 1.00 Additive/indifference 
 DAMP7 0.50
 
Synergy 
 DP71 1.25 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 0.38
 
Synergy 
DM4 DM5 0.50 Synergy 
 DAMP6 1.25 Additive/indifference 
 DAMP7 0.75 Additive/indifference 
 DP71 1.25 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 0.28
 
Synergy 
DM5 DAMP6 1.25 Additive/indifference 
 DAMP7 0.50 Synergy 
 DP71 0.75 Additive/indifference 
 DP72 1.00 Additive/indifference 
 PEN 0.25 Synergy 
DAMP6 DAMP7 1.25 Additive/indifference 
 DP71 1.25 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 1.00 Additive/indifference 
DAMP7 DP71 1.06 Additive/indifference 
 DP72 1.06 Additive/indifference 
 PEN 0.31 Synergy 
DP71 DP72 1.25 Additive/indifference 
 PEN 0.19 Synergy 
DP72 PEN 0.38 Synergy 
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Table 3.11: FIC index of peptide-peptide/penicllin combinations against PISP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aFIC ≤ 0.05 denotes synergism, > 0.5 – 4 denotes indifference, and > 4 denotes antagonism. 
Combinations showing in vitroantipneumococcal synergism: 
Highlighted in yellow: Penicillin-DM1/DM2/DM3/DM4/DM5/DAMP7/DP71/DP72.  
Abbreviations: FIC, fractional inhibitory concentration; NE, Not tested  
Peptide pair FIC index Interpretation
a 
DM1 DM2 0.75 Additive/indifference 
 DM3 0.75 Additive/indifference 
 DM4 0.63 Additive/indifference 
 DM5 0.63 Additive/indifference 
 DAMP6 NE  
 DAMP7 0.75 Additive/indifference 
 DP71 1.00 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 0.50 Synergy 
DM2 DM3 0.75 Additive/indifference 
 DM4 0.63 Additive/indifference 
 DM5 0.63 Additive/indifference 
 DAMP6 NE  
 DAMP7 1.00 Additive/indifference 
 DP71 1.00 Additive/indifference 
 DP72 1.00 Additive/indifference 
 PEN 0.50 Synergy 
DM3 DM4 0.63 Additive/indifference 
 DM5 0.75 Additive/indifference 
 DAMP6 NE  
 DAMP7 1.00 Additive/indifference 
 DP71 1.00 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 0.50 Synergy 
DM4 DM5 0.75 Additive/indifference 
 DAMP6 NE  
 DAMP7 0.75 Additive/indifference 
 DP71 1.25 Additive/indifference 
 DP72 1.00 Additive/indifference 
 PEN 0.50 Synergy 
DM5 DAMP6 NE  
 DAMP7 0.75 Additive/indifference 
 DP71 1.00 Additive/indifference 
 DP72 1.00 Additive/indifference 
 PEN 0.50 Synergy 
DAMP6 DAMP7 NE  
 DP71 NE  
 DP72 NE  
 PEN NE  
DAMP7 DP71 1.00 Additive/indifference 
 DP72 1.00 Additive/indifference 
 PEN 0.31 Synergy 
DP71 DP72 1.25 Additive/indifference 
 PEN 0.50 Synergy 
DP72 PEN 0.50 Synergy 
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Table 3.12: FIC index of peptide-peptide/penicllin combinations against PSSP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aFIC ≤ 0.05 denotes synergism, > 0.5 – 4 denotes indifference, and > 4 denotes antagonism. 
Combinations showing in vitroantipneumococcal synergism: 
Highlighted in yellow: Penicillin-DM1/DM2/DM3/DM4/DM5/DAMP7/DP71/DP72.  
Abbreviations: FIC, fractional inhibitory concentration; NE, Not tested 
 
  
 Peptide pair FIC index 
1.10. Interpretationa 
DM1 DM2 0.63 Additive/indifference 
 DM3 0.63 Additive/indifference 
 DM4 0.63 Additive/indifference 
 DM5 0.63 Additive/indifference 
 DAMP6 NE  
 DAMP7 0.63 Additive/indifference 
 DP71 1.00 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 0.16 Synergy 
DM2 DM3 1.13 Additive/indifference 
 DM4 1.13 Additive/indifference 
 DM5 0.63 Additive/indifference 
 DAMP6 NE  
 DAMP7 1.13 Additive/indifference 
 DP71 1.00 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 0.25 Synergy 
DM3 DM4 1.13 Additive/indifference 
 DM5 1.13 Additive/indifference 
 DAMP6 NE  
 DAMP7 1.13 Additive/indifference 
 DP71 1.00 Additive/indifference 
 DP72 1.00 Additive/indifference 
 PEN 0.19 Synergy 
DM4 DM5 0.63 Additive/indifference 
 DAMP6 NE  
 DAMP7 0.63 Additive/indifference 
 DP71 1.00 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 0.28 Synergy 
DM5 DAMP6 NE  
 DAMP7 1.13 Additive/indifference 
 DP71 1.25 Additive/indifference 
 DP72 1.25 Additive/indifference 
 PEN 0.19 Synergy 
DAMP6 DAMP7 NE  
 DP71 NE  
 DP72 NE  
 PEN NE  
DAMP7 DP71 1.00 Additive/indifference 
 DP72 1.00 Additive/indifference 
 PEN 0.19 Synergy 
DP71 DP72 1.25 Additive/indifference 
 PEN 0.38 Synergy 
DP72 PEN 0.38 Synergy 
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3.2.1.4. Assessing the killing kinetics of peptides against S. pneumoniae 
Based on the MIC results, peptides displaying antipneumococcal activity were 
assayed against each PRSP, PISP, and PSSP isolate to determine the killing kinetics 
over time posttreatment. Penicillin as the commonly used antibiotic against S. 
pneumoniae was also included as standard antibiotic control to compare the 
pneumocidal activity of peptides. Surviving colony forming units (CFU) at 0 
(pretreatment), 30, 60, 120, 150, 180, 210, and 240 mins posttreatment were 
enumerated and expressed as percentage of cells recovered (%) over untreated control 
at the respective time points. 
DAMP7 showed strong and rapid pneumocidal effects noting complete 
clearances (100%) of PRSP and PISP and near complete clearance (96.9%) of PSSP 
immediately at 30 mins posttreatment. This killing kinetics was greater than penicillin 
by 61.1%, 77.8%, and 57.2% against PRSP, PISP, and PSSP, respectively at an 
average of 65.4% (Figure 3.4). In contrast, although comparable PRSP killing rates 
were observed for DAMP6 (59.2%) and penicillin (64.1%) at first 30 mins 
posttreatment, the killing rate over prolonged period were lower for DAMP6 than 
penicillin (Figure 3.4A). As at 150 mins posttreatment, 21.9% of DAMP6-treated 
PRSP was recovered while only 4.8% of penicillin-treated PRSP was recovered. 
DAMP6 was not assayed against PISP and PSSP as it has no detectable MICs against 
these groups of pneumococci. 
The redesigned DP71 and DP72 also displayed strong killing effects. The 
percentages of DP71-treated cells recovered at 30 mins posttreatment was 22.2%, 
21.9%, and 15.3% at an average of 19.8% while that of DP72-treated cells were 
43.7%, 32.2%, and 89.9% at an average of 55.3% for PRSP, PISP, and PSSP, 
respectively at 30 mins posttreatment (Figure 3.5). In comparison, the differences in 
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killing rates over penicillin against PRSP, PISP, and PSSP were 41.9%, 55.9%, and 
45.0% respectively at an average of 47.6% for DP71; 20.4%, 45.6%, and 29.6% at an 
average of 31.8% for DP72. 
Drastic reductions in viable pneumococci were also noted with the five DMs 
(Figure 3.6). Pneumocidal activity of the peptides at 30 mins posttreatment showed 
that while the proportions of penicillin-treated pneumococcal cells recovered 
remained at 60 – 78%, the percentages of DMs-treated pneumococci recovered were 
less than 30% irrespective of the penicillin susceptibility of the isolates. This indicates 
that although the pneumocidal activity varied among the respective DMs, large 
proportions of the pneumococcal cells was rapidly cleared within the first 30 mins and 
the CFU recovered continue to drop until eventual elimination. The pneumocidal 
activities of DMs were dramatically greater than penicillin. The differences in killing 
kinetics against PRSP, PISP, and PSSP over penicillin were 52.9%, 54.2%, and 38.4% 
respectively at an average of 48.5% for DM1; 64.1%, 65.4%, and 54.4% respectively 
at an average of 61.3% for DM2; 60.0%, 76.0%, and 57.7% respectively at an average 
of 64.6% for DM3; 39.0%, 57.8%, and 30.5% respectively at an average of 42.4% for 
DM4; 38.1%, 58.5%, and 36.5% respectively at an average of 44.4% for DM5. The 
results clearly showed that the hybrids were superior to penicillin in pneumocidal 
activities. Notably, the proportions of surviving DM2- and DM3-treated cells were < 
6.0% for all three penicillin susceptible pneumococci at 30 min posttreatment (except 
12.4% by DM2-treated PISP). Moreover, complete bacterial clearance was observed 
with DM2-treated PRSP immediately at the first 30 mins posttreatment. 
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Figure 3.4: Percentage (%) of pneumococcal cells recovered following treatment 
with DAMP6, DAMP7, and PEN. At the specific time intervals, each (A) PRSP, 
(B) PISP, and (C) PSSP  at 5x10
6
 CFU/ml were treated with 2X MIC of the 
respective peptides/PEN and viable cells posttreatment were enumerated using 
plate count method. DAMP7 was strongly pneumocidal at an average of 65.4% 
as compared to PEN at 30 min posttreatment. The killing kinectic of DAMP6 
against PRSP was lower than PEN over prolonged treatment time.   
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Figure 3.5: Percentage (%) of pneumococcal cells recovered following treatment 
with DP71, DP72, and PEN. At the specific time intervals, each (A) PRSP, (B) 
PISP, and (C) PSSP at 5x10
6
 CFU/ml were treated with 2X MIC of the 
respective peptides/PEN and viable cells posttreatment were enumerated using 
plate count method. DP71 was pneumocidal at an average of 47.6% higher 
killing rate than PEN at 30 min posttreatment while that of DP72 was 31.8% 
although the pneumocidal activity of DP72 against PRSP and PSSP was fairly 
comparable to PEN. 
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Figure 3.6: Percentage (%) of pneumococcal cells recovered following treatment 
with DM1 – DM5 and PEN. At the specific time intervals, each (A) PRSP, (B) 
PISP, and (C) PSSP at 5x10
6
 CFU/ml were treated with 2X MIC of the 
respective peptides/PEN and viable cells posttreatment were enumerated using 
plate count method. The five DMs (DM1 – DM5) were strongly pneumocidal at 
an average of 48.5%, 61.3%, 64.6%, 42.4%, and 44.4% higher killing rates than 
PEN at 30 min posttreatment, respectively. 
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3.2.1.5. Effects of peptides on pneumococcal cell morphology 
The changes in cell morphology induced by the five DMs on S. pneumoniae 
were investigated using Transmission Electron Microscopy (TEM). As shown in 
Figure 3.7A, the untreated cell has intact cell wall and cytoplasmic membrane which 
maintain the coccoidal shape of pneumococcus. The cytoplasm was densely packed 
and the pneumococcal cell surface structures especially the capsular polysaccharide 
(CPS) were visible as a thin layer covering the outer layer of the cell (Figure 3.7A, 
black arrow). Following treatment with each DM, the pneumococcal cells were 
extensively enlarged and/or became spherical (Figure 3.7B - K). Severe damages 
accompanied with overwhelming morphological changes of the pneumococcal cells 
were clearly evident. In particular, cell wall and/or cytoplasmic membrane breakages 
of small/large magnitudes were observed (arrow a). Losses in large areas of the cell 
wall were noted especially with DM4- and DM5-treated pneumococci which appeared 
as “balding” thus exposing the cytoplasmic membrane of cells (arrow a1). 
Detachment of the cell wall can be clearly seen, forming large cavity spaces between 
the cell wall and cytoplasmic membrane (arrow b). With the loss of the structural 
support from cell wall and the weakened cytoplasmic membrane, the cells become 
extensively irregular in shape. Leakage of intracellular contents eventually occurred 
(arrow c). As in DM3, the release of cytoplasmic contents seems to happen through 
the breakdown and subsequent formation of cytoplasmic-containing inclusion bodies 
(arrow d, Figure 3.7B, G, K) or through bulging of cytoplasmic membrane leading to 
formation of inclusion bodies as with DM5 (arrow d, Figure 3.7J). Additionally, large 
halos observed in the cytoplasm could probably be due to loss of cytoplasmic content 
(arrow e). For DM2, some intracellular content of the treated cell also appeared 
filamentous and stacked at one pole of the cell (Figure 3.7D, arrow f) as compared to 
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the non-filamentous cytoplasm distributed mainly in the center region of the cell. 
Eventually cells without cellular content appeared as an empty “shell”. 
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Figure 3.7: TEM images of PRSP treated with DM1 – DM5. 
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Figure 3.7 (continued): TEM images of PRSP treated with DM1 – DM5. (A) The 
untreated control showed the normal coccoidal shape morphology of S. 
pneumoniae while severe cell morphological changes following treatment with (B 
& C) DM1, (D & E) DM2, (F & G) DM3, (H & I) DM4, and (J & K) DM5-treated 
pneumococcal cells were evident: (a) cell wall/membrane breakages, (a1) loss of 
cell wall, (b) large cavity between cell wall and plasma membrane, (c) leakage of 
intracellular contents, (d) breakdown of cytoplasm into inclusion bodies, (e) loss of 
cytoplasm, and (f) filamentation of intracellular contents. Bar indicates 200 nm. 
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3.2.2. In vitro cell toxicity of peptides on human cells 
From the hemolytic and cell cytotoxicity assays, the natural AMP 1VM4, the 
designed DAMP6 and DP6 peptides showed no hemolytic activity (HC10 and HC50 > 
250 µg/ml) (Table 3.13) and no cytotoxicity on both NL20 (Table 3.14) and A549 
(Table 3.15) cell lines at IC50 of > 250 µg/ml. 1T51, the template used to design DP5 
peptides, displayed considerable cell toxicities with HC10 at 55.7 µg/ml and possessed 
higher selectivity against A549 cell line as compared to NL20 cell line. DP5 peptides 
showed no cell toxicity in both hemolytic and cell cytotoxicity studies. No hemolytic 
or cytotoxicity was detected for penicillin in the range of concentrations tested. 
As for DAMP7 (Table, 3.13, highlighted in yellow), the hemolytic activity level 
was higher than the template 1HR1 whereby the HC10 and HC50 of DAMP7 were 
approximately two-fold lower at 20.6 µg/ml and 93.0 µg/ml as compared to 1HR1 at 
42.3 µg/ml and > 250 µg/ml, respectively. However, DAMP7-treated NL20 (Table 
3.14, highlighted in yellow) and A549 cells (Table 3.15, highlighted in yellow) had 
higher percentages of cell viability as compared to 1HR1. The Imax of DAMP7 was 
approximately 10% higher than 1HR1 on NL20 cell line. In contrast, the differences 
in IC50 levels were less pronounced over prolonged treatment with DAMP7 and 1HR1 
on the A549 cell line. This is in parallel with the Imax values as the difference in cell 
viability reduced from 10.4% at 24 hrs to 0.2% at 72 hrs. When compared among the 
two cell lines, cytotoxicity of DAMP7 on NL20 cell line (IC50 = 202 - > 250 µg/ml) 
was found to be lower than on the A549 cell line (IC50 = 82 – 102 µg/ml) by 
approximately 2 – 2.5 fold for all three time points investigated.  
Three of the DP7s showed only minimal level of hemolytic (HC10 and 
HC50 >250 µg/ml) and cell cytotoxicities (IC50 > 248.3 µg/ml). The hybrid peptides 
DM1, DM4, and DM5 displayed no hemolytic activity (HC10 > 250 µg/ml, Hmax < 
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1.0%). DM1 was the least cytotoxic peptide among the hybrid series, which showed 
IC50 of > 220 µg/ml against NL20 cell line and ≥195.0 µg/ml against A549 cell line. 
For DM4 and DM5, the overall cell cytotoxicity against NL20 was lower than A549 
cell line although no major difference in cell viability was observed at the Imax level 
(except for DM4-treated A549 cells at 72 hrs). For DM4, the IC50 of NL20 cells were 
160.2 µg/ml, 167.3 µg/ml, and 205.0 µg/ml while the IC50 of A549 cells were 93.3 
µg/ml, 103.0 µg/ml, and 107.5 µg/ml for 24 hrs, 48 hrs, and 72 hrs, respectively. The 
differences in IC50 for DM4-treated NL20 cells were 66.9 µg/ml, 64.3 µg/ml, and 97.5 
µg/ml over DM4-treated A549 cells. For DM5, the IC50 of NL20 cells were 179.2 
µg/ml, 188.2 µg/ml, and 191.7 µg/ml while the IC50 of A549 cells were 97.0 µg/ml, 
106.3 µg/ml, and 101.7 µg/ml for 24 hrs, 48 hrs, and 72 hrs, respectively. The 
differences in IC50 for DM5-treated NL20 cells were 82.2 µg/ml, 81.9 µg/ml, and 90.0 
µg/ml over than DM5-treated A549 cells. 
Although DM3 was the most hemolytic peptide among the hybrid series (Table, 
3.13, highlighted in blue), the hemolytic levels were lower than DAMP7 as is seen in 
the HC50 and HC10 of DM3 (> 250 µg/ml and 52.7 µg/ml, respectively). In contrast, 
the IC50 levels of DM3 (24 hrs = 68.5 µg/ml; 48 hrs = 91.5 µg/ml; 72 hrs = 112.2 
µg/ml) were lower than DAMP7 (24 hrs = > 250 µg/ml; 48 hrs = 213.7 µg/ml; 72 hrs 
= 202.7 µg/ml) on NL20 cell line (Table 3.14, highlighted in yellow). Moreover, the 
Imax levels of DM3 (13.3%, 24.0%, and 12.4%) were lower than DAMP7 (56.4%, 
42.5%, and 38.5%) at the respective time points. For the A549 cell line, the 
cytotoxicity of DM3 and DAMP7 was comparable at 48 hrs and 72 hrs posttreatment 
except that for 24 hrs posttreatment (IC50 DM3 = 56.0 µg/ml, DAMP7 = 102.5 µg/ml) 
(Table 3.15, highlighted in blue). The cytotoxicity of DM3 was observed to be 
different with respect to different cell lines at which in general, its cytotoxicity 
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reduced over prolong incubation time. DM2 which was the second most hemolytic 
hybrid peptide (HC10 = 114.3 µg/ml) showed only minimal level of cytotoxicity on 
NL20 cell line although the cell viability of A549 cell line over extended treatment 
duration was found to be decreasing from IC50 of > 250 µg/ml, 197.7 µg/ml, and 
165.0 µg/ml at 24 hrs, 48 hrs, and 72 hrs, respectively. 
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Table 3.13: Hemolytic activity of natural AMPs and designed AMPs on human 
erythrocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC10 and HC50 were defined as the concentrations of peptide causing 10% and 50% 
hemolysis on human erythrocytes, respectively. 
Hmax was defined as the percentage (%) hemolysis of peptide at the highest 
concentration tested (all peptides - 250 μg/ml; PEN - 4 μg/ml). 
Highlighted in yellow: The hemolytic profile of DAMP7 defined at HC10, HC50, and 
Hmax. 
Highlighted in blue: The hemolytic profile of DM3 defined at HC10, HC50, and Hmax. 
Peptide 
Hemolytic activity (µg/ml) 
HC10 HC50 Hmax 
1VM4 >250 >250 1.0±0.2 
DAMP6 >250 >250 0.1±0.1 
DP61 >250 >250 0.2±0.0 
DP62 >250 >250 0.5±0.4 
DP63 >250 >250 0.3±0.2 
    
1HR1 42.3±5.0 >250 30.8±3.2 
DAMP7 20.6±6.7 93.0±16.5 85.2±5.7 
DP71 >250 >250 5.3±2.1 
DP72 >250 >250 0.4±0.1 
DP73 >250 >250 5.6±0.7 
    
1T51 55.7±4.2 154.3±12.7 84.0±6.6 
DP51 >250 >250 0.2±0.1 
DP52 >250 >250 0.3±0.1 
DP53 >250 >250 0.2±0.1 
    
Hybrid series 
DM1 >250 >250 0.5±0.1 
DM2 114.3±26.1 >250 13.9±2.0 
DM3 52.7±5.5 >250 39.0±2.5 
DM4 >250 >250 0.6±0.1 
DM5 >250 >250 0.9±0.4 
    
PEN >4 >4 0.6±0.3 
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Table 3.14: Cell cytotoxicity of natural AMPs and designed AMPs on NL20 cell line. 
 
 IC50 was concentration of peptide which reduced the cell viability to 50%. 
Imax was defined as the percentage (%) cell viability of peptide at the highest 
concentration tested (all peptides - 250 μg/ml; PEN - 4 μg/ml). 
Highlighted in yellow: The cell cytotoxicity of DAMP7 on NL20 cell line defined at IC50 
and Imax for 24, 48, and 72 hrs. 
Highlighted in blue: The cell cytotoxicity of DM3 on NL20 cell line defined at IC50 and 
Imax for 24, 48, and 72 hrs.  
Peptide 
NL20 cell line (µg/ml) 
24 hrs 48 hrs 72 hrs 
IC50 Imax IC50 Imax IC50 Imax 
1VM4 >250 90.1±6.3 >250 77.9±10.7 >250 82.9±8.0 
DAMP6 >250 104.2±8.9 >250 89.7±5.7 >250 81.1±1.7 
DP61 >250 117.0±8.7 >250 95.9±7.0 .>250 96.4±8.6 
DP62 >250 92.9±7.4 >250 90.2±5.3 >250 91.0±9.6 
DP63 >250 102.5±10.4 >250 96.0±6.3 >250 98.2±5.3 
       
1HR1 213.3±19.4 40.3±8.7 169.5±6.4 32.2±5.7 98.8±20.2 27.2±3.6 
DAMP7 >250 56.4±7.9 213.7±22.9 42.5±5.4 202.7±19.8 38.5±3.9 
DP71 >250 90.7±3.6 248.3±1.5 50.6±2.6 >250 49.9±3.0 
DP72 >250 60.0±10.0 >250 60.3±3.7 >250 56.4±4.0 
DP73 >250 86.4±5.2 >250 80.3±6.2 >250 90.2±8.5 
       
1T51 >250 53.7±6.8 237.7±18.8 50.2±6.8 218.0±37.3 43.6±8.4 
DP51 >250 109.4±7.0 >250 110.0±8.3 >250 107.7±2.7 
DP52 >250 101.4±3.1 >250 109.2±3.5 >250 102.9±5.9 
DP53 >250 110.4±2.7 >250 103.0±7.8 >250 110.8±11.8 
       
Hybrid series      
DM1 221.8±7.8 35.3±6.6 235.7±12.9 42.2±8.6 242.2±7.3 45.9±4.3 
DM2 >250 64.3±7.0 >250 53.3±9.1 241.5±9.0 46.8±4.0 
DM3 68.5±11.0 13.3±2.1 91.5±7.6 24.0±7.6 112.2±8.8 12.4±4.5 
DM4 160.2±11.8 6.9±6.8 167.3±5.9 5.9±2.5 205.0±7.0 30.2±2.9 
DM5 179.2±3.8 7.3±2.4 188.2±4.9 8.3±4.2 191.7±3.5 9.7±5.4 
       
PEN >4 105.2±0.2 >4 106.1±6.2 >4 88.3±0.4 
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Table 3.15: Cell cytotoxicity of natural AMPs and designed AMPs on A549 cell line. 
  
IC50, concentration of peptide which reduced cell viability to 50%. 
Imax, percentage (%) cell viability at maximum concentrations. The maximum 
concentration for all peptides and PEN were 250 μg/ml and 4 μg/ml, respectively. 
Highlighted in yellow: The cell cytotoxicity of DAMP7 on A549 cell line defined at IC50 
and Imax for 24, 48, and 72 hrs. 
Highlighted in blue: The cell cytotoxicity of DM3 on A549 cell line defined at IC50 and 
Imax for 24, 48, and 72 hrs.
Peptide 
A549 cell line (µg/ml) 
24 hrs 48 hrs 72 hrs 
IC50 Imax IC50 Imax IC50 Imax 
1VM4 ≥250 93.6±3.4 ≥250 99.5±1.0 ≥250 95.8±1.8 
DAMP6 ≥250 115.0±7.6 ≥250 112.0±7.4 ≥250 112.2±4.6 
DP61 ≥250 92.3±2.3 ≥250 91.4±8.9 ≥250 95.3±7.8 
DP62 ≥250 94.2±7.6 ≥250 92.3±0.4 ≥250 89.5±5.3 
DP63 ≥250 95.6±2.3 ≥250 93.8±6.2 ≥250 94.4±6.5 
       
1HR1 47.7±14.6 1.8±1.5 62.2±13.2 1.7±1.5 69.2±10.3 3.3±1.9 
DAMP7 102.5±8.3 12.2±5.4 84.8±2.5 7.3±3.9 82.0±1.8 3.5±2.3 
DP71 >250 59.6±4.9 >250 61.3±8.7 >250 66.0±8.2 
DP72 >250 53.5±9.4 >250 66.9±2.3 >250 80.1±1.4 
DP73 >250 66.4±7.6 >250 62.9±9.2 >250 61.5±2.4 
       
1T51 50.7±11.0 7.8±2.9 67.8±19.3 8.1±3.5 82.0±8.9 7.3±3.7 
DP51 >250 92.3±7.2 >250 94.8±9.3 >250 99.0±1.7 
DP52 >250 80.1±7.2 >250 71.3±5.7 >250 83.5±6.6 
DP53 >250 89.4±8.9 >250 96.3±6.2 >250 87.7±4.1 
       
Hybrid series 
DM1 215.3±19.7 38.6±6.2 195.0±25.2 39.8±7.7 >250 66.2±7.2 
DM2 >250 50.7±7.7 197.7±12.6 24.0±6.3 165±14.2 12.0±4.1 
DM3 56.0±9.3 4.2±3.2 80.0±1.7 4.4±2.4 96.2±4.4 3.7±2.1 
DM4 93.3±5.1 8.5±3.8 103.0±17.5 8.9±1.4 107.5±16.3 2,9±2.7 
DM5 97.0±9.8 9.0±1.0 106.3±15.7 7.8±3.8 101.7±9.5 8.0±3.2 
       
PEN >4 95.0±0.4 >4 97.3±0.4 >4 91.1±6.0 
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3.2.3. In vivo toxicity of peptide treatment 
The in vivo toxicity of the five DMs was assessed following the three dose 
regimens given to the mice at 2 hrs, 12 hrs, 24 hrs. Each peptide was initially given the 
highest deliverable dose via subcutaneous (SC, 100 mg/kg), intranasal (IN, 20 mg/kg), 
and intraperitoneal (IP, 100 mg/kg) routes. The immediate physical and behavioral 
abnormalities in mice were recorded for the observations of physical stress, shortness of 
breath, lethargy, and physical inactiveness (Table 3.16). Doses which caused the death 
of mice or if they appear highly stressed were not selected and lower graded doses were 
attempted until an appropriate dose which caused mild/no significant stressful responses 
to the mice. Any occurrence of death of mice was noted. At day 7 posttreatment, the 
whole blood was collected for whole blood haematogram analysis which included 
number of red blood cells (RBC), white blood cells (WBC), B neutrophil, S neutrophil, 
lymphocytes, monocytes, eosinophil, basophil, and thrombocytes, hemoglobin (Hb) 
concentration, packed cell volume (pCV), mean corpuscular volume (MCV), mean 
corpuscular haemoglobin concentration (MCHC), and plasma protein concentration. 
Serum collected was analyzed for serum biochemistry parameters including the 
concentrations of alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), creatinine, urea, lactate dehydrogenase (LDH), and direct and 
total bilirubin. The five major organs (spleen, kidney liver, lung, brain) were processed 
for histological examination.  
For mice treated via SC route at the highest deliverable dose of 100 mg/kg, no 
physical and behavioral abnormality was observed and no death occurred up to day 7 
posttreatment. Statistical analysis found no significant difference (p > 0.05) on the 
whole blood haematogram and serum biochemistry parameters of the mice treated with 
DM3, DM4, and DM5 as compared to the untreated control (Table 3.17). For DM1-
treated mice, significantly higher urea levels (p = 0.033, 9.45 ± 1.25 mmol/l) as 
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compared to the untreated control (7.27 ± 0.93 mmol/l) (Table 3.17, highlighted in 
yellow). DM2-treated mice had lower plasma protein (p = 0.027, 53.67 ± 1.53 g/l) and 
lower creatinine levels (32.67 ± 0.58 µmol/l) as compared to the untreated control (p = 
0.004, 60.33 ± 3.51 g/l and 40.67 ± 0.58 µmol/l, respectively) (Table 3.17, highlighted 
in green). In all the treatment groups, no significant histological abnormality was 
observed in the spleen, kidney, liver, lung, and brain of the mice as compared to the 
untreated control (Figure 3.8). 
 For mice treated via IN route at the highest deliverable dose of 20 mg/kg, no 
physical and behavioral abnormality was observed and no death occurred up to day 7 
posttreatment. Statistical analysis found no significant difference (p > 0.05) on the 
whole blood haematogram and serum biochemistry parameters of the mice treated with 
DM3 and DM4 as compared to the untreated control (Table 3.18). For DM1-treated 
mice, significantly lower thrombocytes count (p = 0.012, 1006.00 ± 197.73 x 10
9
/l) than 
the untreated control (1464.25 ± 209.39 x10
9 
/l) were noted (Table 3.18, highlighted in 
yellow). DM2 treatment mice had significantly lower thrombocytes count (p < 0.001, 
729.50 ± 253.5 x 10
9
/l) which was approximately half of the thrombocytes count in the 
untreated control (Table 3.18, highlighted in blue). DM2-treated mice also had 
significant elevated ALP level (p = 0.026, 220.00 ± 16.00 U/l) as compared to the 
untreated group (136.25 ± 10.34 U/l). Mice treated with DM5 were determined with 
lower creatinine levels (p = 0.028, 22.5 ± 11.73 µmol/l) than the untreated control (45.5 
± 11.24 µmol/l) (Table 3.18, highlighted in green). In all the treatment groups, no 
significant histological abnormality was observed in the spleen, kidney, liver, lung, and 
brain of the mice as compared to the untreated control (Figure 3.9). 
For mice treated via IP route at the highest deliverable dose of 100 mg/kg, various 
physical and behavioral abnormalities were observed with all five DMs treatments 
(Table 3.16). The mice appeared highly stressed, highly lethargic, and became inactive. 
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Deaths within 24 hrs were noted for DM3 at 60 mg/kg (2/4 mice died), 80 mg/kg (4/4 
mice died) and 100 mg/kg (4/4 mice died). Lower graded doses were attempted and 
mice receiving DM1 (5 mg/kg), DM2 (60 mg/kg), DM3 (40 mg/kg). DM4 (5 mg/kg), 
and DM5 (20 mg/kg) displayed no signs of high physical stress and no death occurred 
(Table 3.16, highlighted in yellow). Thus, each DM was tested at the selected dose via 
IP route. Statistical analysis on the whole blood haematogram and serum biochemistry 
parameters showed that mice receiving DM1 (5 mg/kg) and DM2 (60 mg/kg) treatments 
had no significant difference in any of the parameters as compared to the untreated 
control (Table 3.19). For mice treated with DM3 (Table 3.19, highlighted in yellow) at 
40 mg/kg (p = 0.002, 52.25 ± 2.63 fl) and DM5 (Table 3.19, highlighted in blue) at 20 
mg/kg (p = 0.007, 53.00 ± 2.83 fl), significantly lower MCV was detected as compared 
to the untreated control (57.75 ± 0.96 fl). DM4-treated mice had lower AST level (p = 
0.022, 50.88 ± 10.05 U/l) as compared to the untreated control (98.05 ± 34.38 U/l) 
(Table 3.19, highlighted in green). In all the treatment groups, no significant 
histological abnormality was observed in the spleen, kidney, liver, lung, and brain of the 
mice as compared to the untreated control (Figure 3.10). 
For mice receiving low doses of DM3 at 10 mg/kg and 20 mg/kg, the mice 
appeared stressed which resolved within 20 mins and remained physically active (Table 
3.16, highlighted in blue). No death occurred and no significant difference (p > 0.05) in 
any of the whole blood and serum biochemistry parameters was noted (Table 3.20). In 
all the treatment groups, no significant histological abnormality was observed in the 
spleen, kidney, liver, lung, and brain of the mice as compared to the untreated control 
(Figure 3.11). 
The in vivo toxicity of four combinations of DM3 and penicillin were tested 
together via IP route: DM310 – PEN10 (10 mg/kg DM3 and 10 mg/kg PEN), DM310 – 
PEN20 (10 mg/kg DM3 and 20 mg/kg PEN), DM320 – PEN10 (20 mg/kg DM3 and 10 
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mg/kg PEN), and DM320 – PEN20 (20 mg/kg DM3 and 20 mg/kg PEN). The mice 
displayed only slightly stressed appearance which resolved within 20 mins and 
remained physically active (Table 3.21). No death occurred. No significant difference 
(p > 0.05) in any of the whole blood and serum biochemistry parameters was noted 
except the lower urea level in the DM320 – PEN20 group (5.95 ± 1.08 mmol/l) as 
compared to the untreated control (p = 0.001, 8.83 ± 0.98 mmol/l) (Table 3.22, 
highlighted in yellow). In all the treatment groups, no significant histological 
abnormality was observed in the spleen, kidney, liver, lung, and brain of the mice as 
compared to the untreated control (Figure 3.12).  
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Table 3.16: The physical and behavioral abnormalities observed in mice following 
administration of the five DMs at the respective doses via different routes. 
Route Peptide 
Dose 
(mg/kg) 
Observations 
No. of 
dead mice 
IP 
DM1 
100, 80, 
60, 40, 20 
 Highly stressed and lethargic, shortness of 
breath, highly inactive. 
- 
10 
 Moderately stressed and lethargic, shortness of 
breath, moderately inactive. 
- 
5 
 Slightly stressed and lethargic (resolved in 30 
mins), no apparent shortness of breath, 
physically active. 
- 
DM2 
100, 80 
 Highly stressed and lethargic, shortness of 
breath, highly inactive. 
- 
60 
 Slightly stressed and lethargic (resolved in 30 
mins), no apparent shortness of breath, 
physically active. 
- 
DM3 
100 
 Highly stressed and lethargic, shortness of 
breath, highly inactive. 
4/4 
80 
 Highly stressed and lethargic, shortness of 
breath, highly inactive. 
4/4 
60 
 Moderately stressed and lethargic, shortness of 
breath, moderately inactive. 
2/4 
40 
 Slightly stressed and lethargic (resolved in 30 
mins), no apparent shortness of breath, 
physically active. 
- 
20 
 Slightly stressed and lethargic (resolved in 20 
mins), no apparent shortness of breath, 
physically active. 
- 
10 
 Slightly stressed and lethargic (resolved in 20 
mins), no apparent shortness of breath, 
physically active. 
- 
DM4 
100, 80, 
60, 40 
 Highly stressed and lethargic, shortness of 
breath, highly inactive. 
- 
20, 10 
 Moderately stressed and lethargic, shortness of 
breath, moderately inactive. 
- 
5 
 Slightly stressed and lethargic (resolved in 30 
mins), no apparent shortness of breath, 
physically active. 
- 
DM5 
100, 80, 60 
 Highly stressed and lethargic, shortness of 
breath, highly inactive. 
- 
- 
40 
 Moderately stressed and lethargic, shortness of 
breath, moderately inactive. 
- 
20 
 Slightly stressed and lethargic (resolved in 30 
mins), no apparent shortness of breath, 
physically active. 
- 
SC 
DM1 
100 
 Normal, no signs of stress and lethargy, 
physically active. 
- 
DM2 
DM3 
DM4 
DM5 
IN 
DM1 
20 
 Normal, no signs of stress and lethargy, 
physically active. 
- 
DM2 
DM3 
DM4 
DM5 
Highlighted in yellow: Highest deliveable dose of each DM given via IP route to the mice. 
Highlighted in blue: Lower graded doses of DM3 given via IP route to the mice. 
Abbreviations: IP, intraperitoneal; SC, subcutaneous; IN, intranasal. 
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Table 3.17: Whole blood haematogram and serum biochemistry of mice treated by the DMs via subcutaneous route. 
 
a
Given for 3 doses (2 hrs, 12 hrs, and 24 hrs). 
Statistical analysis between treatment groups and untreated control was performed using One-way ANOVA with post hoc Dunnett-t test.  
Mean value (s) showing significant difference (p ≤ 0.05) as compared to the untreated control was highlighted: 
Highlighted in yellow: DM1-treated mice (Urea, p = 0.033). 
Highlighted in green: DM2-treated mice (Plasma protein, p = 0.027; Creatinine, p = 0.004). 
       
Parameter 
SC treatment
a 
Untreated (water) DM1 (100 mg/kg) DM2 (100 mg/kg) DM3 (100 mg/kg) DM4 (100 mg/kg) DM5 (100 mg/kg) 
Whole blood 
      
Erythrocytes, RBC (x10
12
/l) 8.05±0.11 8.13±0.65 7.39±0.44 8.36±0.60 8.07±0.16 8.22±0.62 
Hemoglobin, Hb (g/l) 136.67±1.15 139.75±13.57 130.33±5.13 143.67±5.03 137.67±2.08 142.00±8.98 
Packed cell volume, pCV (l/l) 0.46±0.00 0.47±0.04 0.43±0.02 0.49±0.02 0.45±0.00 0.47±0.04 
Mean corpuscular volume, MCV (fl) 57.33±0.58 57.75±0.96 58.33±0.58 58.33±2.52 55.67±1.53 57.25±1.50 
Mean corpuscular hemoglobin 
concentration, MCHC (g/l) 
297.33±2.31 297.25±3.40 303.00±3.61 295.33±3.06 305.67±4.73 302.25±4.65 
While blood cells, WBC (x10
9
/l) 4.05±1.58 4.21±0.81 2.92±0.42 4.63±1.21 3.31±0.54 3.85±1.13 
B neutrophil (x10
9
/l) 0.06±0.04 0.09±0.05 0.04±0.02 0.14±0.03 0.06±0.03 0.10±0.06 
S neutrophil (x10
9
/l) 0.91±0.37 0.85±0.18 0.90±0.07 1.01±0.18 0.85±0.13 1.10±0.45 
Lymphocytes (x10
9
/l) 2.66±1.13 2.94±0.69 1.68±0.36 3.10±1.18 2.06±0.32 2.26±0.57 
Monocytes (x10
9
/l) 0.31±0.14 0.25±0.04 0.19±0.05 0.31±0.15 0.24±0.06 0.26±0.14 
Eosinophil (x10
9
/l) 0.11±0.10 0.08±0.05 0.10±0.01 0.07±0.03 0.10±0.04 0.14±0.11 
Basophil (x10
9
/l) 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Thrombocytes (x10
9
/l) 1181.33±95.09 1104.50±190.14 1082.00±66.19 1195.00±41.24 1125.33±172.00 1162.00±87.91 
Plasma protein (g/l) 60.33±3.51 58.75±2.99 53.67±1.53 61.00±3.61 61.33±1.15 59.75±1.71 
       Serum biochemistry 
      
Alanine transaminase, ALT (U/l) 35.50±4.19 29.25±2.44 28.83±3.09 32.20±2.72 38.20±8.00 31.50±4.15 
Alkaline phosphatase, ALP (U/l) 142.00±9.54 125.00±29.98 123.33±25.03 127.33±22.55 142.00±28.21 126.50±12.92 
Aspartate aminotransferase, AST (U/l) 121.03±4.86 135.00±21.51 137.67±19.00 107.70±4.07 125.10±35.88 91.83±38.33 
Creatinine (µmol/l) 40.67±0.58 36.75±3.77 32.67±0.58 37.33±2.08 36.67±2.52 37.75±2.22 
Urea (mmol/l) 7.27±0.93 9.45±1.25 8.60±0.95 7.50±0.40 8.10±0.44 8.08±1.06 
Lactate dehydrogenase, LDH (U/l) 1451.33±192.20 1286.25±377.56 1664.33±222.07 1214.67±243.24 1046.67±281.95 1044.25±640.49 
Direct bilirubin (µmol/l) 0.10±0.00 0.10±0.00 0.10±0.00 0.10±0.00 0.10±0.00 0.10±0.00 
Total bilirubin (µmol/l) 2.30±0.46 1.88±0.43 1.83±0.31 2.13±1.02 1.87±0.50 2.05±0.50 
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Figure 3.8: Histology of five major organs from mice treated with DM1 – DM5 
via SC route at 100 mg/kg for in vivo toxicity study. 
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Figure 3.8 (continued): Histology of five major organs from mice treated with 
DM1 – DM5 via SC route at 100 mg/kg for in vivo toxicity study. 
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Figure 3.8 (continued): Histology of five major organs from mice treated with 
DM1 – DM5 via SC route at 100 mg/kg for in vivo toxicity study. Spleen, kidney, 
liver, lung, and brain of untreated control mice (water only) and mice receiving 
the respective DM for three dose regimens (2 hrs, 12 hrs, 24 hrs) were harvested 
at day 7 posttreatment and formalin-fixed before processed for histological 
examination. No significant abnormality was observed in the tissue sections 
between the (A) untreated control mice and (B) DM1, (C) DM2, (D) DM3, (E) 
DM4, and (F) DM5-treated mice. Magnification at 200X, H & E staining. Bar 
indicates 100 µm. 
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Table 3.18: Whole blood haematogram and serum biochemistry of mice treated by the DMs via intranasal route. 
a
Given for 3 doses (2 hrs, 12 hrs, and 24 hrs). 
Statistical analysis between treatment groups and untreated control was performed using One-way ANOVA with post hoc Dunnett-t test.  
Mean value (s) showing significant difference (p ≤ 0.05) as compared to the untreated control was highlighted: 
Highlighted in yellow: DM1-treated mice (thrombocytes, p = 0.012). 
Highlighted in blue: DM2-treated mice (thrombocytes, p = < 0.001; ALP, p = 0.026). 
Highlighted in green: DM5-treated mice (creatinine, p = 0.028).  
Parameter 
IN treatment
a 
Untreated (water) DM1 (20 mg/kg) DM2 (20 mg/kg) DM3 (20 mg/kg) DM4 (20 mg/kg) DM5 (20 mg/kg) 
Whole blood 
      
Erythrocytes, RBC (x10
12
/l) 7.71±0.84 8.86±0.95 7.87±0.19 8.61±0.71 8.71±0.56 7.84±0.38 
Hemoglobin, Hb (g/l) 131.00±2.94 147.67±15.95 130.00±4.00 147.25±9.22 145.75±9.54 134.00±5.72 
Packed cell volume, pCV (l/l) 0.44±0.01 0.49±0.03 0.43±0.01 0.48±0.03 0.48±0.03 0.45±0.02 
Mean corpuscular volume, MCV (fl) 57.00±6.16 55.00±2.65 54.89±0.19 56.25±1.50 55.25±1.71 57.00±0.82 
Mean corpuscular hemoglobin 
concentration, MCHC (g/l) 
301.25±2.99 303.00±13.53 302.42±2.50 305.50±7.33 303.75±7.68 299.50±1.91 
While blood cells, WBC (x10
9
/l) 3.08±0.54 2.27±0.40 3.43±0.54 2.95±0.97 2.21±0.91 2.69±1.37 
B neutrophil (x10
9
/l) 0.09±0.03 0.08±0.03 0.07±0.01 0.10±0.05 0.06±0.02 0.10±0.09 
S neutrophil (x10
9
/l) 1.20±0.79 0.99±0.31 1.37±0.21 0.76±0.19 0.71±0.28 1.12±0.77 
Lymphocytes (x10
9
/l) 1.45±0.32 0.99±0.18 1.64±0.22 1.82±0.66 1.20±0.51 1.25±0.38 
Monocytes (x10
9
/l) 0.24±0.12 0.20±0.07 0.31±0.05 0.25±0.10 0.16±0.05 0.21±0.14 
Eosinophil (x10
9
/l) 0.10±0.06 0.02±0.02 0.04±0.04 0.03±0.03 0.08±0.13 0.02±0.02 
Basophil (x10
9
/l) 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Thrombocytes (x10
9
/l) 1464.25±209.39 1006.00±197.73 729.50±253.50 1590.00±73.21 1470.25±97.66 1205.75±160.80 
Plasma protein (g/l) 59.00±3.46 60.00±2.00 52.50±0.50 56.50±3.42 57.25±5.50 53.50±3.32 
       Serum biochemistry 
      
Alanine transaminase, ALT (U/l) 42.28±17.29 41.97±11.63 37.20±3.30 35.23±17.39 28.95±14.40 29.45±7.93 
Alkaline phosphatase, ALP (U/l) 136.25±10.34 78.00±30.51 220.00±16.00 112.00±42.41 133.75±45.12 108.75±42.53 
Aspartate aminotransferase, AST (U/l) 116.43±29.19 108.33±31.27 128.30±18.80 130.03±54.28 96.88±31.79 104.23±26.59 
Creatinine (µmol/l) 45.50±11.24 26.33±11.02 36.00±2.00 28.75±10.34 31.25±11.59 22.50±11.73 
Urea (mmol/l) 9.78±0.98 6.43±2.77 8.35±1.45 5.93±2.93 8.43±4.64 6.38±2.30 
Lactate dehydrogenase, LDH (U/l) 717.00±125.77 887.67±821.34 678.00±67.00 761.25±259.18 609.00±259.29 547.50±175.16 
Direct bilirubin (µmol/l) 0.10±0.00 0.10±0.00 0.10±0.00 0.10±0.00 0.10±0.00 0.10±0.00 
Total bilirubin (µmol/l) 2.28±1.05 1.83±0.61 2.75±0.15 2.45±0.51 1.88±0.73 1.53±0.59 
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Figure 3.9: Histology of five major organs from mice treated with DM1 – DM5 
via IN route at 20 mg/kg for in vivo toxicity study. 
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Figure 3.9 (continued): Histology of five major organs from mice treated with 
DM1 – DM5 via IN route at 20 mg/kg for in vivo toxicity study. 
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Figure 3.9 (continued): Histology of five major organs from mice treated with 
DM1 – DM5 via IN route at 20 mg/kg for in vivo toxicity study. Spleen, kidney, 
liver, lung, and brain of untreated control mice (water only) and mice receiving 
the respective DM for three dose regimens (2 hrs, 12 hrs, 24 hrs) were harvested 
at day 7 posttreatment and formalin-fixed before processed for histological 
examination. No significant abnormality was observed in the tissue sections 
between the (A) untreated control mice and (B) DM1, (C) DM2, (D) DM3, (E) 
DM4, and (F) DM5-treated mice. Magnification at 200X, H & E staining. Bar 
indicates 100 µm. 
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Table 3.19: Whole blood haematogram and serum biochemistry of mice treated by the DMs via intraperitoneal route. 
a
Given for 3 doses (2 hrs, 12 hrs, and 24 hrs). 
b
Value < 0.1 was assumed to be 0.1 to allow statistical analysis. 
Statistical analysis between treatment groups and untreated control was performed using One-way ANOVA with post hoc Dunnett-t test.  
Mean value (s) showing significant difference (p ≤ 0.05) as compared to the untreated control was highlighted: 
Highlighted in yellow: DM3-treated mice (MCV, p = 0.002). 
Highlighted in blue: DM5-treated mice (MCV, p = 0.007). 
Highlighted in green: DM4-treated mice (AST, p = 0.022). 
Parameter 
IP treatment
a 
Untreated (water) DM1 (5 mg/kg) DM2 (60 mg/kg) DM3 (40 mg/kg) DM4 (5 mg/kg) DM5 (20 mg/kg) 
Whole blood 
      
Erythrocytes, RBC (x10
12
/l) 7.09±0.31 7.00±0.27 7.55±0.24 7.66±0.60 6.67±0.16 7.93±0.78 
Hemoglobin, Hb (g/l) 123.25±5.06 123.00±4.40 131.00±6.22 121.50±10.08 115.25±2.99 127.25±8.96 
Packed cell volume, pCV (l/l) 0.41±0.01 0.41±0.02 0.43±0.02 0.40±0.03 0.38±0.01 0.42±0.02 
Mean corpuscular volume, MCV (fl) 57.75±0.96 59.00±1.41 56.50±1.29 52.25±2.63 56.50±0.58 53.00±2.83 
Mean corpuscular hemoglobin 
concentration, MCHC (g/l) 
300.75±5.68 298.50±6.61 306.50±5.20 303.75±8.10 305.25±2.06 304.75±9.43 
While blood cells, WBC (x10
9
/l) 4.54±1.06 3.23±0.58 3.50±0.61 4.91±0.46 3.42±0.53 4.35±1.07 
B neutrophil (x10
9
/l) 0.15±0.04 0.10±0.04 0.15±0.03 0.15±0.03 0.09±0.02 0.18±0.04 
S neutrophil (x10
9
/l) 1.10±0.34 0.89±0.21 1.11±0.34 1.25±0.21 0.85±0.18 1.26±0.28 
Lymphocytes (x10
9
/l) 2.77±0.66 1.93±0.33 1.87±0.24 2.95±0.26 2.01±0.43 2.30±0.48 
Monocytes (x10
9
/l) 0.30±0.07 0.22±0.08 0.26±0.20 0.33±0.04 0.26±0.06 0.36±0.20 
Eosinophil (x10
9
/l) 0.21±0.09 0.09±0.04 0.11±0.07 0.23±0.13 0.21±0.13 0.26±0.13 
Basophil (x10
9
/l) 0.01±0.03 0.01±0.02 0.01±0.02 0.00±0.00 0.00±0.00 0.01±0.03 
Thrombocytes (x10
9
/l) 856.50±260.67 929.25±108.85 1082.25±96.85 1202.25±248.66 1098.00±102.49 768.00±247.84 
Plasma protein (g/l) 48.25±4.35 50.00±2.83 49.00±2.45 54.00±3.27 47.50±1.73 49.75±3.77 
       Serum biochemistry 
      
Alanine transaminase, ALT (U/l) 29.15±5.71 26.70±2.42 33.28±11.64 43.90±5.67 22.33±1.87 42.18±11.03 
Alkaline phosphatase, ALP (U/l) 124.25±29.66 125.00±14.83 127.25±23.77 121.67±16.17 116.50±20.94 91.25±10.72 
Aspartate aminotransferase, AST (U/l) 98.05±34.38 58.00±10.59 77.05±24.78 59.73±13.73 50.88±10.05 75.60±14.97 
Creatinine (µmol/l) 39.75±1.71 35.50±5.26 37.00±2.83 46.00±4.58 39.00±1.63 40.75±1.50 
Urea (mmol/l) 6.90±1.02 6.95±1.43 7.50±1.02 7.67±0.47 7.80±1.68 5.80±0.53 
Lactate dehydrogenase, LDH (U/l) 986.33±256.87 750.25±94.15 775.75±141.00 659.33±117.52 702.75±113.99 728.75±158.71 
Direct bilirubin (µmol/l)
b 
0.10±0.00 0.18±0.15 0.10±0.00 0.10±0.00 0.10±0.00 0.10±0.00 
Total bilirubin (µmol/l) 2.15±1.20 1.88±0.45 2.03±0.30 1.93±0.15 2.28±0.51 1.95±0.34 
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Figure 3.10: Histology of five major organs from mice treated with DM1 – DM5 
via IP route at the respective doses for in vivo toxicity study. 
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Figure 3.10 (continued): Histology of five major organs from mice treated with 
DM1 – DM5 via IP route at the respective doses for in vivo toxicity study. 
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Figure 3.10 (continued): Histology of five major organs from mice treated with 
DM1 – DM5 via IP route at the respective doses for in vivo toxicity study. 
Spleen, kidney, liver, lung, and brain of untreated control mice (water only) and 
mice receiving DM1 (5 mg/kg), DM2 (60 mg/kg), DM3 (40 mg/kg), DM4 
(5mg/kg), and DM5 (20 mg/kg) for three dose regimens (2 hrs, 12 hrs, 24 hrs) 
were harvested at day 7 posttreatment and formalin-fixed before processed for 
histological examination. No significant abnormality was observed in the tissue 
sections between the (A) untreated control mice and (B) DM1, (C) DM2, (D) 
DM3, (E) DM4, and (F) DM5-treated mice. Magnification at 200X, H & E 
staining. Bar indicates 100 µm. 
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Table 3.20: Whole blood haematogram and serum biochemistry of mice treated with low doses DM3 via intraperitoneal route. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
Given for 3 doses (2 hrs, 12 hrs, and 24 hrs). 
b
Value < 0.1 was assumed to be 0.1 to allow statistical analysis. 
Statistical analysis between treatment groups and untreated control was performed using One-way ANOVA with post hoc Dunnett-t test.  
Mean value (s) showing significant difference (p ≤ 0.05) as compared to the untreated control was highlighted (no significant difference was noted).  
Parameter 
IP treatment
a 
Untreated (water) DM3 (10 mg/kg) DM3 (20 mg/kg) 
Whole blood 
   
Erythrocytes, RBC (x10
12
/l) 6.38±0.47 6.71±0.08 6.90±0.10 
Hemoglobin, Hb (g/l) 110.25±8.42 112.50±1.91 116.75±5.56 
Packed cell volume, pCV (l/l) 0.38±0.02 0.39±0.01 0.41±0.02 
Mean corpuscular volume, MCV (fl) 59.25±1.89 58.50±1.73 58.50±2.65 
Mean corpuscular hemoglobin concentration, MCHC (g/l) 292.00±7.96 287.00±3.92 286.50±5.92 
While blood cells, WBC (x10
9
/l) 3.20±0.26 4.07±0.31 4.00±0.53 
B neutrophil (x10
9
/l) 0.11±0.03 0.15±0.03 0.11±0.03 
S neutrophil (x10
9
/l) 0.95±0.24 1.36±0.17 1.12±0.17 
Lymphocytes (x10
9
/l) 1.83±0.36 1.98±0.27 2.28±0.44 
Monocytes (x10
9
/l) 0.20±0.02 0.52±0.13 0.39±0.11 
Eosinophil (x10
9
/l) 0.12±0.03 0.06±0.04 0.11±0.07 
Basophil (x10
9
/l) 0.00±0.00 0.00±0.00 0.00±0.00 
Thrombocytes (x10
9
/l) 931.50±66.29 924.50±103.91 820.75±188.90 
Plasma protein (g/l) 42.50±2.52 43.00±0.82 45.50±3.00 
    Serum biochemistry 
   
Alanine transaminase, ALT (U/l) 31.58±7.67 36.63±7.45 80.65±51.70 
Alkaline phosphatase, ALP (U/l) 194.50±33.93 198.75±78.46 175.00±46.80 
Aspartate aminotransferase, AST (U/l) 87.45±14.88 142.43±76.33 127.28±54.67 
Creatinine (µmol/l) 28.25±3.30 24.50±3.11 27.50±3.87 
Urea (mmol/l) 9.13±0.95 6.70±1.44 7.35±1.70 
Lactate dehydrogenase, LDH (U/l) 1767.00±718.75 1184.75±375.55 1243.25±499.73 
Direct bilirubin (µmol/l)
b 
0.55±0.57 0.10±0.00 0.10±0.00 
Total bilirubin (µmol/l) 1.75±1.28 2.23±1.07 1.53±0.24 
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Figure 3.11: Histology of five major organs from mice treated with low doses DM3 via IP route 
for in vivo toxicity study. DM3 at 10 mg/kg (middle column) and 20 mg/kg (right column) were 
given for three dose regimens (2 hrs, 12 hrs, 24 hrs) and compared to untreated control (left 
column). Spleen, kidney, liver, lung, and brain (top to bottom) were harvested at day 7 
posttreatment and formalin-fixed before processed for histological examination. No significant 
abnormality was observed in the tissue sections between the untreated control mice and the 
treated mice. Magnification at 200X, H & E staining. Bar indicates 100 µm. 
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Table 3.21: The physical and behavioral abnormalities observed following administration of the DM3 – PEN combinations via IP route. 
  
Group 
Dose 
(mg/kg) 
Observations 
No. of dead 
mice 
DM3 PEN 
DM310-PEN10 10 10 
 Slight discomfort (resolved in 20 mins) and 
then appeared normal, physically active. 
- 
DM310-PEN20 10 20 
 Slight discomfort (resolved in 20 mins) and 
then appeared normal, physically active. 
- 
DM320-PEN10 20 10 
 Slight discomfort (resolved in 20 mins) and 
then appeared normal, physically active. 
- 
DM320-PEN20 20 20 
 Slight discomfort (resolved in 20 mins) and 
then appeared normal, physically active. 
- 
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Table 3.22: Whole blood haematogram and serum biochemistry of mice treated with DM3 – PEN combinations via intraperitoneal route. 
 
a
Given for 3 doses (2 hrs, 12 hrs, and 24 hrs). 
b
Value < 0.1 was assumed to be 0.1 to allow statistical analysis.    
Statistical analysis between treatment groups and untreated control was performed using One-way ANOVA with post hoc Dunnett-t test.  
Mean value (s) showing significant difference (p ≤ 0.05) as compared to the untreated control was highlighted. 
Highlighted in yellow: DM320 -PEN20 treated mice (Urea, p = 0.001). 
 
IP treatment
a 
Parameter Untreated (water) DM310 - PEN10 DM310 – PEN20 DM320 - PEN10 DM320 – PEN20 
Whole blood 
     
Erythrocytes, RBC (x10
12
/l) 6.32±0.46 6.14±0.27 6.28±0.30 6.15±0.14 6.18±0.15 
Hemoglobin, Hb (g/l) 110.25±8.42 105.75±2.87 111.25±1.89 103.33±4.16 106.75±4.27 
Packed cell volume, pCV (l/l) 0.38±0.02 0.36±0.02 0.39±0.01 0.36±0.01 0.37±0.01 
Mean corpuscular volume, MCV (fl) 60.25±2.06 59.25±0.96 61.25±2.50 59.00±1.73 60.25±0.96 
Mean corpuscular hemoglobin concentration, MCHC (g/l) 290.00±6.06 292.00±8.12 288.75±4.72 284.33±7.09 286.75±8.54 
While blood cells, WBC (x10
9
/l) 2.98±0.50 3.80±1.04 3.58±0.87 3.07±0.76 3.25±0.51 
B neutrophil (x10
9
/l) 0.09±0.04 0.15±0.08 0.11±0.06 0.08±0.02 0.11±0.05 
S neutrophil (x10
9
/l) 0.90±0.23 1.14±0.39 1.00±0.27 0.91±0.27 1.19±0.28 
Lymphocytes (x10
9
/l) 1.75±0.37 2.01±0.46 1.96±0.44 1.60±0.44 1.54±0.43 
Monocytes (x10
9
/l) 0.17±0.04 0.38±0.17 0.35±0.15 0.24±0.11 0.28±0.12 
Eosinophil (x10
9
/l) 0.08±0.04 0.13±0.06 0.16±0.11 0.23±0.22 0.14±0.04 
Basophil (x10
9
/l) 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Thrombocytes (x10
9
/l) 895.00±36.76 879.00±62.25 800.75±55.07 933.00±36.76 818.33±38.08 
Plasma protein (g/l) 41.00±1.15 41.25±2.87 44.00±1.63 42.00±3.46 42.00±1.63 
      Serum biochemistry 
     
Alanine transaminase, ALT (U/l) 31.50±7.71 23.63±7.59 29.00±6.92 36.00±17.47 34.20±11.88 
Alkaline phosphatase, ALP (U/l) 174.50±10.54 183.75±46.36 162.75±5.85 142.33±14.47 137.50±22.35 
Aspartate aminotransferase, AST (U/l) 84.15±15.29 81.75±20.16 95.08±36.56 125.37±65.23 95.08±32.83 
Creatinine (µmol/l) 25.50±2.52 24.75±4.65 25.00±1.83 23.33±1.15 25.25±1.26 
Urea (mmol/l) 8.83±0.98 8.65±1.55 7.50±1.06 6.47±1.04 5.95±1.08 
Lactate dehydrogenase, LDH (U/l) 1661.25±819.00 1991.75±785.73 1129.25±84.92 2362.00±432.35 1129.50±771.26 
Direct bilirubin (µmol/l)
b 
0.55±0.57 0.23±0.25 0.60±0.53 0.93±1.44 0.68±0.68 
Total bilirubin (µmol/l) 1.93±0.67 1.80±0.52 1.73±0.22 2.60±0.82 1.90±0.43 
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Figure 3.12: Histology of five major organs from mice treated with the 
combinations of DM3 – PEN via IP route for in vivo toxicity study. 
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Figure 3.12 (continued): Histology of five major organs from mice treated with 
the combinations of DM3 – PEN via IP route for in vivo toxicity study. 
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Figure 3.12 (continued): Histology of five major organs from mice treated with 
the combinations of DM3 – PEN via IP route for in vivo toxicity study. Spleen, 
kidney, liver, lung, and brain of untreated control mice (water only) and mice 
receiving the respective formulations for three dose regimens (2 hrs, 12 hrs, 24 
hrs) were harvested at day 7 posttreatment and formalin-fixed before processed 
for histological examination. No significant abnormality was observed in the 
tissue sections between the (A) untreated control mice and (B) DM310-PEN10, 
(C) DM310-PEN20, (D) DM320-PEN10, and (E) DM320-PEN20-treated mice. 
Magnification at 200X, H & E staining. Bar indicates 100 µm. 
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3.2.4. Therapeutic efficacy of peptides in two lethal pneumococcal infection 
models 
Two in-house lethal pneumococcal infection models induced by a penicillin-
resistant pneumococcal strain mimicking the two major types of pneumococcal 
infections in human were developed to assess the therapeutic efficacy of peptides in 
vivo. The lethal pneumococcal systemic infection model was developed by infecting the 
mice with the selected inoculums of 1.5 x 10
2
 CFU/mouse via IP route to simulate the 
manifestation of pneumococcal bacteremia while the lethal pneumococcal pneumonia 
model was developed by infecting the mice with the selected inoculums of 5 x 10
3
 
CFU/mouse via intrathoracic route (IT) to simulate the manifestation of pneumococcal 
pneumonia. 
In both models, mice infected with S. pneumoniae displayed various symptoms 
such as hunching of body posture, ruffled fur, lethargy, less responsive to physical 
sensitization, loss of body temperature, and failed defecations (Figure 3.13A & B). All 
these infected mice died within two to four days postinfection. Upon necropsy, the 
lungs of the infected mouse were significantly presented with redness and swelling, 
depicting severe inflammation. In addition, leakage of body fluid into peritoneal cavity 
and thoracic cavity, swelling and loss of the arrangement and compaction of digestive 
tract especially the small and large intestines were observed (Figure 3.13C & D). 
Cultures of blood and homogenates of five major organs (spleen, kidney, liver, lung, 
and brain) of the dead/moribund mice following infections via both IP and IT routes 
detected pneumococci as compared to the uninfected control mice.  This indicates the 
rapid and uncontrolled spread of the inoculated pneumococcus in infecting the organs 
and establishing severe infection state.  
Since all five DMs displayed strong antipneumococcal activities from the in vitro 
studies, the therapeutic efficacy of the peptides were tested in both the infection models. 
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The treatment regimens for each DM followed the highest deliverable doses that have 
been determined from the in vivo toxicity assessment at 2 hrs, 12 hrs, and 24 hrs 
postinfection (Table 3.16, highlighted in yellow). For IP route of administration, each 
DM1, DM2, DM3, DM4, and DM5 were given at 5 mg/kg, 60 mg/kg, 40 mg/kg, 5 
mg/kg, and 20 mg/kg, respectively. For SC route of administration, the DMs were given 
at 100 mg/kg and for IN route of administration, the DMs were given at 20 mg/kg, 
respectively.  
In pneumococcal systemic infection model, preliminary testing using groups of 
three mice found that mice treated with DM1, DM2, DM3, and DM5 at the respective 
doses had enhanced survival (Table 3.23, highlighted in yellow). These four peptides 
were then selected for testing using groups of 10 mice. Results showed that DM3 at 40 
mg/kg protected 50% of the lethally infected mice from mortality up to day 7 
postinfection with statistically significant survival analysis (p = 0.004) (Figure 3.14). 
Although DM1, DM2, and DM5 appeared to have therapeutic effects in the preliminary 
testing, subsequent therapeutic efficacy using groups of 10 mice had no mice survived 
up to day 7 postinfection. Survival analysis up to day 7 postinfection showed that 
treatment using DM2 (p = 0.009) and DM5 (p = 0.045) significantly enhanced survival 
of the systemically infected mice as compared to untreated control. Treatment via SC 
and IN had no survival at day 7 postinfection and found no significant survival analysis 
(p > 0.05) in the systemic infection model.  
Mice receiving penicillin treatments via IP route at 10 mg/kg, 20 mg/kg, 40 
mg/kg, and 80 mg/kg were determined to have 20%, 50%, 60%, and 90% survival up to 
day 7 postinfection and were statistically significant (p < 0.001) (Figure 3.15). 
Moreover, mice receiving the lower graded doses of DM3 at 10 mg/kg and 20 mg/kg 
had 10% (p = 0.424) and 20% (p = 0.019) survival rates at day 7 postinfection for which 
only DM3 at 20 mg/kg conferred statistically significant (p = 0.019) survivability to the 
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mice. All the mice survived up to day 7 were humanely sacrificed and plating of blood 
and the homogenates of the sample tissues from spleen, kidney, liver, lung, and brain 
found no growth of S. pneumoniae.  
In the pneumococcal pneumonia model, treatment via IP, SC, and IN had no 
survival up to day 7 postinfection (Table 3.23). Thus, these peptides and the respective 
treatment regimens were not selected for subsequent therapeutic efficacy testing in 
groups of 10 mice. In all testing, no pneumococcus was detected from blood and the 
five major organs (spleen, liver, kidney, lung, brain) of the mice that survived and had 
no presentation of illnesses as compared to the untreated control that grew overcrowded 
pneumococcal cells from blood agar plating and were severely ill. 
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Figure 3.13: Images showing the physical abnormalities observed in pneumococcal systemic infection model of mice. Clinical 
symptoms of infection were observable beginning day 2 postinfection including (A) ruffled fur, hunched posture, presence of fluid 
around the orbital regions, and (B) difficulty in defecation. Upon necropsy, the various organs of (C) the systemically infected 
mouse especially lungs were presented with exudates, swelling, and redness denoting severe inflammations as compared to the (D) 
uninfected control. 
A B 
C D 
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 Table 3.23: Number of mice survived at day 4 and day 7 (n = 3) following DMs 
treatment in two pneumococcal infection models induced by a PRSP strain.  
  
Dose 
(mg/kg) 
No. of mice survived 
Route Peptide Systemic infection Pneumonia 
Day 4 Day 7 Day 4 Day 7 
IP 
DM1 5 1/3 0/3 0/3 0/3 
DM2 60 1/3 0/3 0/3 0/3 
DM3 40 2/3 2/3 0/3 0/3 
DM4 5 0/3 0/3 0/3 0/3 
DM5 20 1/3 0/3 0/3 0/3 
Untreated Water 0/3 0/3 0/3 0/3 
Uninfected Water  3/3 3/3 3/3 3/3 
 
SC 
DM1 100 0/3 0/3 0/3 0/3 
DM2 100 0/3 0/3 0/3 0/3 
DM3 100 0/3 0/3 0/3 0/3 
DM4 100 0/3 0/3 0/3 0/3 
DM5 100 0/3 0/3 0/3 0/3 
Untreated Water 0/3 0/3 0/3 0/3 
Uninfected Water  3/3 3/3 3/3 3/3 
 
IN 
DM1 20 0/3 0/3 0/3 0/3 
DM2 20 0/3 0/3 0/3 0/3 
DM3 20 0/3 0/3 0/3 0/3 
DM4 20 0/3 0/3 0/3 0/3 
DM5 20 0/3 0/3 0/3 0/3 
Untreated Water 0/3 0/3 0/3 0/3 
Uninfected Water  3/3 3/3 3/3 3/3 
Highlighted in yellow: Treatments conferring enhanced survival postinfection as 
compared to untreated control postinfection - to be further tested for therapeutic efficacy 
using group of 10 mice.  
(C) 
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Treatment  Dose (mg/kg)  Survival %
a
  Significance
b
  
DM1  5  0  0.159  
DM2  60  0  0.009  
DM3  40  50  0.004  
DM5  20  0  0.045  
Untreated  0  -  
Uninfected  100  -  
a
Survival rate at day 7.  
b
Kaplan-Meier with log-rank (Mantel-Cox) test for each treatment vs 
untreated group  
Figure 3.14: Survival function analysis of mice with lethal pneumococcal 
systemic infection treated with DM1, DM2, DM3, and DM5 for three doses 
regimen (2 hrs, 12 hrs, 24 hrs) via IP route postinfection. Statistical analysis was 
performed for each treated group versus untreated group using Kaplan-Meier 
with log-rank test (Mantel-Cox). DM3 treatment at 40 mg/kg conferred 
significant survival function (p = 0.004) with 50% survival rate up to day 7 
postinfection. Mice treated with DM2 (p = 0.009) and DM5 (p = 0.045) showed 
statistically significant enhanced survival although no survival was noted up to 
day 7 postinfection.        
Cumulative survival of lethal pneumococcal systemic infection mice treated 
with DMs (n = 10) 
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Treatment  Dose (mg/kg)  Survival %
a
  Significance
b
  
PEN  
80  90 < 0.001 
40 60 < 0.001 
20  50 < 0.001 
10 20 < 0.001 
DM3  
20 20 0.019 
10  10 0.424 
Untreated  0  -  
Uninfected  100  -  
a
Survival rate at day 7. 
b
Kaplan-Meier with log-rank (Mantel-Cox) test for each treatment vs 
untreated group  
Cumulative survival of lethal pneumococcal systemic infection mice treated 
with PEN and low doses DM3 (n = 10) 
Figure 3.15: Survival function analysis of mice with lethal pneumococcal 
systemic infection treated with penicillin and low doses DM3 for three doses 
regimen (2 hrs, 12 hrs, 24 hrs) via IP route postinfection. Statistical analysis 
was performed for each treated group versus untreated group using Kaplan-
Meier with log-rank test (Mantel-Cox). Penicillin treatment at 10 mg/kg, 20 
mg/kg, 40 mg/kg, and 80 mg/kg showed highly significant survival function (p 
< 0.001) with 20%, 50%, 60%, 90% survival rates up to day 7 postinfection. 
While for lower graded DM3 doses of 10 mg/kg and 20 mg/kg, there were 10% 
(p = 0.424) and 20% (p = 0.019) survival rates, respectively. 
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3.2.5. Therapeutic synergism of DM3 in combination with penicillin 
Among the hybrids, standalone treatment with DM3 at 40 mg/kg was found to 
confer significant survivability to mice lethally challenged by a PRSP strain 
systemically. To evaluate the therapeutic synergism of DM3 in combination with the 
standard antibiotic penicillin, lower doses of DM3 (10 mg/kg, 20 mg/kg) and penicillin 
(10 mg/kg, 20 mg/kg) were tested using the same systemic infection model in four 
treatment formulations: DM310 - PEN10 (10 mg/kg of DM3 and 10 mg/kg of penicillin), 
DM310 – PEN20 (10 mg/kg of DM3 and 20 mg/kg of penicillin), DM320 - PEN10 (20 
mg/kg of DM3 and 10 mg/kg of penicillin), and DM320 – PEN20 (20 mg/kg of DM3 and 
20 mg/kg of penicillin). While treatment with low doses of standalone DM3 and 
penicillin (Figure 3.15) conferred only minimal survivability whereby DM3 at 10 mg/kg 
and 20 mg/kg protected 10% and 20% of mice and penicillin at 10 mg/kg and 20 mg/kg 
protected 20% and 50% of mice, respectively. Testing using group of 10 mice showed 
that DM310 - PEN10, DM310 – PEN20, DM320 - PEN10, and DM320 – PEN20 treatments 
conferred 50%, 80%, 90%, and 100% survival (p < 0.001) in mice lethally infected with 
pneumococcal systemic infection at day 7 postinfection (Figure 3.16). These survival 
rates were higher than the sum of the survival rates for the respective peptide/antibiotic 
in its standalone form by 20%, 20%, 50%, and 30%, respective for DM310 - PEN10, 
DM310 – PEN20, DM320 - PEN10, and DM320 – PEN20 groups. Notably, all mice (100%) 
survived when DM3 and penicillin were both given in combination at 20 mg/kg. Hence, 
DM3 and penicillin displayed potent therapeutic efficacy in a synergistic fashion. In 
addition, the mice survived from the lethal infection following the treatments remained 
physically active with no sign of physical or behavioral abnormality.   
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Treatment Dose (mg/kg)  
Survival %
a
  Significance
b
  
DM3 PEN 
10 10 50 < 0.001 
10 20 80 < 0.001 
20 10 90 < 0.001 
20 20 100 < 0.001 
Untreated  
 
-  
Uninfected  100  -  
a
Survival rate at day 7. 
b
Kaplan-Meier with log-rank (Mantel-Cox) test for each treatment vs 
untreated group  
Cumulative survival of lethal pneumococcal systemic infection mice treated 
with combinations of DM3 and penicillin (n = 10) 
Figure 3.16: Survival function analysis of mice with lethal pneumococcal 
systemic infection treated with combinations of DM3 and penicillin at 
DM310 – PEN10, DM310 – PEN20, DM320 – PEN10, and DM320 – PEN20 for 
three doses regimen (2 hrs, 12 hrs, 24 hrs) via IP route postinfection. 
Statistical analysis was performed for each treated group versus untreated 
group using Kaplan-Meier with log-rank test (Mantel-Cox). The 
combination treatments showed significant (P < 0.001) survival function 
and 50%, 80%, 90%, and 100% survival rates were achieved with DM310 – 
PEN10, DM310 – PEN20, DM320 – PEN10, and DM320 – PEN20, respectively.    
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3.2.6. Histological examination of the pneumococcal infected mice 
The histological examinations of the systemically infected mice with and without 
treatment are shown in Figure 3.17. Overall, the infected organs showed severe 
inflammation and tissue damages. Lungs represent the most severely affected organ 
with significant postinfection changes. As compared to the uninfected normal mice 
(Figure 3.17A), several pathological changes were noted in the lung of the infected 
control mice including high vascular congestion, highly thickened alveolar wall with 
foci consolidation due to excessive capillary congestion and edema, and alveolar 
exudates filled with inflammatory cells mainly neutrophils and macrophages (Figure 
3.17B, black arrow). Heavy infiltrations of erythrocytes into the alveolar spaces and 
pulmonary tissues strongly indicate pulmonary hemorrhage (Figure 3.17B, blue arrow). 
This is of significant contrast to the uninfected mice displaying the highly aerated 
alveolar spaces with thin layer of alveolar wall in the normal lung. The highly congested 
lung can be seen left with little alveolar spaces (Figure 3.18, Lung - A). The exudative 
process is typical for bacterial lung infection which was S. pneumoniae in the current 
study as confirmed by plating the homogenates of the organs on blood agar. Severe 
damage was also seen with spleen especially at the white pulp area (Figure 3.18, spleen 
- A, black arrow).  
In addition, the infected control mice displayed acute glomerulonephritis as 
observed with severe inflammation causing large areas damages and loss of glomerular 
structures (Figure 3.18, kidney - A, black arrow). The inflammatory cells and 
erythrocytes can be seen infiltrating the affected area (Figure 3.18, kidney - A, yellow 
and blue arrows) as compared to the normal kidney with intact glomerular structures 
(Figure 3.18, kidney - B). The formation of large lesions can be clearly observed in the 
kidney of infected control mice (Figure 3.18, kidney - A, yellow arrow). The epithelial 
cells surrounding the lumen can be seen damaged and are surrounded by inflammatory 
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cells. For brain, the presence of erythrocytes was detectable (Figure 3.18, brain – A, 
blue arrow) although the extent of inflammation was less significant as compared to the 
other organs.    
For the respective treatments including DM3 at 10 mg/kg, 20 mg/kg, and 40 
mg/kg as well as the combination treatments of DM310 – PEN10, DM310 – PEN20, 
DM320 – PEN10, and DM320 – PEN20, it was observed that although the lesions (if any), 
inflammatory events, and the extent of tissues damages can be found in these organs, 
however, the quantity and the magnitude of the damage were significantly lower than 
the infected control mice. For instance, all the lungs of the treated mice showed only 
low level vascular congestion and slight thickening of the alveolar wall even though 
these conditions were still detectable in the mice (Figure 3.18, lung – C to I). However, 
the inflammation and damages were minimal as compared to the infected lung which 
showed almost 90% congestion. In the liver, the epithelial cells and hepatocytes 
surrounding the vascular lumen can be seen damaged with large lesions (Figure 3.18, 
liver - A) as compared to the other groups of mice which had only small lesions with 
few inflammatory cells. Also, the treated mice had significantly lower lesions 
quantitatively in the liver as well. Similarly, the glomerular filtration unit and the 
proximal/distal convoluted tubules in the kidney of treated mice appeared normal with 
no major inflammation/lesions. Moreover, there was no hemorrhage or only minimal in 
the treated mice as compared to the infected control mice.                   
.  
  
 179 
 
  
Figure 3.17: Histology of lung tissues from mice infected lethally by S. 
pneumoniae. As compared to the (A) uninfected control, the lung from (B) 
infected control displayed significant changes with thickening of alveolar wall  
and excessive alveolar exudates filled with inflammatory cells mainly the 
neutrophils (black arrow). The infiltrations of erythrocytes into the alveolar 
wall and alveolar spaces strongly indicate pulmonary hemorrhage.      
Magnification at 1000X, H & E staining. Bar indicates 100 µm.  
A 
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Figure 3.18: Histology of five major organs of mice lethally infected by S. 
pneumoniae. 
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Figure 3.18 (continued): Histology of five major organs of mice lethally infected 
by S. pneumoniae. 
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Liver 
Figure 3.18 (continued): Histology of five major organs of mice lethally infected 
by S. pneumoniae. 
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Figure 3.18 (continued): Histology of five major organs of mice lethally infected 
by S. pneumoniae. 
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Figure 3.18 (continued): Histology of five major organs of mice lethally infected 
by S. pneumoniae. Images showing tissues from mice receiving (A) infected 
control, (B) uninfected control (normal), (C) DM3 at 10 mg/kg, (D) DM3 at 20 
mg/kg, (E) DM3 at 40 mg/kg, (F) DM310 – PEN10, (G) DM310 – PEN20, (H) 
DM320 – PEN10, and (I) DM320 – PEN20. Organs from the infected control mice 
showed multiple lesions (yellow arrow), infiltration of erythrocytes andor 
vascular congestion (blue arrow), and damage of tissue structure (black arrow). 
Heavy alveolar congestion in the lung can be observed (green arrow). These 
histoplogical changes in the treated mice were significantly minimal as 
compared to the inected control mice. Magnification at 200X, H & E staining. 
Bar indicates 100 µm.  
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4.1. Pneumococcal serotype distribution and penicillin susceptibility 
The on-demand information on the antibiotic susceptibility and serotype distribution 
of S. pneumoniae among the local population is relatively limited. A few studies conducted 
previously have reported different findings, probably due to the study designs, different 
geographical distributions and hence the populations involved in the respective studies 
(Cheong et al., 1988; Choo et al., 1990; Hussain et al., 1998; Jamal et al., 1987; Lim et al., 
2007; Rohani et al., 1999b; Tee, 1993). For these reasons, comparing study outcomes 
reported by other researchers is not always feasible due to the variations in study design. 
Moreover, the epidemiological data available on the pneumococcal carriage and 
infections in Malaysia throughout the years is extremely scarce (Le et al., 2012). 
From the current study, the incidence of penicillin nonsusceptible S. pneumoniae 
(PNSP) were remarkably high which constituted half of the total pneumococcal isolates 
obtained (Le et al., 2011b). Our study clearly addresses the overwhelming penicillin 
resistance among the local isolates of S. pneumoniae in recent years. Such drastic 
increment especially the nonsusceptible strains could mean further reduction in 
treatment outcomes for patients infected with pneumococcal diseases. To evaluate the 
temporal fluctuations in pneumococcal penicillin resistance among the Malaysian 
population, we compiled all findings reported by various research groups over 24 years 
from year 1984 – 2009 (except 2001 and 2004) regardless of the study designs (Cheong 
et al., 1988; Desa et al., 2003; Le et al., 2011b; Rohani et al., 1999a; Rohani et al., 
1999b; Rohani et al., 2011). To have the same penicillin minimum inhibitory 
concentrations (MICs) interpretative breakpoint among these studies (susceptible, ≤ 
0.06 µg/ml, intermediate, 0.12 - 1.0µg/ml, resistant, ≥ 2.0µg/ml), the penicillin (oral) 
criteria was followed for Rohani et al. (2011). The major trend observed was that 
pneumococcal susceptibility to penicillin has decreased over the period from 1984 to 
2007 followed by a slight increase in year 2008/2009 (Figure 4.1). In the mid 1980s, 
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PNSP strains made up only less than 5% of the reported cases. However, the situation 
continued to change with consistent expansion of PNSP strains in the mid 1990s. 
Beginning year 2000, PNSP constituted 30% - 50% of the Malaysian isolates and 
penicillin-intermediate S. pneumoniae represent the dominant portion of PNSP which 
remained stable throughout the years. The increased proportion of PNSP isolates can be 
attributed to the underlying expansion of PISP as well as penicillin-resistant S. 
pneumoniae (PRSP).    
A similar trend of penicillin susceptibility was also observed when comparing 
studies with similar study design as ours which covers patients of all age groups and 
isolates from various clinical sites. The percentage of PNSP had increased substantially 
from 10.9% (Rohani et al., 1999a) to 31.0% (Desa et al., 2003) within four years time 
and further increased to 50.3% based on current study followed by a drop to 33.9% in 
year 2009 (Rohani et al., 2011). Additionally, the proportion of PRSP had also 
Figure 4.1: Penicillin susceptibility of Malaysian pneumococci over 24 years 
from 1984 – 2009 (Le et al., 2012). 
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increased from 5.5% (Rohani et al., 1999a) to 20.0% (Desa et al., 2003) and 21.2% 
(current study) which later decreased to 5.44% (Rohani et al., 2011). Since both studies 
by Rohani et al. included pneumococcal isolates from multiple hospitals while those by 
Desa et al. and our current data were based in University Malaya Medical Centre 
(UMMC) only, we speculate that the rate of PRSP in Malaysia is still considerably low 
(< 6.0%) but in densely populated areas especially the states of Selangor and the nearby 
Kuala Lumpur, the PRSP isolates could be encountered at a rate of four times higher 
than other less-densely populated areas.  
 The current study also investigated on the pneumococcal serotype epidemiology 
and its relationships with various underlying factors such as pneumococcal penicillin 
susceptibility, invasiveness of isolates, and the age of patients. Children < 5 years old 
and the elderly adults were the major age group frequently infected with pneumococcal 
diseases. The respiratory tract remains as the most important clinical site for 
pneumococcal infections where large numbers of isolates were recovered from 
nasopharyngeal site (NP), sputum, and tracheal secretions. The prevailing serotype 19F 
dominated as high as one third of the pneumococcal isolates among the local 
populations followed by serotypes 23F, 1, 6A/6B were the predominant serotypes (Le et 
al., 2011b). Serotypes 19F and 23F alone constituted approximately half of all serotypes. 
Although serotype 19F isolates were from rather noninvasive sites, of concern is that 
majority (78.6%) of the serotype 19F isolates was nonsusceptible to penicillin and half 
of them were penicillin-resistant. Serotype 19F was essentially the most abundant 
serotype particularly among younger age patients. On the other hand, serotype 19A was 
associated with penicillin-susceptible S. pneumoniae (PSSP). This serotype showed 
high invasive tendency to cause invasive pneumococcal disease at which 75.0% of the 
isolates were obtained from blood and was commonly affecting the 5 – 59 years old age 
group. Furthermore, it was noticed that the pool of serotypes became less diversified 
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with increasing penicillin resistance. This means that only certain serotypes were in the 
PISP and PRSP groups.  Serotypes 19F, 23F, and 6A/6B were present persistently in all 
three susceptibility groups. On the other hand, serotype 34 and 9V/9A were present 
neither in PSSP nor PISP but only in PRSP group and this suggests the tendency in 
developing penicillin resistance might be serotype-specific. 
The recent five year trend in serotype distribution among the Asian countries was 
evaluated in relation to the finding obtained from the current study (Le et al., 2011a).  
The distribution of prevailing serotypes in Malaysia was mainly heptavalent 
pneumococcal conjugate vaccine (PCV7) vaccine serotypes which was also comparable 
to the neighboring country Thailand (Baggett et al., 2009; Srifeungfung et al., 2010) 
and the East Asian countries more distantly situated from Malaysia such as China (Chen 
et al., 2010; Liu et al., 2008b; Xue et al., 2010; Yao et al., 2011; Zhang et al., 2011; 
Zhou et al., 2011), Taiwan (Hsieh et al., 2008), South Korea (Baek et al., 2011; Choi et 
al., 2008; Song et al., 2009), and Sri Lanka (2008). West Asian countries/territories 
such as Oman (Al-Yaqoubi & Elhag, 2011) and Israel (Somech et al., 2011) also found 
to have seroepidemiology resembling those for the Malaysian population. This pattern 
of serotype distribution was also relatively different from Singapore (Hsu et al., 2009; 
Jefferies et al., 2011), Hong Kong (2011; Ho et al., 2011; Hon et al., 2010; Ip et al., 
2007), Japan (Chiba et al., 2010; Hotomi et al., 2008; Oishi et al., 2011; Sakai et al., 
2011; Suzuki et al., 2010). The incorporation of PCV7 vaccine into the childhood 
immunization program has led to the reports of reduced vaccine serotypes in the United 
States (Farrell et al., 2007; Grijalva et al., 2007; Kaplan et al., 2004; 2010), Germany 
(Ruckinger et al., 2009), Norway (Vestrheim et al., 2008), France (Dubos et al., 2007; 
Lepoutre et al., 2008), Canada (Kellner et al., 2009), and Australia (Roche et al., 2008). 
The nonvaccine serotypes are emerging considerably through serotype replacement in 
place of the reduction in vaccine serotypes. For instance, the predominant serotypes 
 190 
among children with invasive pneumococcal disease (IPD) were serotypes 19A, 7F, 3, 
and serogroup 15 (McNeil et al., 2009). Despite PCV7 vaccine serotypes being the 
predominant serotypes prior to the introduction of PCV7 vaccine in year 2002 in 
Canada, serotypes 5, 8, 3, 14, and 22F have now been the most common serotypes 
based on distribution from 2002 – 2007. Pneumococcal conjugate vaccines have not 
been commonly in use in Asian countries despite Hong Kong, Singapore, and Japan 
having included PCV7 vaccine in their routine childhood immunization. This late 
implementation (after year 2009) means that it is still too early to assess the significant 
changes in serotype distribution and continued surveillances are needed.          
To evaluate the potential efficacies of PCV7 vaccination among the Malaysian 
population, serotypes covered under the vaccine were analyzed. This PCV7 vaccine 
covers serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F and also provides protection against 
those serotypes of the same serogroup as the formulated types. As the prevailing 
serotypes have been formulated under PCV7 vaccine, it was determined that 87.5% 
PRSP (28/32), 79.5% PISP (35/44), and 45.3% PSSP (34/75) are covered by the current 
PCV7 vaccine. PCV7 is thus predicted to have 64.2% of coverage (97/151). Therefore, 
effectiveness of PCV7 vaccine in our community would be encouraging. Towards 
reducing the morbidity and mortality associated with pneumococcal infections, it is 
highly recommended that PCV7 vaccine to be incorporated in the regular vaccination 
scheme for children in Malaysia. This will help to reduce the incidence directly in those 
young children as well as indirectly as a result of herd community effect. Children with 
certain chronic diseases or preexisting medical conditions which put them at high risk of 
developing IPD should be considered for the vaccination. This includes sickle cell 
disease, asplenia, immunosuppression, renal disease, cerebrospinal fluid leaks, HIV 
infection, and others. Nonetheless, it is difficult to predict the shift in serotype 
prevalence in the future. Thus, continuing surveillance of pneumococcal carriage and 
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diseases-related cases will help to characterize the effectiveness of PCV7 vaccine and 
monitoring of disease burden due to nonvaccine serotypes are certainly needed. This 
information will also provide the local regulatory body to recommend suitable vaccines 
to be used.   
It is particularly interesting to note how these serotypes are related to penicillin-
resistance and the associated intracellular alterations that lead to the changes against 
penicillin stress. Many other minor and non-prevalent serotypes have also been detected 
among all three groups. This may be due to variations in the geographical area, disease, 
and age groups of the patients. However, the high prevalence of penicillin resistance in 
this study suggests the rapid spread of resistant clones among pneumococci strains in 
this region.  
Since pneumococci has the ability to switch serotypes by horizontal transfer 
recombination and other genetic events, it is important to monitor the frequency of the 
serotype exchanges in order to predict long term efficacy of new vaccines. Therefore 
continuous monitoring of antimicrobial resistance and serotype distribution of S. 
pneumoniae is important for disease management and various disease-control policies 
among the Malaysian population. The current study supports the need for a long term 
surveillance program and appropriate vaccination strategy towards prevention and 
control of pneumococcal infections. We hope that current study will contribute to the 
regional body of knowledge on S. pneumoniae serotypes distribution in Malaysia, such 
as the Asian Strategic Alliance for Pneumococcal Diseases Prevention (ASAP) in align 
to their mission on control and contain pneumococcal diseases in Asian countries. 
 
4.2. Designing antimicrobial peptides with improved antimicrobial activity 
The increase in reports of pneumococcal infections associated with antibiotic 
resistant strains has prompted for better disease-control and prevention strategies. Newer 
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generation antibiotics with high antimicrobial potential especially against the antibiotic 
resistant S. pneumoniae have been the major interest. Synthetic derivatives of 
antimicrobial peptides (AMPs) with enhanced antimicrobial activity have been 
increasingly documented. The antimicrobial potential of AMPs is frequently recognized 
by a set of common rules, with multiple cationic charges and high hydrophobicity 
representing the principal factors for AMPs to be actively antimicrobials (Chen et al., 
2007; Dathe et al., 1997; Leptihn et al., 2010; Yin et al., 2012; Yu et al., 2010). The 
cationicity of AMPs represents the primary factor governing the initial contact with the 
oppositely charged bacterial surface via electrostatic interactions to facilitate subsequent 
actions (Dathe et al., 2001; Matsuzaki et al., 1997a; Yeaman & Yount, 2003). 
Furthermore, the presence of specific amino acids allocated at the precise position in the 
peptide chain is also crucial for the expression of antimicrobial activity. This probably 
happens as the amino acids, each with unique functional group, possesses a variety of 
physicochemical properties of great variety and the allocation of these amino acids at 
precise positions in the peptide chain thus ensuring the structural integrity and stability 
of AMPs required for specific interaction with the targets. Moreover, this also implies 
that there exist limitations in the maximal antimicrobial activity of any given peptide 
with definite chain length due to the limitation in the number of possible sequence 
combinations. For these reasons, systematic alterations of specific amino acids and the 
physicochemical properties of AMPs represent a straightforward yet effective approach 
towards improving the antimicrobial activity of AMPs. Nevertheless, such 
considerations should be AMPs family-specific as it is unrealistic to expect two entirely 
unrelated AMPs families with high sequence diversity but which possess similar 
physicochemical properties to exhibit identical antimicrobial activity based solely on 
the physicochemical values without considering its unique sequence identity that 
defines the specific antimicrobial activity of the AMPs. 
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The primary focus of this study was to design novel designed AMPs with high 
potency against S. pneumoniae, in particular, the penicillin-resistant isolates. The 
carefully designed peptides displayed widely different level of antipneumococcal 
activity. Even so, several common features were noted whereby the pneumococcal-
active designed AMPs including DAMP7, DP71, DP72, and especially the highly 
potent DM1 – DM5 were able to exert antipneumococcal activity irrespective of the 
penicillin susceptibility of the isolates. These designed AMPs also exhibited strong 
pneumocidal effects with significantly higher rates than the conventional antibiotic 
penicillin. Interestingly, the co-presence of these designed AMPs were found to enhance 
the antipneumococcal activity of penicillin in one way or another in a synergistic 
manner even against the penicillin-resistant S. pneumoniae. Hence, the potential 
application of these designed AMPs as the combination therapeutic agents to support 
the course of penicillin treatment are encouraging. Moreover, the antipneumococcal 
synergism produced with the different peptide-peptide pairs involving DM5 with DM1, 
DM2, DM4 and DAMP7 and DM3 with DAMP7 pairs indicate that they were able to 
synergize the inhibitory effects of the specific paired designed AMPs.  
Besides, the potential applications of the DMs can be extended to other common 
bacterial infections owing to their broad spectrum antibacterial activity. This spectrum 
of activity did vary with the respective DMs. The comparable effective ranges against 
pneumococci and against other bacteria suggest that the dose range to be used against 
pneumococci will be as effective against multiple bacteria as well. Interestingly, these 
hybrids were essentially non-hemolytic as with DM1, DM4, and DM5 or at the minimal 
level only as with DM2. Although DM3 was the most hemolytic peptide among other 
DMs, the level was considerably lower than the template DAMP7 by as much as 40% at 
250 μg/ml. Besides, the strong inhibitory potency of DP73 specifically against S. aureus 
suggested that DP73 could be a potential novel antistaphylococcal agent. 
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The step-wise procedures in designing the first group peptides based on the 
natural AMPs and the subsequent redesigning of the second group peptides are 
illustrated in Figure 4.2. The procedures in generating the five DMs by fragment 
hybridizations of DAMP6 and DAMP7 has been shown in Figure 3.3. Upon analyzing 
into the relationship between physicochemical properties and in vitro antipneumococcal 
activity of 1HR1-derived designed AMPs, net charge (NetC) of +5 and above appeared 
to be the prerequisite threshold to initiate antipneumococcal activity in this peptide 
series. This is based on the notions that both the 1HR1 (+4) and DP73 (+3) which 
displayed no antipneumococcal activity have lower NetC as compared to the 
pneumococcal-active peptide DAMP7 (+5). This also explains the high positive charges 
of both DP71 (+7) and DP72 (+7) probably contribute to the increase in 
antipneumococcal activity of peptides over DAMP7. However, whether increasing the 
NetC beyond +7 would further produce additional antipneumococcal activity is yet to 
be determined. The importance of the cationicity window for the optimal expression of 
antimicrobial activity of AMPs had also been documented (Dathe et al., 2001; Jiang et 
al., 2008; Tossi et al., 2000). V13K analogs with NetC of < +4 were found to be 
inactive but analogs with higher NetC from +4 to +10 were correlated well with 
increasing antimicrobial activity although drastic increment in hemolytic activity was 
also noted at the level of > +8. Therefore, Giangaspero et al. had suggested the optimal 
cationicity window to be +4 - +8 for this particular peptide family. In addition, the 
cationicity window of between +4 to +6 are commonly observed among the natural 
AMPs (Giangaspero et al., 2001). In another study, the synthetic analogs of magainins 2 
with NetC up to +5 displayed increasing antimicrobial activity (Dathe et al., 2001). 
However, further increasing the NetC above +5 to +7 had no advantageous 
antimicrobial effects but the hemolytic activity levels became prominent. 
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Natural AMP Sequence 
1VM4 GLFDIVKKLVSDF 
1HR1 ILAWKWAWWAWRR 
Natural 
AMP 
Sequence 
Designed 
AMP 
Sequence 
1VM4 GLFDIVKKLVSDF DAMP6 GLFDIWKKLVSDF 
1HR1 ILAWKWAWWAWRR DAMP7 ILWWKWAWWRWRR 
Peptide 
Sequence generated 
1
st
 cycle 2
nd
 cycle  
DAMP6 
GLFDIWKKLVSDF 
GLFDIWKKKKSDF GLFDTNKKKKSDF DP61 
GLFDIWKKKKSDF GTTDIWKKKKSDF DP62 
GLFDKKKKLVSDF GSKDKKKKLVSDF DP63 
DAMP7 
ILWWKWAWWRWRR 
PHWWKWAWWRWRR PHWWKWAWWHHRR DP71 
KHWWKWAWWRWRR KHWWKHDWWRWRR DP72 
ILWWLLAWWRWRR ILWWLLAWWRWPH DP73 
1T51 
ILGKIWEGIKSLF 
ILGKIWEGIVLLF ILGGDWEGIVLLF DP51 
ILGGGWEGIKSLF ILGGGWEGIVGLF DP52 
ILGKILVGIKSLF ILGKILVHHKSLF DP53 
First round 
Second round (redesigned) 
Figure 4.2: The step-wise procedures in designing the peptides beginning from 
the natural AMPs, first round design which generated DAMP6 and DAMP7, 
and the second round redesigned which generated the DP6, DP7, and DP5 series 
of peptides (after two cycles of predictions). 
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The hydrophobicity property also affects the antimicrobial activity of peptides in 
a similar fashion as cationicity. As reported by Chen et al., an optimal hydrophobicity 
window (analogous to the cationicity window) which influenced the biological activity 
of peptides was noted (Chen et al., 2007). High hydrophobicity (as well as 
amphipathicity) also enhanced the hemolytic activity of peptides. Based on the charge 
density (ChD) analysis into DAMP7, DP71, and DP72, ChD of ≥0.38 up to 12.7 would 
enhance the antipneumococcal potency of this peptide family.  
Further supporting the findings were analysis based on the 1T51 natural AMP 
which had previously been reported with highly potent antibacterial activity (Lee et al., 
2004b). Indeed, the current study also found 1T51 to be the most potent natural AMP 
against S. pneumoniae. Nevertheless, drastic change was seen with DP5 series peptides. 
As observed with DP51 and DP52, decreasing the cationicity to neutral or negatively-
charged also resulting in loss of potency in spite of the increase in hydrophobicity. 
Although DP53 has high cationicity as compared to 1T51 it still failed to produce 
antipneumococcal activity. Therefore, the antipneumococcal activity of 1T51 was 
suggested to be related to the paired relationship of both cationicity and hydrophobicity. 
Combining these, the possible approach towards enhancing the antipneumococcal 
potency of 1T51 series peptides was to elevate the positive charges while lowering the 
hydrophobicity of 1T51. In fact, detailed analysis into the five 13 amino acids 1T51 
synthetic analogues and the antibacterial activity reported in a previous study by Lee et 
al. also supports this proposition (Lee et al., 2004b). 
Combining these findings, higher cationicity and lower hydrophobicity could be 
the favorable approach towards designing high potency designed AMPs effective 
against S. pneumoniae particularly for the indolicidin and IsCT series of peptides. 
Indeed, a recent study had demonstrated that multiple factors including the positive 
charges, charges distribution, core segment hydrophobicity, peptide helicity and others 
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should be in optimal balance to obtain effective AMPs with low hemolytic activity  
(Yin et al., 2012). These findings also emphasized that the antimicrobial activity of 
AMPs is essentially family-specific as AMPs of different families could perform 
distinctively different even possessing identical physicochemical properties. Thus, 
designing synthetic AMPs should be based on careful consideration of the unique 
features associated with the AMPs family. 
Additionally, previous findings by Subbalakshmi et al. stated that Trp was 
responsible for cell cytotoxicity of indolicidin peptides but served a negligible role in 
antimicrobial activity (Subbalakshmi et al., 2000; Subbalakshmi et al., 1996). This 
could be the possible explanation causing the elevated hemolytic activity in DAMP7, 
which has 8% higher Trp ratio than 1HR1. In the redesigning, lowering the DP7s Trp 
ratio to 38% as in 1HR1 suppressed the hemolytic activity. Further strengthening the 
notion was that DMs that possess 16 – 31% lower Trp ratio demonstrated significantly 
better hemolytic profiles than DAMP7. Interestingly, DP7 peptides were non-hemolytic 
as compared to 1HR1. Hence, it was suggested that other associated factors might be 
affecting the hemolytic activity of the peptides as well.  
The natural AMPs 1HR1 and 1T51 were found to be able to significantly select 
the human lung epithelial adenocarcinoma A549 cell line over the human lung epithelial 
normal NL20 cell line. These natural AMPs might possess valuable anticancer 
properties that warrant further investigations. Further analysis into the cytotoxicity 
levels of the peptides noted that the peptides could produce drastically different 
cytotoxicity at high concentration which reflects the unique interactions of peptides 
when presented at high concentrations on human cells. In addition, the four designed 
AMPs including DAMP7, DM2, and DM3 appeared to be more selective against A549 
than NL20 cell line. 
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 The most surprising outcomes were seen with the five 13 amino acids hybrid 
peptides designed by gradual hybridization of fragments of different length of both 
DAMP6 and DAMP7. All five DMs displayed superior antipneumococcal activity 
independent of the penicillin resistance level of the isolates These pneumococci 
susceptible to the hybrid peptides included a variety of serotypes such as the highly 
prevalent serotypes 19F, 23F, and 6A/B, the less prevailing serotypes including 11A/D, 
15A/F, 16F, 22F/A, 3F, and the nontypeable pneumococci. Therefore, the 
antipneumococcal activity of DMs was irrespective of the serotypes of S. pneumoniae. 
The rapid pneumocidal kinetic was greater than the conventional antibiotic penicillin. 
Besides S. pneumoniae, the DMs displayed broad spectrum antibacterial activity against 
multiple clinically important bacteria irrespective of the gram types of the bacteria. 
Morphologically, the overwhelming changes observed in the DMs-treated 
pneumococcal cells clearly demonstrated the detrimental effects induced by DMs at the 
supra-MIC concentrations. Although the detailed underlying mechanisms might differ 
between the respective DMs, for instance, DM1 caused direct leakage of intracellular 
contents while DM5 caused the bulging and eventual formation of cytoplasm-
containing inclusion bodies through exocytosis. Two major mechanisms that were 
clearly evident were cell wall and cytoplasmic membrane disruptions. Interestingly, 
DM3 was able to induce the collapse of cytoplasm into small inclusion bodies while the 
cell wall remained intact. Based on this, DM3 was suggested to have gained entry by 
translocation without significant impact on the cell wall to act upon the membrane. 
Since the pneumococcal cells were treated at supra-MIC level by the DMs thus the 
predominant mechanism of actions at lower concentration such as the MIC or sub-MIC 
level remained unclear. This is because AMPs could be membrane-active when 
presented at high concentration while become intracellular-targeting at low 
concentration or both (Friedrich et al., 2000; Friedrich et al., 2001).                   
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The presence of specific amino acid residue is sometime crucial for the 
antimicrobial activity of the peptides. Previous study conducted by Tsai et al. had also 
determined that Lys
13
 and Arg
22
 residues were critical for the anticandidal activity of 
Histatin-5 whereby replacing the Lys
13
 and Arg
22
 residues with Glu
13
 and Gly
22
 residues 
caused a dramatic reduction in the anticandidal activity of the Histatin-5 variant m68 
(Tsai et al., 1996). Furthermore, Subbalakshmi et al. suggested that the tryptophan 
residues were responsible for the hemolytic activity of indolicidin analogs but has no 
contribution to the antimicrobial activity (Subbalakshmi et al., 1996).  
Based on the sequences of the hybrid peptides, it was noticed that the central 
WKW residues at the 6
th
 to 8
th
 position could be crucial to the antipneumococcal 
activity of the DMs. Substituting Lys
7
 to Ala
7
 of the highly potent DM3 slightly reduced 
the antipneumococcal activity of DM1 and DM2. Similar outcomes were noticed for 
DM4 and DM5 with Trp
8
 to Lys
8
 substitution. No significant relationship can be drawn 
between the antipneumococcal activity of designed AMPs and the physicochemical 
properties of peptides. Thus, cationicity and hydrophobicity do not seem to be the 
primary influencing factors for these peptides in this peptide family but the presence of 
certain amino acids appears to govern the antimicrobial activity of the peptides. Since 
both the N- and C-terminal fragments were unaltered purposefully during the 
redesigning of DMs, thus the sequence GLFD-X-WKW-X-RWRR-NH2 (X denotes 
random residue) was suggested to be the potential template to further designing better 
antimicrobial peptides.   
Towards evaluating the actual therapeutic efficacy of peptides in biological 
systems of living organisms, the peptides were tested in two lethal mouse models of 
pneumococcal infections challenged by a PRSP strain. Based on the in vitro MIC 
findings, all five hybrid peptides were selected as they displayed the most promising 
antipneumococcal effects in terms of overall effective range and overall effective 
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percentage and the low cell toxicity levels. Among the three routes of administrations 
(IP, SC, IN) assessed in the lethal pneumococcal systemic infection and pneumonia 
models, DM3 showed great therapeutic potential with statistically significant survival 
function (p ≤ 0.05) and cured 50% of the lethally infected mice as compared to the 
untreated vehicle without treatment intervention. Although DM2, and DM5 also showed 
significant survival function with delayed deaths, however, the peptides were unable to 
prevent lethality in the pneumococcal systemic infection model.  
Apart from this, the use of two or more antimicrobial agents in combination 
therapy have been the alternative strategy to improve treatment outcome in the clinical 
setting (Caballero & Rello, 2011). This is especially valuable in patients with critical 
pneumococcal infections. For instance, combination therapy with both penicillin and 
macrolide would be considered especially when the patient is in critical pneumococcal 
bacteremic condition (Baddour et al., 2004). The β-lactam antibiotic penicillin is 
commonly prescribed as empirical therapy against pneumococcal infections 
(Appelbaum, 1996; Klugman, 1990). However, the penicillin treatment outcome in 
patients has been increasingly complicated by the escalating incidences of penicillin-
resistance (Jacobs, 2003; Jones, 1999). Hence, DM3 which conferred significant 
therapeutic efficacy and survivability to the lethally infected mice in its standalone form 
was further tested for in vivo therapeutic synergism in combination with penicillin. 
Based on the in vitro findings, DM3 had been determined to produce 
antipneumococcal synergism with penicillin irrespective of the penicillin susceptibility 
of the isolates. Interestingly, combination of DM3 and penicillin also produced 
therapeutic synergism in vivo in the mouse model of lethal pneumococcal systemic 
infection. The survival rates in mice receiving the combination treatment of DM3 and 
penicillin at varying dosage combinations were dramatically increased by 20% - 50% as 
compared to the sum of the survival rates of the standalone treatment. Also, while all 
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untreated mice died from severe systemic pneumococcal challenge within two days 
postinfection, complete survival was achieved with DM320 – PEN20 formulation at day 7 
postinfection and all mice showed no signs or symptoms of sickness as well as physical 
or behavioral abnormality. The mice were cleared from the pneumococcal challenged as 
evident from the clear agar plating in blood and the five major organs examined. As the 
synergistic survival rate of DM320 – PEN20 (30%) was expected to be higher than 
DM320 – PEN10 (50%) due to the higher penicillin dose (20 mg/kg), the actual 
synergistic survival rate has probably been underestimated as masked by the maximal 
(100%) survival rate achieved. These combination treatments as well as the standalone 
DM3 were determined to be nontoxic in vivo to the mice based on the whole blood and 
serum biochemistry parameters analysis as well as histological examination. Of note, no 
nephronotoxicity and hepatotoxicity detected. 
The severe organ tissues inflammations and damages caused by S. pneumoniae in 
the lethally infected mice have been clearly demonstrated based on the histological 
findings (Figure 3.17 & Figure 3.18). This indicates that the spread and establishment of 
pneumococci began rapidly following the inoculation and continued for two to four 
days until the mice were moribund/dead. Interestingly, such histological alterations in 
the five organs of the mice survived from the lethal pneumococcal systemic infection 
following treatments with DM3 (10 mg/kg, 20 mg/kg, 40 mg/kg) and the four 
combination therapies with penicillin (DM310 - PEN10, DM310 – PEN20, DM320 - PEN10, 
and DM320 – PEN20) were minimal and was dramatically lower than the infected control 
mice. Although minor histological changes were still observable in these mice, this 
shows that the pathological sequelae caused by the highly virulent S. pneumoniae 
infection were almost unavoidable once the bacteria spread to the organs. However, the 
current treatments were able to significantly clear the invaded pneumococci from the 
 202 
tissues and reduce these damages to the minimal level. In addition, the mice survived 
remained physically active with no apparent sign of physical or behavioral abnormality.      
It was found that the dose of DM3 affects the therapeutic outcome much greater 
than the dose of penicillin. Increasing the dose of standalone penicillin by 10 mg/kg 
from 10 mg/kg (20%) to 20 mg/kg (50%) would enhance the protection by 30%, giving 
the expected survival rate of 80% in DM310 – PEN20 group over the expected survival 
rate of 50% in DM310 - PEN10 group and this is observed in the in vivo therapeutic 
synergism experiments. Similarly, increasing the dose of standalone DM3 by 10 mg/kg 
from 10 mg/kg (10%) to 20 mg/kg (20%) would enhance the protection by 10%, giving 
the expected survival rate of 60% in DM320 - PEN10 over DM310 - PEN10 (50%). 
Interestingly, the DM320 - PEN10 group recorded 90% survival rate which is 30% higher 
than the expected value. In other word, changes in the dose of DM3 will have greater 
effect than penicillin on the resulting therapeutic efficacy of the DM3-penicillin 
formulation. However, the importance of penicillin should not be neglected as both 
components are equally critical in the formulation.  
Although the mechanism of antimicrobial actions of the DMs was not the focus of 
the current study, findings gathered based on various in vitro antimicrobial studies 
performed has led to the hypothesis that the DMs could possibly be cell wall and/or 
plasma membrane targeting. This is because the potent antimicrobial activities of the 
DMs were (1) independent of penicillin susceptibility and thus the penicillin-binding 
proteins which are responsible for cell wall biosynthesis processes as well as the 
molecular resistance mechanisms involve in penicillin resistance, (2) independent of 
pneumococcal serotype and thus ruled out the specific capsular polysaccharide-targeting 
potential of the DMs,  (3) high killing rate immediately following treatment and thus 
should not have dependent upon the metabolic mechanisms of S. pneumoniae for its 
activity, (4) broad spectrum against variety of bacteria of both gram types in general and 
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thus the differences in cell wall composition have no significant interference on the 
DMs, and (5) images from Transmission Electron Microscopy provide clear evidence 
showing severe damages especially on cell wall and plasma membrane of pneumococci. 
Therefore, cell wall/membrane perturbation appears to be the most potential mechanism. 
However, we do not exclude the possibility of the involvement of other cooperative 
mechanisms which contribute to the antimicrobial activity of the DMs. We also 
speculate that in its standalone form, the biological activity of DM3 might have been 
interfered by various neutralizations or enzymatic reactions especially in the blood 
components of animals. With the presence of penicillin that targets the PBPs and 
weakens the cell wall of S. pneumoniae, the peptide molecule can now act much rapidly 
and directly to the cell wall and other cellular components thus reducing the time and 
probably the number of peptide monomers required per pneumococcal cell to initiate 
killing. Finally, the therapeutic effects of DM3 can be expressed more efficiently. Thus, 
the specific antimicrobial actions of DM3 on S. pneumoniae as well as other bacteria 
will need further investigations to allow better understanding of the mechanism of 
actions of the peptides.     
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The escalating reports of antibiotic resistance S. pneumoniae has prompted for the 
search for better disease prevention and treatment strategies in the course of 
pneumococcal infections. Those at the extreme age groups represent the most 
commonly infected groups by pneumococcal diseases and vaccinations against S. 
pneumoniae represent the most important prevention strategy. The 23-valent 
pneumococcal polysaccharide vaccine was designed for the elderly adults and various 
generations of pneumococcal conjugate vaccines (PCV7, PCV10, PCV13) have been 
developed for the younger children. However, these pneumococcal vaccines are 
essentially serotype-specific and thus continued surveillance is needed to predict the 
effectiveness of vaccines among the local population. Such information is very limited 
in Malaysia. Our single-center surveillance study based in the densely-populated area of 
Selangor showed that the prevailing serotypes belonged to the PCV7 vaccine-serotypes. 
Thus, the PCV7 vaccine is predicted to cover 64.2% of the total cases. In addition, the 
proportion of penicillin nonsusceptible isolates remains high which constituted half of 
the cases. Notably, the PCV7 vaccine also covers 87.5%, 79.5%, and 45.3% of the 
PRSP, PISP, and PSSP, respectively. Hence, the use of PCV7 vaccine and the newer 
generations of PCVs would benefit the Malaysian population. 
The widespread use of conventional antibiotics for the past decades has led to the 
selection of antibiotic resistant S. pneumoniae which complicates empirical therapy and 
patient management. Newer antimicrobial agents are increasingly demanded for the 
treatment against this pathogen which has developed substantial tolerability to the 
conventional antibiotics. We have generated a total of five designed AMPs (DM1, DM2, 
DM3, DM4, and DM5) which showed potent in vitro antipneumococcal activity 
irrespective of the penicillin susceptibility of the pneumococcal isolates. The 
pneumocidal kinetics were clearly higher than penicillin and the treated pneumococci 
were observed with extensive damages especially the cell wall and plasma membrane 
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which leads to cell death. These peptides were broad spectrum against various gram-
positive and gram-negative bacteria that frequently cause life-threatening infections in 
patients. Among the five hybrids, DM3 was the most potent antimicrobial peptide.  
From the therapeutic efficacy testing in mice lethally infected by a PRSP strain, 
DM3 at 40 mg/kg protected half (50%) of the mice from deaths. The mice showed no 
apparent sign or symptoms of infections. Notably, the combination treatments with 
penicillin greatly enhanced the therapeutic outcome of the infected mice in a synergistic 
manner. This synergism was also seen in in vitro assays. Almost all (90%) of protection 
was achieved with the low doses combination of DM3 at 20 mg/kg with penicillin at 10 
mg/kg. Using both agents at 20 mg/kg ensured all (100%) mice survived in the 
otherwise lethally infected mice.  
DM3 showed great potential to be further developed into a clinically useful 
therapeutic drug whether as a standalone agent or in combination therapy with penicillin 
to support the conventional antibiotics to improve treatment outcomes especially 
involving antibiotic resistance strains of pneumococci.    
From the current study, the antimicrobial activity and toxicity of DM3 have been 
investigated using various in vitro and in vivo procedures. Even so, the actual 
mechanism of actions of DM3 in its antipneumococcal activity remains largely unclear. 
The computational simulation would be a valuable technique towards predicting the 
docking of peptide onto the specific potential target that eventually leads to the killing 
of S. pneumoniae. In addition, evaluating the pharmacokinetic/pharmacodynamic 
aspects of the peptide will be as important to study the various changes and interactions 
that take place upon administered into the body of animal as well as human. These 
information are crucial and shall form the basis in our future explorations towards 
developing DM3 as a potential novel antibiotics. 
 207 
In conclusion, antimicrobial peptides represent the most promising class of 
antimicrobial agents for the development of novel antibiotics. Its simplicity in the 
primary amino acid sequence and the secondary structure would allow the design of 
new AMPs with less computational burden. With the rapid expansion in the 
understanding and strategies in designing of peptides, AMPs could be the next-
generation antibiotics with potent antimicrobial activity and low toxicity. We further 
emphasized the importance of continuous surveillance in order to better understand the                  
local pneumococcal serotype and antibiotic susceptibility patterns.   
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APPENDICES 
APPENDIX 1: PREPARATION OF CULTURE MEDIA, REAGENTS, AND 
CHEMICALS   
 
Gram staining reagents 
1) Crystal violet  
a. Solution 1; Crystal violet (2 g), ethanol 95% (20 ml) 
b. Solution 2: Ammonium oxalate (0.8 g), distilled water (80 ml) 
c. Solution 1 and 2 were mixed and allowed to stand for at least 24 hrs, and 
filtered before use. 
 
2) Lugol‟s iodine 
a. Potassium iodide (2 g) 
b. Iodine (1 g) 
c. Distilled water (300 ml) 
 
3) Diluted carbol fuschin 
a. Stock solution: Safranin O (2.5 g), ethanol 95% (100 ml) 
b. Working solution: Stock solution (10 ml), distilled water (90 ml) 
 
Standard biochemical reagents 
1) Bile reagent: 
a. Sodium deoxycholate (0.2 g) 
b. Distilled water (10 ml) 
 
2) Catalase reagent: 
a. Hydrogen peroxide (3%) 
b. Store in refrigerator 
 
3) Phosphate buffered saline 
a. 1 PBS table/100ml distilled water 
b. Autoclave sterilized 
 
4) Tris-EDTA (TE) buffer: 
a. 1 M Tris-HCl, pH 8.0 (1ml, final concentration of 10 mM) 
b. 0.5 M EDTA (200 µl, final concentration of 1 mM) 
c. Distilled water (100 ml) 
d. Autoclave sterilized. 
 
5) Tris-acetate EDTA (TAE) buffer (50X) 
a. Tris base (242 g) 
b. Glacial acetic acid (57.1 ml) 
c. EDTA (18.61 g) 
d. Distilled water (1000 ml) 
e. Autoclave sterilized. 
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6) Electrophoresis 2% agarose gel 
a. Agarose powder (1.5g) 
b. Distilled water (100 ml) 
c. Microwave boiled until all powder completely dissolved.  
 
7) Magnesium stock solution (10 mg Mg2+ /ml) 
a. Powder magnesium chloride hexahydrate, MgCl2 . 6H2O (8.36 g) 
b. Deionized distilled water (100 ml) 
c. The powder was dissolved completely and filter sterilized using 0.2 µm 
syringe filter membrane. Stored at 2 
o
C – 8 oC.  
 
8) Calcium stock solution (10 mg Ca2+ /ml) 
a. Powder calcium chloride dihydrate, CaCl2 . 2H2O (3.68 g) 
b. Deionized distilled water (100 ml) 
c. The powder was dissolved completely and filter sterilized using 0.2 µm 
syringe filter membrane. Stored at 2 
o
C – 8 oC. 
d. The powder was dissolved completely and filter sterilized using 0.2 µm 
syringe filter membrane. Stored at 2 
o
C – 8 oC. 
 
9) Proteinase K solution (10 mg/ml) 
a. Proteinase K powder (25 mg) 
b. Distiller water (2.5 ml) 
c. Dissolved completely. Stored at -20oC. 
 
10) Lysostaphin solution (50 mg/ml) 
a. Lysostaphin powder (25 mg) 
b. Distilled water (0.5 ml) 
c. Dissolved completely. Stored at -20oC. 
 
11) 10% buffered formalin 
a. PBS tablet (10 tablets) 
b. 40% formalin (R & M chemicals, UK) (100 ml) 
c. Distilled water (900 ml) 
d. PBS tablets were dissolved in distilled water followed by addition of 100 ml 
40% formalin to make 10% buffered formalin. 
 
Bacterial culture agar/broth 
1) Blood agar 
a. Tryptone/peptic digest of animal tissue (10 g) 
b. Brain heart infusion (500 g) 
c. Sodium chloride (5 g) 
d. Agar (15 g) 
e. Distilled water (950 ml) 
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f. Autoclave sterilized. Media was cooled to 50oC – 55oC and 50 ml of 
preheated (45
o
C) defibrinated sheep blood was added before agar pouring. 
 
2) Mueller Hinton Agar: 
a. Beef infusion (300 g) 
b. Starch (1.5 g) 
c. Casein (17.5 g) 
d. Agar (17 g) 
e. Distilled water (1000 ml) 
f. Autoclave sterilized. Media was cooled to 50oC – 55oC before agar pouring. 
For blood supplement 50 ml of preheated (45
o
C) defibrinated sheep blood 
may be added. 
 
3) Mueller Hinton broth: 
a. Beef infusion (300 g) 
b. Starch (1.5 g) 
c. Casein (17.5 g) 
d. Distilled water (1000 ml) 
e. Autoclave sterilized. 
 
4) Cationically-adjusted Mueller Hinton broth (CAMHB) 
a. Mueller Hinton broth (997.32 ml) 
b. Chilled calcium stock solution (2 ml) 
c. Chilled magnesium stock solution (0.68 ml) 
d. Both calcium and magnesium stock solutions were added to Mueller Hinton 
broth mixed well.   
 
5) Nutrient agar: 
a. Nutrient agar (Oxoid, UK) (28 g) 
b. Distilled water (1000 ml). 
c. Autoclave sterilized. 
 
6) Brain Heart Infusion broth: 
a. Calf brain infusion (12.5 g) 
b. Beef heart infusion (5 g) 
c. Glucose (2 g) 
d. Proteose peptone (10 g) 
e. Sodium chloride (5 g) 
f. Disodium phosphate (2.5g ) 
g. Distilled water (1000 ml) 
d. Autoclave sterilized. 
 
7) Bacteria stocking medium 
e. Brain heart infusion broth (90 ml) 
f. Glycerol (10 ml) 
g. Autoclave sterilized. 
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Cell culture media and reagents 
1) RPMI-1640 medium (serum free) 
a. RPMI-1640 (supplemented with L-glutamine) in powder form (Flowlab, 
Australia) 
b. Sodium bicarbonate (3.7 g) 
c. Distilled water (1000 ml) 
d. Filtered sterilized. 
  
2)  RPMI-1640 growth medium (with 10% fetal bovine serum) 
a. Serum free RPMI-1640 medium (900 ml) 
b. Fetal bovine serum (heat-inactivated) (100 ml) 
 
3) RPMI-1640 maintenance medium (with 2% fetal bovine serum) 
a. Serum free RPMI-1640 medium (980 ml) 
b. Fetal bovine serum (heat-inactivated) (20 ml) 
 
4) Ham‟s F12 medium (serum free) 
a. Liquid Ham‟s F12 medium (Hyclone) 
 
5) Ham‟s F12 medium growth medium 
a. Liquid Ham‟s F12 medium (Hyclone) (900 ml) 
b. Fetal bovine serum (heat-inactivated) (100 ml) 
 
6) Ham‟s F12 medium maintenance medium 
a. Liquid Ham‟s F12 medium (Hyclone) (980 ml) 
b. Fetal bovine serum (heat-inactivated) (20 ml) 
 
7) Cell line stocking medium 
a. Serum free RPMI-1640/Ham‟s F12 (24 ml) 
b. Fetal bovine serum (12 ml) 
c. Dimethyl sulfoxide (4 ml) 
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Presented at the 9
th
 International Symposium on Antimicrobial Agents and Resistance 
(ISAAR 2013), 13
th
 – 15th Mac 2013, Kuala Lumpur Convention Centre, Kuala Lumpur, 
Malaysia. 
 
DM3, A Novel synthetic antimicrobial peptides with potent in vitro and in vivo 
antimicrobial activities against Streptococcus pneumoniae  
CF Le
a
, MA Abdulla Hassan
b
, MY Md Yusof
a
, SD Sekaran
a
 
a
Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 
Malaysia 
b
Department of Biomedical Science, Faculty of Medicine, University of Malaya, 
Malaysia 
 
Background: Streptococcus pneumoniae is a major human bacterial pathogen causing 
significant morbidity and mortality worldwide. The increasing reports of antibiotic-
resistant pneumococci have prompted the search for novel antibiotics. Methods: Five 
synthetic antimicrobial peptides (DM1-5) were designed and tested by standard 
methods such as minimum inhibitory concentration (MIC), killing kinetics, transmission 
electron microscopy (TEM), hemotoxicity, and cell cytotoxicity against lung cell lines. 
In vivo acute toxicity and therapeutic efficacy was evaluated using an in-house mouse 
pneumococcal infection model. Results: The five DMs showed potent 
antipneumococcal activities against 60 pneumococcal isolates irrespective of penicillin 
resistance of the isolates (MIC = 7.81- 250μg/ml) with broad spectrum activity against 
multiple bacterial pathogens. Pneumococcal killing kinetics was higher than penicillin 
by 30 – 75% and the DMs induced overwhelming cellular damages leading to 
pneumococcal cell death. Hemolytic activity was minimal (HC50 > 250 μg/ml) while 
IC50 against lung cell lines ranged from 96 - >250μg/ml. Intraperitoneal treatment with 
DM3 (40mg/kg) protected 50% of mice from a lethal pneumococcal systemic infection 
model challenged by a penicillin-resistant strain. Combinations of DM3 and penicillin 
produced therapeutic synergism by enhancing the survival rates to 90% (DM3 20mg/kg, 
PEN 10mg/kg) and 100% (DM3 20mg/kg, PEN 20mg/kg). Conclusion: DM3 showed 
great potential as a standalone antimicrobial candidate or in formulation with 
conventional antibiotics to enhance treatment outcome in pneumococcal infections 
especially cases involving resistant pneumococci. 
 
All authors have no conflicts of interest with regard to this presentation 
 
  
 275 
Poster presentation 1 
 
Presented at the 9
th
 International Symposium on Antimicrobial Agents and Resistance 
(ISAAR 2013), 13
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PNEUMOCOCCAL SEROTYPE DISTRIBUTION IN MALAYSIA 
CF Le
a
, MY Md Yusof
a
, SD Sekaran
a
 
a
Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 
Malaysia 
 
Background: S. pneumoniae causes a significant proportion of pneumonia and 
meningitis in Malaysia. Pneumococcal-conjugate vaccines (PCVs) have been the most 
promising immunization strategy to the younger children. However, PCVs are serotype-
specific and local serotype distribution is important to evaluate the potential coverage of 
PCVs. Methods: Multiplex serotyping was performed on 208 pneumococcal isolates 
obtained from the microbiology laboratory of University of Malaya Medical Centre, 
Kuala Lumpur from 1997 – 2012 (except 2001 and 2004).  Minimum inhibitory 
concentration (MIC) was determined using agar dilution method (isolates obtained on 
2007 and before) and broth microdilution method (isolates obtained after year 2007). 
Grouping of penicillin susceptibility followed the penicillin (oral). Statistical analysis 
was performed using chi-squared or fisher‟s exact tests whenever appropriate.Results: 
Serotype 19F represented the major serotype (33%), followed by 23F (9%), 6A/B (6%), 
1 (6%), and 14 (5%). Half of the total isolates (51%) were penicillin non susceptible 
(PNSP). Serotypes were found to highly associated with penicillin susceptibility 
(p<0.001) with serotype 19F being the most resistant serotype (62%). In fact, 78% of 
serotype 19F was PNSP. Most isolates (30%) were obtained from nasopharyngeal (NP), 
followed by sputum (26%) and blood (24%). Statistical test showed that serotype 19A 
was associated with invasive site (11%) while 19F was associated with non invasive site 
(44%). Interestingly, the invasive isolates were likely to be penicillin susceptible while 
non invasive isolates were likely to be PNSP. Conclusion: PCV7, PCV10, and PCV13 
are expected to cover 56%, 63%, and 71% of Malaysian serotypes. The use of PCVs in 
Malaysia is still limited and incorporation of PCVs under the childhood immunization 
scheme is encouraged.         
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Novel synthetic antimicrobial peptides with potent in vitro and in vivo 
antimicrobial activities against Streptococcus pneumoniae 
Le Cheng Foh
a
, Mohd Yasim Md Yusof
a
, and Shamala Devi Sekaran
a
  
a
Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 
50603, Kuala Lumpur, Malaysia  
Corresponding author: shamalamy@yahoo.com 
 
Abstract 
Streptococcus pneumoniae is a major human bacterial pathogen causing 
significant morbidity and mortality worldwide. The increasing reports of antibiotic-
resistant pneumococci have prompted the imperative search for novel antimicrobial 
agents. We have generated a series of synthetic antimicrobial peptides and found that 
five peptides (DM1-5) showed potent antipneumococcal activities and rapid killing 
rates irrespective of the penicillin resistance of the pneumococcal strains. These 
peptides induced overwhelming pneumococcal cell wall and cell membrane damages 
which eventually lead to cell death as observed using Transmission Electron 
Microscopy. The DMs were able to produce synergism in combination with the 
conventional antibiotic penicillin. Interestingly, DMs also displayed broad spectrum 
antibacterial activity against other common clinically-encountered bacterial pathogens 
such as Staphylococcus aureus, methicillin-resistant S. aureus, E. coli, Pseudomonas 
aeruginosa, and others. The hemolytic activities were low while cytotoxicities against 
two human lung cell lines varied among the DMs. Further testing of these peptides in 
mouse infection model found that intraperitoneal treatment with DM3 (40mg/kg) for 
three doses at 2hrs, 12hrs, and 24hrs protected 50% of mice from lethal pneumococcal 
infection by a penicillin-resistant strain. Mice treated with this DM3 regimen have no 
major abnormalities in blood haematogram and serum biochemistry parameters as well 
as histopathology of five major organs (spleen, liver, lung, kidney, brain). Interestingly, 
combination treatments using DM3 and penicillin produced in vivo therapeutic 
synergism. While DM3 (20mg/kg) and penicillin (20mg/kg) conferred 20% and 50% 
protection to the mice, all mice (100%) treated with this DM3-penicillin combination 
survived from the lethal pneumococcal challenge. Antimicrobial peptides represent the 
promising novel antimicrobial agent and here we have developed DM3 showing great 
potential as antimicrobial candidate in standalone form or to be formulated in 
combination with conventional antibiotics to enhance pneumococcal infections 
treatment outcome especially those involving pneumococcal-resistant strains. 
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Presented at the BioMalaysia 2012, 5
th
 – 7th November 2012, Kuala Lumpur 
Convention Centre, Kuala Lumpur, Malaysia. 
 
DM3, a novel designed antimicrobial peptides protects mice from lethal 
pneumococcal infections. 
Shamala Devi Sekaran
a
, Mohd Yasim Md Yusof
a
, Le Cheng Foh
a
 
a
Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 
50603 Kuala Lumpur, Malaysia. 
 
Description of innovation 
Streptococcus pneumoniae is responsible for life-threatening infections 
including meningitis, bacteremia, and pneumonia affecting primarily children < 2 years 
of age and the elderly adults. Treatment against pneumococcal infections depends 
mainly on beta-lactam antibiotics such as penicillin and cephalosporins. Nevertheless, 
increasing reports of antibiotic-resistant S. pneumoniae have greatly restricted the 
choice of antibiotics as well as the treatment outcome. Novel antimicrobial agents are 
urgently needed as the alternatives therapeutic choices.  
We have designed a novel peptide-based antimicrobial drug, DM3 which is 
completely different from the conventional antibiotics in terms of the chemical structure 
and the antibacterial properties. DM3
 
displayed potent antimicrobial activity against S. 
pneumoniae including the penicillin-resistant strains. DM3
 
is also broad spectrum 
against multiple common clinically encountered bacteria including Staphylococcus 
aureus, methicillin-resistant S. aureus, Pseudomonas aerugenosa, Escherichiae coli, 
Acinetobacter baumanii, Enterococcus cloacae, and Citrobacter spp.. These have been 
experimentally proven in our laboratory using various antimicrobial testing methods. 
DM3
 
eliminated >95% pneumococcal cells almost instantaneously post treatment and 
the activity was superior to penicillin by >55%. DM3 synergized and enhanced the 
antipneumococcal potency of penicillin when both are given in combination. DM3
 
is 
considerable non-toxic in that toxicity was only seen at 125μg/ml which was two-fold 
higher than the MIC range. In in vivo experiment, DM3
 
protected a significant portion 
of mice infected with a highly lethal strain of S. pneumoniae with no manifestation of 
clinical illnesses post treatment. Thus, continued development of DM3
 
is envisioned to 
provide an alternative choice in treatment of bacterial infections whether as standalone 
or to support the conventional treatment regimen especially in cases involving 
antibiotic-resistant strains. This type of peptide-based antibiotics is novel to the 
pharmaceutical industry and hence indicates that the potential for this new generation 
antibiotics is exceptionally great. 
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New self-designed drug for treatment of Streptococcus pneumoniae infections. 
Shamala Devi Sekaran
a
, Le Cheng Foh
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a
Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 
50603 Kuala Lumpur, Malaysia. 
b
Virtual Reality Centre, Institute of Research Management and Monitoring, University 
of Malaya, 50603 Kuala Lumpur, Malaysia. 
 
Description of innovation 
Streptococcus pneumoniae is one of the major human bacterial pathogens 
causing life threatening diseases such as meningitis, bacteremia, and pneumonia. 
Children <2 years of age and the elderly adults are the most heavily infected groups. 
Treatment against pneumococcal infections depends mainly on beta-lactam antibiotics 
such as penicillin and cephalosporins. Nevertheless, increasing reports of antibiotic-
resistant S. pneumoniae have greatly restricted the choice of antibiotics as well as the 
treatment outcome. Hence, the search for new generation antimicrobial agents is 
urgently needed. 
Current innovation described the development of three novel peptide-based 
antibiotics, strepDM1, strepDM4, strepDM5. The peptides are different from and not 
the synthetic variants of the conventional antibiotics and hence the inherent resistances 
exhibited by the pneumococci are not readily expressed against our peptides. These 
have been experimentally proven in vitro in our laboratory using the broth microdilution 
assay. In addition, the individual peptide cleared >60% of pneumococcal load within 30 
minutes posttreatment by just single dose use and the killing persists thereafter and 
cleared ≥99% of cells in 90 – 180 minutes. Furthermore, our peptides also exhibited 
broad-spectrum antibacterial activity against diverse bacterial pathogens of both gram 
types, including Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), 
Pseudomonas aerugenosa, Escherichiae coli, Acinetobacter baumanii, Enterococcus 
cloacae, and Citrobacter spp. Most importantly, the peptides exhibited no hemotoxicity 
at concentration equal to or higher than the bacterial inhibitory concentrations. 
We envision that our innovation, strepDM could provide alternative choices in 
treatment of bacterial infections especially cases involving antibiotic-resistant S. 
pneumoniae. The excellent toxicity profile allows wider choice both in the selection of 
route and regimens of administrations. Although our peptides are still in early stage of 
development, they have the potential to be further developed as supporting agents with 
conventional antibiotics marketed or as standalone therapeutic agents. 
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Synthetic antimicrobial peptide as alternative to antibiotic for the treatment of 
Streptococcus pneumoniae infections 
Le Cheng Foh
a
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a
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a
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a
Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 
50603 Kuala Lumpur, Malaysia. 
b
Virtual Reality Centre, Institute of Research Management and Monitoring, University 
of Malaya, 50603 Kuala Lumpur, Malaysia. 
 
Description 
Streptococcus pneumoniae is one of major human pathogens, causing various 
life-threatening diseases such as meningitis, sepsis, pneumonia, otitis media, and others. 
Although penicillin remain as principal drug for treating pneumococcal infections, the 
increase emergence of penicillin-resistant Streptococcus pneumoniae will eventually 
render the antibiotic ineffective. Therefore, there is an urgent need in search of novel 
therapeutics against the bacteria. 
The natural antimicrobial peptides (NAMPs) are increasingly recognized as 
important components constituting the first line of defense in mammalian innate 
immunity. They are generally short and rapid acting polycationic antimicrobial peptides 
exhibit broad spectrum antimicrobial activities against diverse array of bacteria, fungi, 
parasites, and some viruses. They can be found naturally from various organisms from 
human, mammals, insects, amphibians, and others.  
Although many natural peptides have been described, there is great potential for 
the development of synthetic analogs, based on existing structures, with increased 
antimicrobial activity. By using various biocomputationl approaches, we have designed 
a group of synthetic antimicrobial peptides (DAMPs) that targeting the penicillin-
binding proteins (PBPs) of S. pneumoniae. Two of our designed peptides, DAMP 6 and 
DAMP 7 found to have substantial antipneumococcal activity, with DAMP 6 having no 
toxicity although DAMP 7 has observed concentration-dependent toxicity.  
Although this product are still at the earlier stage of testing, with future works on 
the in vivo and preclinical evaluation of peptides, the successful development of this 
products as new therapeutic against S. penumoniae will bring about great impact to the 
community. The direct benefit is seen as improving the health status of the people. Each 
year at least 1 million children younger than 5 years of age die of pneumonia and 
invasive diseases in developing countries. Mortality rates for pneumonia and meningitis 
are especially high for young children, the elderly, and immunocompromised 
individuals, including patients with human immunodeficiency virus. The demand for 
antibiotics are always high. For commercialization, these peptides can potentially be 
marketed as a new drug for S. pneumoniae, giving the patients and physicians a new 
choice of drug. In addition, this can help to reduce the financial burden of individual as 
well as the government, at which billions of Ringgit can be saved from the country‟s 
each year for development of country.  
Previous works from other researchers have focused mainly on membrane active 
peptides, which owes its activity via perturbation of cell membrane leading to cell lysis. 
However, our design strategy in this study does not utilize the same approach, instead 
we target the penicillin-binding protein (PBPs). To our knowledge, this strategy is first 
implicated in drug design from similar field. The advantage over the membrane-
 280 
disruption approach is due to the possible cytotoxicity arise as a result of non-specific 
activity of peptides on both the desirable bacterial membrane targets, as well as the 
undesirable activity on human cells, especially erythrocytes.  
Although the stage of drug development in the current study is still early, but the impact 
that it can bring about is massive to the field of drug development. Basically, the idea 
applied is simple: to manipulate the sequences of peptides which are critical to their 
actions in order to generate new products with altered properties. Similar approaches 
can be use for design of synthetic peptides against other components of S. penumoanie 
or other pathogens. In addition, the discovery that can be made here is unlimited 
because we can virtually generate any sequences of peptides of various length and 
multiple combination of amino acids, not taking account others (N-terminal and C-
terminal modifications, D-amino acids, succinylation, amide cyclic, disulfide bridge, 
and etc). 
  
 281 
Poster Presentation 6 
 
Presented at the International Congress of Malaysian Society for Microbiology 
(ICMSM 2009), 1
st
 – 4th December 2009, Park Royal Hotel Penang, Penang, Malaysia. 
 
Identification of novel antibiotic resistance targets and development of 
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Abstract 
Streptococcus pneumonia, a gram-positive, alpha-hemolytic aerotolerant 
diplococcus that present as normal flora in the upper respiratory tracts. It was a major 
cause of pneumonia in the late 19
th
 century and also causes many other life-threatening 
diseases. Moreover, the increasing reports of multi-drug resistant S. pneumoniae 
worldwide is no more an issue, it is catastrophic if no alternative therapeutic agents be 
made available in years time. In this study, we utilize natural antimicrobial peptides 
(NAMP) as our reference peptides against which the synthetic antimicrobial peptides 
(DAMP) were designed from, with S, pneumoniae penicillin-binding protein as the 
target site . We constructed a small library of NAMP via screening into several peptide 
databases. Methods employed in designs and modifications of DAMP include simple 
amino acid substitution, addition/deletion, and/or short chain hybridization in order to 
generate DAMP with variable biochemical properties. In vitro assays were performed to 
profile the antimicrobial, cytotoxicity, and hemolytic activities of peptides. Our 
preliminary MIC results showed promising antipneumococcal activity by several 
peptides tested. Furthermore, most of the peptides tested are either having no or only 
with minimum level of hemolytic and cytotoxic activities. The results presented here 
illustrate that antimicrobial peptides can be generated through construction of small 
libraries. We hope that the findings from this study could lead to more progressive 
development of antimicrobial peptides against S. pneumoniae.  
 
